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Preface
The necessity of on-site, fast, sensitive, and cheap complex laboratory analysis, associated
with the advances in the microfabrication technologies and the microfluidics, made it possi‐
ble for the creation of the innovative device lab-on-a-chip (LOC), by which we would be
able to scale a single or multiple laboratory processes down to a chip format. The present
book is dedicated to the LOC devices from two points of view: LOC fabrication and LOC
application.
The first section, “LOC Fabrication,” addresses the photolithography-based technologies for
mass production of three-dimensional microstructures; the currently used complementary
metal oxide semiconductor technologies allowing the functional integration of sensors, sig‐
nal conditioning, and processing circuits to develop a lab-on-a-chip; the magnetic field–
based technologies for the possible non-contact manipulation of biological and chemical
samples; and the application of lumped element modeling for the rapid design and simula‐
tion of a new generation of centrifugal microfluidic systems.
The second section, “LOC Application,” includes comprehensive reviews, which comment
on the advances and potential application of cell- and organ-on-chip devices, as well as on
the digital nucleic acid detection by means of microfluidic LOC systems for pathogen analy‐
sis, food safety, and clinical diagnosis purposes. Experimental works, demonstrating the ap‐
plication of a multiple chamber chip reactor filled with enzyme-coated magnetic
nanoparticles for the investigation of the biotransformation of l-phenylalanine and of a high-
performance silicon-based functional devices for biomedical applications, namely for the la‐
bel-free detection of different types of tumor cells, are presented, too.
The book offers a professional multidisciplinary look and up-to-date information on the var‐
ious aspects of the lab-on-a-chip device development and application.
All the contributing authors are gratefully acknowledged for their time and efforts and for
their commitment with the present project.
DSc. Eng. Margarita Stoytcheva, DSc. Eng.
Ph.D. Eng. Roumen Zlatev, PhD, Eng.







Fabrication of Three-Dimensional Concave or Convex
Shell Structures with Shell Elements at Micrometer
Resolution in SU-8
Louis WY Liu, Qingfeng Zhang and Yifan Chen
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/62405
Abstract
This chapter presents a photo-lithographically-based technology for mass production of
three-dimensional (3D) micro-structures with shell elements. In this technology, shell
elements are photo-lithographically fabricated at micron or sub-micron resolution by
illuminating with ultraviolet light radiating an ultraviolet light beam onto UV-opaque
SU-8 monomer. The technology does not require any steps involving micro-injection
molding  or  micro-stereolithography.  Several  prototypes  have  been  fabricated  to
demonstrate the feasibility of this technology.
Keywords: SU-8, Micro-fabrication, Injection molding, Micro-stereolithography,
Graytone lithography
1. Introduction
Micrometer features with hollow parts are increasingly common in many applications [1]. Micro-
needles, drug delivery systems, and vacuum micro-electronics operating at millimeter-wave
frequencies all have hollow micro-structures with dimensions that extend from half millime‐
ter to 1 μm scale. However, mass producing hollow objects at micron resolution is a known
challenge in the field of micro-fabrication [2]. Preliminary information about the enabling
technologies for realization of suspended or hollow micro-structures is discussed in the sections
which follow.
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
2. Micro-injection molding
Micro-injection molding is currently the technology most widely used for mass-fabrication of
three-dimensional (3D) hollow micro-structures [3,4,11–13]. In micro-injection molding,
thermoplastic granules are first melted in the plastifying unit of a micro-injection machine.
Then, the molten plastic is injected at high pressure into the hollow space of an injection
molding tool. After a cooling process, the injection tool is disassembled and the molded object
removed. Although micro-injection molding is an established technology that supports mass
production of hollow objects, the process is not without limitations. To date, the sizes of hollow
objects made in conventional micro-injection molding technology are typically in millimeter
range, not in micron range. Injection molding of an object at millimeter resolution is not
possible without a special injection machine and auxiliary equipment. The mold to be used for
formation of object at millimeter resolution has to be equipped with inlets and outlets in order
to allow high-speed injection, gas evacuation, and the expulsion. More importantly, the process
of micro-injection molding involves many energy intensive steps which are eco-unfriendly.
3. Micro-stereolithography
Another most widely used 3D micro-fabrication technology is micro-stereolithography [1,2,8].
It works by scanning an UV laser on a liquid monomer, curing the monomer into solid
polymeric slices layer by layer, and stacking together all these polymeric slices with various
contours. This UV-induced photo-polymerization repeats in a layer-by-layer fashion until the
desired 3D object is fully formed. This technology has made it possible to fabricate any form
of 3D micro-structures. The surface profile of a fabricated micro-structure can be as compli‐
cated as a human face. However, micro-stereolithography is a time-intensive process. The
typical scanning speed of a micro-stereolithography machine is about 200–300 layers per hour
[8], depending on the geometry and the resolution of the 2D slice to be formed on each layer.
Fabricating a simple 3D object of 1 mm in height can take more than 30 minutes. Fabricating
a small array of micro-needles can take anywhere between 50 minutes and several hours.
Micro-stereolithography technology is currently being pushed developed aggressively
focusing on for improvements in both resolutions, speed and flexibility in choice of photo-
curable materials. However, due to the use of a laser and a scanner system, the initial invest‐
ment costs of a micro-stereolithography-based process are unavoidably high.
4. Graytone lithography
Graytone lithography [9,10] is another inexpensive 3D micro-fabrication technology. This
technology has been evolved to one step mask-less fabrication using SU-89. For the applica‐
tions not requiring or not suited with no access to using an expensive micro-stereolithography
machine, gray tone lithography is an interesting alternative to micro-stereolithography.
Graytone lithography is a modification of conventional 2D optical lithography. It works by
exposing a positive photoresist to a UV light through a grayscale mask which defines the
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patterns of 3D micro-structures to be formed. The UV light through the grayscale mask
produces local intensity modulation. Following a UV exposure, the 3D profile on the surface
of the positive photoresist can be formed on the substrate by stripping off the UV-exposed
photoresist. While this technology is well known for its potential for mass production, the
technology itself is not without limitation. One such limitation is that grayscale lithography
based on a positive photoresist does not support fabrication of hollow or suspended micro-
structures without change in the technology.
5. Comparison between different 3D micro-fabrication technologies
To the authors' knowledge, to date, there has not been any cost-effective approach dedicated
to mass production of hollow micro-structures at micron or sub-micron resolution. In this
paper, the proposed fabrication process presented is a fundamentally different approach based
on an improved version of another process published in references [5,6]. The proposed process
can be carried out photo-lithographically with conventional photo-lithographic equipment. It
provides a convenient alternative for researchers without no access to a micro-stereolithogra‐
phy machine or other expensive fabrication facilities. It is not intended as a replacement of
other already established and accessible 3D micro-fabrication technologies. Instead, we believe
that the proposed process should be used in conjunction with other 3D micro-fabrication
technologies to optimizing maximize the advantages in speed, precision, repeatability, and
costs of manufacture. Unlike micro-stereolithography, which is only suitable for fabricating
small objects in the micron range, the proposed technology can be used to fabricate larger
objects with dimension in excess of 1 mm with no sacrifice of speed. The fabricated structures
or micro-structures are optically smooth. Table 1 summarizes the advantages and disadvan‐
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No Yes Yes Yes
Resolution Micron range Millimeter range Micron range Micron range
Suitability for mass-
production
No Yes Yes Yes
Table 1. Comparison between different 3D micro-fabrication technologies.
6. SU-8 combined with a UV-blocking impurity
Figure 1. (a) A cross-sectional view showing that SU-8 mixed with a UV-opaque impurity is exposed to ultraviolet
light. The gray region represents the UV-exposed area where cross-linking of SU-8 monomers occurs and (b) a cross-
sectional view showing that the UV-exposed structure from Figure 1a is subjected to heat. The uncured SU-8 resin
melts into a liquid because of the elevated temperature.
Standard SU-8 fabrication processes normally require a UV-transparent SU-8 [14–17] to
proceed. To start fabricating a micro-structure with shells or suspended layers, however, we
need a custom-made SU-8 monomer. This SU-8/impurity composite essentially contains a
mixture of an SU-8 monomer and a UV-opaque impurity. The UV-opaque impurity is an
organic chemical compound satisfying the following criteria: i) it must be opaque to UV lights,
ii) it must be highly soluble in SU-8, and iii) it must be substantially non-adhesive. Our
experimental results suggest store-bought plasticines or synthetic rubber Blu-TackTM can be
used as an example of the UV-opaque impurities in the proposed process. In this study, Blu-
Tack plasticine is the UV-opaque impurity added to the SU-8 to increase its UV opacity. The
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ratio of SU-8 to Blu-Tack is 5:3 by volume. The mixture is then baked at 110°C for 4 hours to
evaporate off the majority of the solvent (i.e. GBL).
Before exposure to any UV light, it is essential to ensure that the SU-8/impurity composite can
be reshaped upon heating and retain its chemical properties after cooling down. However,
when this SU-8/impurity composite is exposed to a UV light, as shown in Figure 1a, only the
surface exposed on which the ultraviolet light has shone to can be polymerized into in a thin
layer. The thickness of this layer can be changed by changing the duration of the UV exposure.
In general, the longer the UV exposure, the thicker this layer will be.
Since the UV light cannot reach the SU-8/impurity composite underneath the UV exposed
surface, the SU-8/impurity composite underneath the UV-exposed surface will remain
uncured. The heat then applied to this experimental setup will melt this uncured SU-8/
impurity composite into a liquid, as illustrated in Figure 1b. Since the removed SU-8/impurity
composite removed remains photo-curable, it can be reused to fabricate other hollow parts.
7. Fabrication of an embossing stamp
Another key element for mass production of micro-structures is an embossing stamp, as shown
in Figure 2e. The embossing stamp serves as a patterned template for casting the desired 3D
patterns on the surface of the SU-8/impurity composite. A variety of methods can be used to
fabricate this embossing stamp. If the 3D features to be formed have many complicated
contours, then gray tone lithography or micro-stereolithography [1–4] should be used. If the
3D patterns to be formed are just a combination of several arbitrarily profiled sidewalls, then
the method illustrated in [5,7,18] may be adopted.
8. Casting of three-dimensional micro-structures and formation of
suspended or hollow parts
Once the embossing stamp and the SU-8/impurity are available, we can proceed to replicate
the desired 3D micro-structures and fabricate suspended and hollow parts. This process is
illustrated in Figure 2a–h.
In step 1, as shown in Figure 2a, several height-defining blocks of equal height are fabricated
onto the corners of the wafer. These height-defining blocks are used to ensure the SU-8
monomer to be deposited on the wafer becomes even and accurate in thickness.
In step 2, as shown in Figure 2b, the SU-8/impurity composite is deposited onto the surface of
the substrate until its thickness slightly exceeds the height of the height-defining blocks. The
wafer is then heated so that its temperature is slightly above about 70–80°C. The SU-8/impurity
composite is heated at this temperature for a prolonged period until the SU-8/impurity
composite is void of any solvent.




In step 3, as shown in Figure 2c, the top surface of the SU-8/impurity is pressurized and ironed
flat with a glass slice. Then, the heat source is removed.
In step 4, as shown in Figure 2d, patterns defining the hollow or suspended regions are
metalized. This metallization process can be carried out by painting with metal ink followed
by etching. The purpose of this step is to create an embedded mask which allows selective UV
exposure in the later step. After the UV exposure step, the embedded mask created in this step
will become a sacrificial layer to be removed in the final step.
In step 5, as shown in Figure 2e, the embossing stamp fabricated in the previous stage is
manually aligned with a mask-aligner and pressed downwards slowly. This step not only casts
the conical pattern on the right of Figure 2e, but it also forms hemispherical solids by pressing
the metal layers downwards. Since the top surface of the semi-molten SU-8/impurity compo‐
site has its own surface tension, this step will ensure that a smooth surface with a spherical
profile is formed on the top of the hemispherical package.
In step 6, as shown in Figure 2f, the embossing stamp is removed from the wafer. The wafer
is then cooled down for about 3 hours until the 3D patterns on the SU-8/impurity composite
become fully solidified. This step further eliminates the surface adhesion on the top of the
wafer.
In step 7, as shown in Figure 2g, areas requiring hollow or suspended parts are selectively
exposed to a UV light. This step can be realized by two methods. We can expose the wafer to
an ordinary UV light through a photomask that defines the patterns of hollow or suspended
parts. Since the SU-8/impurity composite has been mixed with a UV-opaque impurity, the UV-
exposed surface of the SU-8/impurity composite can be polymerized into a polymeric layer.
This polymeric layer can be easily thickened by increasing the duration of the UV exposure.
This polymeric layer can be as thin as a membrane or as thick as the application demands. The
SU-8/impurity underneath the UV-exposed surface will remain uncured and become remov‐
able by melting.
In step 8, as shown in Figure 2h, the wafer is baked at 110°C. This heat temperature not only
hardens the polymerized surface from step 7 but also melts the uncured SU-8/impurity mixture
underneath the UV-exposed surface, into a liquid. Traces of the SU-8/impurity not removable
by melting can be further removed by developing in an appropriate SU-8 developer.
The fabricated component on the top left corner of Figure 2h is a hemispherical package used
to protect RF-MEMS devices against humidity. This hemispherical package has been glued
onto a metallic washer which serves as a radiofrequency ground for a radiofrequency-printed
circuit board. The package is intended to be capped on the substrate of a printed circuit board
on which the RF-MEMS devices are mounted. The interface between the hemispherical
package and the substrate can be further sealed with PDMS.
The fabricated component on the top middle Figure 2h is a spherical hollow object with a
diameter equal to approximately 500 μm. It is realized by gluing together two hemispherical
shell elements fabricated using the same process as illustrated in Figure 2a–h. Gluing the two
hemispherical shell elements together involves manual alignment under a microscope.
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The component in the top right corner of Figure 2h is a conical funnel with base diameter equal
to approximately 50 μm.
Figure 2. (a–h) Cross-sectional view illustrating the process flow of the technology for fabricating hollow or suspended
micro-structures.




9. Fabricating devices for drug delivery applications
Over the past decades, there has been no shortage of interest in nano- or micro-fabrication in
the field of drug delivery. Among all drug delivery devices, micro-needles appear to be the
most popular apparatus in terms of the number of papers that have been published over the
past three decades. With the above fabrication technique, fabricating a micro-needle or similar
devices would be as easy as brewing coffee. Formation of hollow objects at micro-scale is
undoubtedly one of known challenges in the field of micro-fabrication, especially polymer
micro-fabrication. The following sections demonstrate how the previously developed techni‐
ques [14–19] can be employed for realization of conical micro-funnels for drug delivery
applications. As explained in the previous sections, our fabrication methodology is based
purely on photo-lithography.
In step 1, as shown in Figure 3a, we need to prepare a pre-cured SU-8 which is UV opaque. A
standard SU-8 monomer resin is first mixed with a UV-opaque impurity at an elevated
temperature until the final mixture becomes almost opaque in the UV spectrum. This UV-
opaque impurity can be an appropriate plasticine that is opaque to UV lights and does not
form any complex in SU-8. In addition, this UV-opaque SU-8 resin will have to undergo a
prolonged dehydration bake to increase its viscosity and to decrease its surface adhesion. The
wafer of this pre-cured SU-8 will be maintained at an elevated temperature (preferably slightly
above the glass transition temperature) so that this UV-opaque SU-8 resin becomes partially
molten and its upper surface becomes non-adhesive. In so doing, this UV-opaque SU-8 resin
should be able to be reshaped upon heating without excessive change in its physical and
chemical properties.
In step 2, as shown in Figure 3b, we need to fabricate an embossing stamp which is basically
a master mold having an array of cylindrical rods. This embossing stamp will be used as a
patterned template for casting of the inverted conical patterns on the surface of the UV-opaque
SU-8 from step 1. A variety of methods can be employed to fabricate this embossing stamp. In
the present study, an embossing stamp with high aspect ratio micro-rods was fabricated using
a high-quality standard UV-lithographic process but high aspect ratio is not really a pre-
requisite in the present application.
In step 3, as shown in Figure 3c, the upper surface of the UV-opaque SU-8 resin from step 1 is
physically deformed by a mechanical impact produced by the embossing stamp moving
downwards at high speed. At the same time, the wafer temperature is tuned down. As a result
of this impact, an array of micro-conical wells will be 3D cast on the upper surface of the UV-
opaque SU-8. It is important to understand that the stroke speed of stamping will determine
the sharpness of the tip of each conical well and the surface profile of the inner wall. In general,
if the stroke speed is higher, the sharp tip of each conical well will accordingly become sharper.
In step 5, as shown in Figure 3d, the embossing stamp is removed from the wafer while the
wafer is being cooled down. Following this cooling step, the conical micro-wells will become
highly solidified.
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Figure 3. Cross-sectional illustration of the procedure for fabrication of a micro-funnel. (a) A wafer containing a bath of
UV-opaque highly dehydrated SU-8 resin. (b) Cross-sectional view that illustrates the embossing stamp with micro-
rods. The diameter of each micro-rod is 40 μm. The length of each micro-rod is 200 μm. (c) Casting of micro-wells by
surface deformation using the embossing stamp. (d) Removal of the embossing stamp from the wafer. (e) UV expo‐
sure. (f) Removal of uncured SU-8 resin by melting at an elevated temperature.
In step 4, as shown in Figure 3e, the shell of each micro-funnel is formed and thickened by
increasing the dosage of UV exposure. The micro-well patterns on the wafer can be photo-
lithographically defined, patterned, and exposed to a UV light using a photomask. Since the
SU-8 resin in the wafer contains a UV-opaque impurity, the micro-wells become partially
transparent at ultraviolet spectrum. In the presence of the UV-opaque impurity, the interior




surface of each micro-well is the only region fully exposed to the UV lights. The SU-8 resin
attached to the opposite side of the UV-exposed surface will be partially cured. As a result, the
interior surface of each micro-well will be polymerized into a hard and thick layer. The
thickness of this polymeric layer can be easily increased by increasing the duration of the UV
exposure. In general, this polymeric layer can be as thin as a membrane or as thick as the
application demands, depending on the duration of UV exposure.
In step 5, the uncured UV-opaque SU-8 resin attached to each of the micro-well is removed
from the micro-well by melting at an elevated temperature. The SU-8 resin attached to the
opposite side of the UV-exposed surface will remain uncured and melted into a liquid when
the wafer is subjected to a strong heat. As a result of this heat, the UV-exposed surface will be
significantly hardened. Traces of the uncured photosensitive resin which remain attached to
the micro-well array can be stripped off by developing in 1-methoxy-2-propanol acetate.
In step 6, a hole is formed on the tip of each conical micro-well by dry etching. This step is
intended to turn each conical micro-well into a micro-funnel. A hole can be formed on the tip
of each conical micro-well by dry-etching the wafer in oxygen plasma for 100 seconds using a
Trion RIE/PECVD tool. The oxygen plasma also sharpens the tip of each micro funnel during
the dry etching process. In the present study, the process parameters were 90% O2, 10% CF4,
an RF power of 100 w, and a chamber pressure of 1.6 Torr.
10. Results and discussions
Figure 4 shows one of the micro-funnels which have been fabricated using the abovementioned
method. The micro-funnels were designed to have a sharp tip and wide top, that is a low aspect
ratio geometry. This design allows a larger amount of drug to be encapsulated per micro-
funnel. The conical geometry used in this study had a volume in excess of 24.4 nl. In addition,
the micro-funnels were found to have sufficient mechanical strength for inserting into the
Figure 4. Photo illustrating a fabricated micro-funnel.
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human skin. The smallest tip diameter which has been achieved in this study is within 50 μm,
which is sharp enough to pierce the human skin.
The proposed fabrication methodology can be further improved and extended to realize other
more complicated systems involving 3D micro-structures.
11. Conclusion
For the first time, this article has presented a method that enables concave or convex micro-
structures with shells elements or hollow space to be photo-lithographically fabricated. The
method comprises four basic stages. The first stage involves preparation of a composite
containing a mixture of SU-8 monomer and a UV-opaque impurity. The second stage involves
fabrication of an embossing stamp for casting the desired 3D patterns. In the third stage, the
desired 3D hollow or suspended micro-structures are cast using the embossing stamp. In the
final stage, features requiring with suspended or hollow parts are selectively polymerized by
UV exposure. The concepts of this technology have been demonstrated by fabrication of
prototypes.
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Abstract
Complementary metal oxide semiconductor (CMOS) technology allows the functional
integration of sensors, signal conditioning, processing circuits and development of fully
electronic integrated lab‐on‐a‐chip. On the other hand, lab‐on‐a‐chip is a technology which
changed the traditional way by which biological samples are inspected and tested in
laboratories. A lab‐on‐a‐chip consists of four main parts: sensing, actuation, readout circuit
and microfluidic chamber. Lab‐on‐a‐chip gives the promise of many advantages including
better and improved performance, reliability, portability and cost reduction. This chapter
reviews the currently used lab‐on‐a‐chips based on CMOS technology. Also, this chapter
presents and discusses the features of the existing CMOS based lab‐on‐a‐chips and their
applications at the cell level.
Keywords: lab‐on‐a‐chip, biochips, biological cells, CMOS technology, integrated sen‐
sors
1. Introduction
Integration and miniaturization are the two main factors in the device engineering research,
and these two factors are also the main features of the lab‐on‐a‐chip technology. The main
contributor for this major trend is the fast advances of integrated circuit (IC) technology. As a
result of miniaturization, portable and cheaper equipment replaced the traditional bulky and
expensive equipment.
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
In the field of cell biology, the use of micro‐ and nano‐fabricated lab‐on‐a‐chip using active
substrates and integrated sensors [1] is still at experimental stage. In order to replace traditional
optical inspection techniques, these techniques have been tested for the identification of objects
at microscopic level to envision several applications [2].
Many research groups believe that lab‐on‐a‐chip technology will be the major contributor to
novel diagnostic tools. The target of these research groups is to have lab‐on‐a‐chip systems
that will allow healthcare suppliers and workers in poorly equipped clinics to do different tests
which need more sophisticated equipment in a simpler way, for example, nucleic acid assays
and immunoassays tests [3]. Thus, lab‐on‐a‐chip innovation is a vital part of the endeavors to
upgrade and enhance worldwide healthcare system, especially through the advancement of
clinics and laboratories’ testing techniques [4].
One dynamic area of lab‐on‐a‐chip research includes approaches to analyze and oversee HIV
infections. In view of UNAIDS 2014 report [5], more than 40 million individuals are tainted
with HIV around the world; 13 million of these individuals get hostile to retroviral treatment.
Around 55% of individuals with HIV have never been tested for the infection [5].
Measuring the quantity of CD4+ T lymphocytes in a man’s blood is an exact and right approach
to figure out whether a man has HIV and to track the advancement of a HIV contamination.
Right now, flow cytometry is the brilliant standard for acquiring CD4 checks; yet, flow
cytometry is a confounded method that is not accessible in most developing regions since it
requires prepared professionals and costly instruments [6, 7].
The vicinity of the complementary metal oxide semiconductor (CMOS) technology allows the
integration of sensors, amplifiers, filters and other circuitry on a single chip. Also, CMOS
technology leads to a totally electronic integrated lab‐on‐a‐chip utilizing a homogenous
technology [8, 9]. CMOS is an innovation used in building integrated circuits. It is used in
microcontrollers, static RAM, registers, microchips and other digital circuits. CMOS technol‐
ogy is utilized also for a wide assortment of analog circuits, for example, image sensors,
amplifiers, analog to digital converters, and transceivers for communication modules. Low
static power consumption and high noise immunity are two advantages of CMOS devices [10].
Numerous specialists and research teams have begun to utilize the CMOS technology in lab‐
on‐a‐chip applications [11, 12]. These applications incorporate, yet not restricted to, identifi‐
cation of neurons’ activities, microorganism discovery and portrayal, electric field imaging,
flow cytometry and polymerase chain reaction (PCR) applications [13–17].
This chapter covers and presents the state of the art in CMOS circuits and systems for lab‐on‐
a‐chip applications. It summarizes and reviews different circuits and systems of CMOS‐based
lab‐on‐a‐chip technology at the cell level. These circuits and systems include: polymerase chain
reaction (PCR), microorganism detection and characterization, neuronal activity detection,
flow cytometry and electric field imaging applications.
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2. Lab‐on‐a‐chip based on CMOS technology
2.1. Polymerase chain reaction (PCR)
CMOS‐based lab‐on‐a‐chip has numerous applications in the science and biomedical fields. It
is likewise utilized as a part of numerous different fields, for example, environmental appli‐
cations. In medicine, lab‐on‐a‐chip can be utilized as a part of real‐time polymerase chain
reaction (PCR) applications to identify bacteria, viruses and cancers [18, 19]. PCR is a bio‐
chemical technology in molecular biology to duplicate one or few DNA pieces, creating
thousands to a huge number of duplicates of a specific DNA sequence [20].
The incredible preference about PCR is in the snappy and specific enhancements of target
qualities through a cyclic and enzyme‐catalyzed [21]. PCR procedures have been connected to
mutation analysis and DNA [18, 19, 21]. As of late, Norian et al. [22] displayed an ongoing PCR
lab‐on‐a‐chip that was implemented using 0.35 μm CMOS technology. It performs electro‐
wetting droplet‐based transport, reagent heating, temperature sensing and integrated
fluorescence measurements.
Figure 1 demonstrates the 4 × 4mm chip. It has a 7 × 8 array of 200 × 200 μm electrodes [22].
Using electrowetting‐on‐dielectric transport technique, each droplet can be dislodged [23]. The
three temperature zones on the top of the chip are managed by a heater and temperature
sensors. Based on this PCR lab‐on‐a‐chip, a droplet can be allocated at a thermal cycled area
on the chip. Also, a thermal equilibrium can be obtained in a 500 ms at most, if a droplet's
volume is under 1nL. Likewise, fluorescent measurement using integrated Geiger‐mode
single‐photon avalanche photodiodes (SPADs) allows for sensitive fluorescent detection.
Figures 2 and 3 show the on‐chip thermal regulation and PCR thermal cycling on chip,
respectively.
Figure 1. PCR Chip [22].
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Figure 2. On‐chip thermal regulation. (a) Layout of metal‐resistor temperature sensors; (b) layout of polysilicon heat‐
ers; (c) cross‐sectional COMSOL simulation; (d) IR image displays distinct temperature region generated by a single
polysilicon heater [22].
Figure 3. PCR thermal cycling on chip. (a) Fluorescence measurements for Staphylococcus aureus target; (b) on‐chip tem‐
perature profile [22].
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Figure 2. On‐chip thermal regulation. (a) Layout of metal‐resistor temperature sensors; (b) layout of polysilicon heat‐
ers; (c) cross‐sectional COMSOL simulation; (d) IR image displays distinct temperature region generated by a single
polysilicon heater [22].
Figure 3. PCR thermal cycling on chip. (a) Fluorescence measurements for Staphylococcus aureus target; (b) on‐chip tem‐
perature profile [22].
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2.2. Dielectrophoresis (DEP)
Lab‐on‐a‐chip based on CMOS technology is utilized as a part of biochemical tests, where it is
utilized to quantify the presence of a target element which can be a biochemical substance or
a medication or a cell in a sample [24]. Diverse range of uses is the dielectrophoresis applica‐
tions where CMOS‐based lab‐on a‐chip is utilized to recognize microbes, bacteria and cancer
cells [14].
Figure 4. The lab‐on‐a‐chip architecture for cells manipulation and sensing [25].
Manaresi et al. [25, 26] proposed a CMOS lab‐on‐a‐chip for cell control and identification. The
proposed lab‐on‐a‐chip is fabricated on a standard 0.35 μm CMOS technology. This CMOS
lab‐on‐a‐chip comprises three principle parts, they are: actuation, sensing and microfluidic
package. The lab‐on‐a‐chip framework, see Figure 4, has two‐dimensional array of microsites;
these microsites provide the following functions: (1) produce the electric field which is
important to make dielectrophoretic cages and (2) optically sense the existence of a single
particle or cluster on the top of the microsite. Each microsite comprises of an actuation
electrode, executed with a top metal plate, and underneath embedded circuitry for program‐
ming and identification. Row and column decoders can address any microsite in a random
access mode, for both actuation and sensing. Particles are detected by photodiodes, embedded
in the substrate that measure signal variations from uniform light impinging on the chip
surface. Recently, Miled et al. presented a CMOS‐based lab‐on‐chip system for dielectropho‐
resis‐based cell manipulation and detection [27]. The lab‐on‐a‐chip based on CMOS technology
is fabricated utilizing a CMOS full‐custom chip and a microfluidic chamber. The CMOS chip
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is used to pass on all parameters required to control the dielectrophoresis (DEP) parameters,
for instance, electric field intensity, speed of the field and the profile of the electric field applied
on the lab‐on‐a‐chip.
2.3. Flow cytometry
Flow cytometry applications are implemented using CMOS‐based lab‐on‐a‐chip. In flow
cytometry, fluorescence markers are used to tag either biological cells or single particle that is
immersed in an aqueous media. These cells are hydrodynamically focused and made to
traverse a small region of space across which a focused laser beam is used [28].
The input laser light will be scattered and/or fluorescence produced light will be released when
a cell passes on a light source. These optical signs provided by the particles will be aggregated
as spectral components of predominantly visible light. Utilizing optical multipliers and other
light instrumentation, the obtained signals can be utilized to recognize and evaluate the
biochemical or biophysical attributes of the cell sample.
Hartley et al. introduced a CMOS‐based platform for microfluidic cytometry, where optical
image detecting is incorporated on the microfluidic substrate. The stage is using flip‐chip
bundling innovation. Figure 5 shows a schematic diagram of the general flip‐chip digital
cytometry [29].
Figure 5. Photograph of the linear active pixel CMOS sensor chip with interface pads, digital logic block and analog
signal path indicated [29].
As of late, Dupont et al. displayed a lab‐on‐a‐chip that was manufactured based on silicon
involving a framework of 84 diodes, i.e., single photon avalanche diodes (SPADs), to
distinguish and separate fluorescently labeled single cells and fluorescent beads in a
polydimethylsiloxane (PDMS) cartridge that is situated on the CMOS chip [30]. The
identification depends on the diverse photon tally when either a fluorescent or a non‐
fluorescent bead or cell is available over a SPAD, because of the extra photons radiated from
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a fluorescent item. This strategy permits magnifying instrument‐less fluorescence recognition
and allows simple trade of the expendable microfluidic cartridge [30, 31].
2.4. Neuronal activity monitoring
Neurons are biological cells specialized in transmission and processing of information [32].
The basic neural signals are action potentials, which are transient changes of the voltage drop
across the cell membrane with a typical and defined shape.
The action potential is typically 70 mV peak‐to‐peak. Today’s standard devices utilized to
measure the action potential are patch pipettes [32] or microelectrodes [33]. These apparatuses
have prompted awesome change in the field of neural cell observing. Though, these strategies
face downsides, for example, they require an elaborate mechanical setup, which permits
observing not many cells in parallel as it were. Along these lines, they are for the most part not
suitable to satisfy high‐throughput prerequisites. Additionally, long‐time recording is not
feasible, because of the intrusive sort of contact, decreasing the life time of the cell.
Figure 6. Architecture of sensor array with complete system [34].
Noninvasive (extracellular) recording techniques open a way to overcome these drawbacks
[34–36].
In extracellular recording strategy, cells are refined straightforwardly on top of a transducing
component, which is for the most part either a metallic cathode or a floating gate transistor [34,
35]. At the point when an action potential happens in a cell, the nearby stream of particles all
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through the cell causes the membrane to be polarized in a non‐uniform way. The ionic current
streams over the cleft resistance and sets up an electric field which prompts electrical charge
in the fundamental transducer, which is the recorded signal.
Eversmann et al. proposed a CMOS lab‐on‐a‐chip for non‐invasive recording and detection of
neuronal activity [34, 35]. Figure 6 shows the system setup and chip architecture. Heer et al.
[37] presented a CMOS lab‐on‐a‐chip for bidirectional communication (stimulation and
recording). Figure 7 shows a picture of the CMOS lab‐on‐a‐chip. Figure 8 shows a schematic
of the overall system.
Figure 7. Micrograph of the chip [37].
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Figure 8. Block schematic of the overall system architecture [37].
Recently, Rothberg et al. [38] presented a CMOS sensor chip which can be used to harbor
neurons and glial cells in vitro. The CMOS chip incorporates a vast cluster of sensor compo‐
nents, each with a single floating gate connected to an underlying ion‐sensitive field‐effect
transistor (ISFET), to gauge the pH [39].
2.5. Electric field imager
Ghallab et al. [12, 40] presented a CMOS‐based lab‐on‐a‐chip. The used technology is CMOS
180 nm TSMC technology. This lab‐on‐a‐chip is utilized to get electric field images for biocells.
These images depend on the electrical characteristics of the cells which can be utilized to
distinguish between various sorts of cells [12]. Figure 9 shows the die picture; the total die area
is 0.75 × 0.6 mm. The CMOS‐based lab‐on‐a‐chip includes two main parts. They are: (1) the
actuation part, that generates the planned non‐uniform electric field pattern; the actuation part
has four electrodes that generate a DEP force to levitate the cell that should be identified; (2)
the sensing part, which is an array of the differential electric field sensitive field effect transistor
(DeFET) sensor [12, 40, 41].
2.5.1. The actuation part
The actuation electrodes are the quadrupole setup, see Figure 9. Utilizing this arrangement,
the profile of the non‐uniform electric field can be controlled by associating the entire four
electrodes or few of them. Likewise, the quadrupole levitator contains an azimuthally
symmetric electrode arrangement fit for supporting passive stable molecule levitation [42].
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Figure 9. The Die picture shows the quadrupole electrodes and the DeFET sensors [42].
2.5.2. The sensing part
The sensing part is made out of an array of DeFETs. This array is situated around the center
of the chip, where the cell is levitated (suspended). In DEP levitation, the controlling electric
field is a non‐uniform electric field. Consequently, we can recognize the electric field by
utilizing the electric field sensitive field effect transistor [eFET] as an electric field sensor.
Figure 10. Physical structure of an eFET [12, 42].
Figure 10 demonstrates the physical structure of the eFET. It comprises of two neighboring
drains, two nearby floating gates with separation space “d” between the two floating gates,
and one source.
For the eFET, it is proportionate to two indistinguishable enhancement MOSFET transistors.
Affected by the non‐uniform electric field, different current passes through each drain. Because
of the drain current reliance on the gate voltage, the eFET can sense the difference between the
two gate voltages, which mirrors the magnitude of the used non‐uniform electric field. To
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increase the measurement range of the eFET, CMOS technology is used to implement the
differential electric field sensitive field effect transistor (DeFET) sensor, and this sensor will be
the basic sensor in the sensing part of the proposed electric field imager [40–42].
2.5.3. DeFET sensor
The DeFET consists of two complementary eFETs, one is a P eFET and the second one is an N
eFET [12, 42]. The equivalent circuit of the DeFET is shown in Figure 11.
Figure 11. An equivalent circuit of a DeFET [12], the two gates of P eFET and N eFET are connected with each other,
and there is a cross coupling between the two drains of the P eFET and the N eFET. The output current IOut is equal to
the difference between the two drain currents Ip − In (i.e., IOut = Ip − In,). Ip and In are functions of the two applied gate
voltages Vin1 and Vin2, respectively.
The DeFET is intended to accomplish a voltage VOut, specifically identified with the difference
between the two gate voltages (Vin1 − Vin2), and Vin1 − Vin2 is equivalent to the generated electric
field over the two gates (E) (E) multiplied by the distance between them (Vin1 − Vin2/Y = E),
where Y is the distance between the two split gates, which is constant. Thus, VOut is related
straightforwardly to the non‐uniform electric field's intensity. In this way by measuring VOut,
the non‐uniform electric field intensity can be obtained.
To extract an expression that relates VOut and E, and from Figure 11, the output current (Iout)
is:
out p nI I I= - (1)
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where gm is the transconductances of the transistors M2 and M4, which have equal gm and Y
is the distance between the two gates.
From (2)
out ConstantI SE= + (3)
The output voltage (Vout) can be expressed in terms of the sensitivity and the electric field:
out out L L UniV I R SE R V= = + (4)
where Vuni is the output voltage due to a uniform electric field (i.e., Vin1 = Vin2), and RL is the
load resistance. From (2) into (4)
m Lo Uni
V g Y R E V= + (5)
From equation (5), it can be observed that Vo is related linearly to the intensity of the non‐
uniform electric field generated on the top of the DeFET sensor. Thus, in an array form of
DeFET sensors, an image related to the electric field intensity at different locations can be
extracted.
2.5.4. Experimental results
The CMOS electric field imager is experimentally examined with micro‐beads having a relative
permittivity of 2.5 and radius of 4.5 and 10.45 μm, respectively. The experiment was done in
two steps. First, the chip is tested on air. Second, it is tested with micro‐beads suspended on
medium. This CMOS electric field imager allows sensing the impact of the cells on the electric
field intensity profile.
Figures 12 and 13 show sample of the results. The configuration used is as follows: (1) a 3V
sinusoidal signal with 3 MHz frequency is connected to Electrode 2 and Electrode 4, see
Figure 9; (2) an out of phase (−3V) sinusoidal signal with 3 MHz is connected to Electrode 1
and Electrode 3. The cells were suspended in de‐ionized water with a measured conductivity
between 1.3 and 1.9 μs/cm. A microscope with digital camera is used to observe the particles
from the top.
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Figure 12. Levitated polystyrene cell with diameter 8.9 μm [42].
Figure 13. Levitated polystyrene cell with diameter 20.9 μm [42].
Figures 12 and 13 demonstrate a trapped cell not long after the electric field is turned on, simply
over the center of the imager. The levitated/trapped cell shows up out of focus of the micro‐
scope's focal length [42]. Figure 14 shows the measured output voltage from the DeFET sensor
numbers 1, 4, 7 and 10, in air and after adding the suspending fluid, which contains 4.5 and
10.5 μm radius polystyrene microspheres. From this figure, it can be noticed that DeFETs 4
and 7 show lower readings compared with DeFETs 1 and 10. Also, note from Figure 14 that
for the cells with 20.9 μm diameters, DeFETs 1, 4 and 10 provide high readings, while DeFET
7 does not. Leading to the surmise that there are cells above 1, 4, and 10, but no cells above
DeFET 7 [42].
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Figure 14. The DeFET sensors’ response in air and in fluid contains different cell size [42].
3. Conclusion
In this chapter, up‐to‐date, advances in CMOS circuits and systems based lab‐on‐a‐chip are
provided and discussed. Additionally, distinctive applications of CMOS lab‐on‐a‐chip are
presented. CMOS‐based lab‐on‐a‐chip guarantees many advantages to be provided to the
biology and medicine fields. These advantages are portability, disposability and miniaturiza‐
tion. Also, these advantages allow scientists to do complex experiments anywhere with
portable devices. However, until now, there is an unmet need for lab‐on‐a‐chip to effectively
deal with the biological systems at the cell level.
Acknowledgements
This research was partially funded by Zewail City of Science and Technology, AUC, the STDF,
Intel, SRC, Mentor Graphics, ASRT and MCIT.
Author details
Yehya H. Ghallab1,2* and Yehea Ismail2*
*Address all correspondence to: yghallab@zewailcity.edu.eg and yismail@zewailcity.edu.eg
Lab-on-a-Chip Fabrication and Application30
Figure 14. The DeFET sensors’ response in air and in fluid contains different cell size [42].
3. Conclusion
In this chapter, up‐to‐date, advances in CMOS circuits and systems based lab‐on‐a‐chip are
provided and discussed. Additionally, distinctive applications of CMOS lab‐on‐a‐chip are
presented. CMOS‐based lab‐on‐a‐chip guarantees many advantages to be provided to the
biology and medicine fields. These advantages are portability, disposability and miniaturiza‐
tion. Also, these advantages allow scientists to do complex experiments anywhere with
portable devices. However, until now, there is an unmet need for lab‐on‐a‐chip to effectively
deal with the biological systems at the cell level.
Acknowledgements
This research was partially funded by Zewail City of Science and Technology, AUC, the STDF,
Intel, SRC, Mentor Graphics, ASRT and MCIT.
Author details
Yehya H. Ghallab1,2* and Yehea Ismail2*
*Address all correspondence to: yghallab@zewailcity.edu.eg and yismail@zewailcity.edu.eg
Lab-on-a-Chip Fabrication and Application30
1 Department of Biomedical Engineering, Helwan University, Cairo, Egypt
2 Centre of Nanoelectronics and Devices (CND) at Zewail City of Science and Technology/
American University in Cairo, Cairo, Egypt
References
[1] Huang Y. et al. Lab‐on‐CMOS integration of microfluidics and electrochemical sensors.
Lab Chip. 2013; 13: 3929–3934. DOI: 10.1039/C3LC50437A
[2] Huang C, Huang Y, Yen P, Tsai H, Liao H, Juang Y, Lu S, Lin C. A CMOS wireless
biomolecular sensing system‐on‐chip based on polysilicon nanowire technology. Lab
Chip. 2013; 13: 4451–4459. DOI: 10.1039/C3LC50798J
[3] Jackson S, Cole D. Graduate global public health education: activities and outcomes in
relation to student prior experience. Global Journal of Health Science; 2013; 5:54–63
DOI: 10.3402/gha.v7.24526
[4] Yager P, Edwards T, Fu E, Helton K, Nelson K, Tam M, Weigl B. Microfluidic diagnostic
technologies for global public health. Nature. 2006; 442: 412–418. DOI:10.1038/
nature05064
[5] UNAIDS Report 2014, http://www.unaids.org/en available on line [internet]
[6] Pratt G. et al. Monitoring HIV drug adherence with a paper‐based assay. IEEE Point‐
of‐Care Healthcare Technologies (PHT): IEEE; 2013; 69–71
[7] Craig I, Xiaohua X. Can HIV/AIDS be controlled? Applying control engineering
concepts outside traditional fields. IEEE Magazine for Control Systems. 2005; 25: 80–
83. DOI: 10.1109/MCS.2005.1388805
[8] Welch D, Blain Christen J. Seamless integration of CMOS and microfluidics using flip
chip bonding. Journal of Micromechanics and Microengineering, 2013; 23.035009
[9] Mudanyal O. et al. Wide‐field optical detection of nanoparticles using on‐chip micro‐
scopy and self‐assembled nanolenses. Nature Photonics. 2013; 7: 247–254. DOI: 10.1038
[10] Adam T. et al. Nano lab‐on‐chip systems for biomedical and environmental monitor‐
ing. African Journal of Biotechnology. 2013; 12: 5486–5495. DOI: 10.5897/AJB11.3826
[11] Ghallab Y H, Ismail Y. CMOS based lab‐on‐a‐chip: applications, challenges and future
trends. IEEE Circuit and Systems Magazine.2014; Q2: 27–47.
[12] Ghallab Y H, Badawy W. Lab‐on‐a‐Chip: Techniques, Circuits and Biomedical Appli‐
cations. Artech House Publisher, USA, 2010. ISBN: 978‐1‐59693‐418‐4.
CMOS Circuits and Systems for Lab‐on‐a‐Chip Applications
http://dx.doi.org/10.5772/63303
31
[13] Gulari M N, Ghannad‐rezaie M, and Chronis N. “A compact, optofluidic system for
measuring red blood cell concentration”, IEEE conference on Solid‐ State Sensors,
Actuators and Microsystems. 2013; 2552–2555.
[14] Amine M. et al. Dielectrophoresis‐based integrated lab‐on‐chip for nano and micro‐
particles manipulation and capacitive detection. IEEE Transactions on Biomedical
Circuits and Systems. 2012; 6: 120–132. DOI: 10.1109/TBCAS.2012.2185844
[15] Esfandyarpour R. et al. Simulation and fabrication of a new novel 3D injectable
biosensor for high throughput genomics and proteomics in a lab‐on‐a‐chip device.
Nanotechnology; 2013; 24, DOI: 10.1088/0957‐4484/24/46/465301
[16] Adam T. et al. Nano lab‐on‐chip systems for biomedical and environmental monitor‐
ing. African Journal of Biotechnology. 2013; 12: 5486–5495. DOI: 10.5897/AJB11.3826
[17] Huang Y. et al. Lab‐on‐CMOS integration of microfluidics and electrochemical sensors.
Lab Chip. 2013; 13: 3929–3934. DOI: 10.1039/C3LC50437A
[18] Alrifaiy A. et al. Polymer‐based microfluidic devices for pharmacy, biology and tissue
engineering. Polymers; 2012: 4, 1349–1398. DOI: 10.3390/polym4031349
[19] Park D. et al. Titer plate formatted continuous flow thermal reactors for high through‐
put applications: fabrication and testing. Journal of Micromechanics and Microengin‐
eering; 2010: 20,291–300 DOI:10.1088/0960
[20] Myong J. et al. Detection of bacterial pathogen DNA using an Integrated complemen‐
tary metal oxide semiconductor microchip system with capillary array electrophoresis.
Journal of Chromatography B. 2003; 783: 501–508. DOI: 1570‐0232/02
[21] Cheng S. et al. Effective amplification of long targets from cloned inserts and human
genomic DNA. PNAS. 1994; 91: 5695–5699.
[22] Norian H. et al. Integrated CMOS quantitative polymerase chain reaction lab‐on‐chip.
Symposium on VLSI Circuits (VLSIC).2013. IEEE>. C220–C221.
[23] Lee J. et al. Electrowetting and Dielectrowetting‐on‐dielectric for microscale liquid
handling. Sensors and Actuators A. 2002; 95: 259–268. DOI: 10.1016/S0924‐
4247(01)00734‐8
[24] Sawan M. et al. Cmos/microfluidic lab on‐ chip for cells‐based diagnostic tools.
Engineering in Medicine and Biology Society (EMBC), 2010 Annual International
Conference of the IEEE, 2010. IEEE. 5334–5337.
[25] Medoro G. et al. Lab on a chip for live‐cell manipulation. IEEE Design & Test of
Computers. 2007; 24: 26–36. DOI: 10.1109/MDT.2007.21
[26] Manaresi N. et al. A CMOS chip for individual cell manipulation and detection. IEEE
Journal of Solid State Circuits. 2003; 38: 2297–2305. DOI: 10.1109/JSSC.2003.819171
Lab-on-a-Chip Fabrication and Application32
[13] Gulari M N, Ghannad‐rezaie M, and Chronis N. “A compact, optofluidic system for
measuring red blood cell concentration”, IEEE conference on Solid‐ State Sensors,
Actuators and Microsystems. 2013; 2552–2555.
[14] Amine M. et al. Dielectrophoresis‐based integrated lab‐on‐chip for nano and micro‐
particles manipulation and capacitive detection. IEEE Transactions on Biomedical
Circuits and Systems. 2012; 6: 120–132. DOI: 10.1109/TBCAS.2012.2185844
[15] Esfandyarpour R. et al. Simulation and fabrication of a new novel 3D injectable
biosensor for high throughput genomics and proteomics in a lab‐on‐a‐chip device.
Nanotechnology; 2013; 24, DOI: 10.1088/0957‐4484/24/46/465301
[16] Adam T. et al. Nano lab‐on‐chip systems for biomedical and environmental monitor‐
ing. African Journal of Biotechnology. 2013; 12: 5486–5495. DOI: 10.5897/AJB11.3826
[17] Huang Y. et al. Lab‐on‐CMOS integration of microfluidics and electrochemical sensors.
Lab Chip. 2013; 13: 3929–3934. DOI: 10.1039/C3LC50437A
[18] Alrifaiy A. et al. Polymer‐based microfluidic devices for pharmacy, biology and tissue
engineering. Polymers; 2012: 4, 1349–1398. DOI: 10.3390/polym4031349
[19] Park D. et al. Titer plate formatted continuous flow thermal reactors for high through‐
put applications: fabrication and testing. Journal of Micromechanics and Microengin‐
eering; 2010: 20,291–300 DOI:10.1088/0960
[20] Myong J. et al. Detection of bacterial pathogen DNA using an Integrated complemen‐
tary metal oxide semiconductor microchip system with capillary array electrophoresis.
Journal of Chromatography B. 2003; 783: 501–508. DOI: 1570‐0232/02
[21] Cheng S. et al. Effective amplification of long targets from cloned inserts and human
genomic DNA. PNAS. 1994; 91: 5695–5699.
[22] Norian H. et al. Integrated CMOS quantitative polymerase chain reaction lab‐on‐chip.
Symposium on VLSI Circuits (VLSIC).2013. IEEE>. C220–C221.
[23] Lee J. et al. Electrowetting and Dielectrowetting‐on‐dielectric for microscale liquid
handling. Sensors and Actuators A. 2002; 95: 259–268. DOI: 10.1016/S0924‐
4247(01)00734‐8
[24] Sawan M. et al. Cmos/microfluidic lab on‐ chip for cells‐based diagnostic tools.
Engineering in Medicine and Biology Society (EMBC), 2010 Annual International
Conference of the IEEE, 2010. IEEE. 5334–5337.
[25] Medoro G. et al. Lab on a chip for live‐cell manipulation. IEEE Design & Test of
Computers. 2007; 24: 26–36. DOI: 10.1109/MDT.2007.21
[26] Manaresi N. et al. A CMOS chip for individual cell manipulation and detection. IEEE
Journal of Solid State Circuits. 2003; 38: 2297–2305. DOI: 10.1109/JSSC.2003.819171
Lab-on-a-Chip Fabrication and Application32
[27] Amine M. et al. Dielectrophoresis‐based integrated lab‐on‐chip for nano and micro‐
particles manipulation and capacitive detection. IEEE Transactions on Biomedical
Circuits and Systems. 2012; 6: 120–132. DOI: 10.1109/TBCAS.2012.2185844
[28] Wang Z. Measurements of scattered light on a microchip flow cytometer with inte‐
grated polymer based optical elements. Lab. Chip.2004; 4: 372–377. DOI: 0.1039/
b400663a
[29] Hartley L. et al. Hybrid integration of an active pixel sensor and microfluidics for
cytometry on a chip. IEEE Transactions on Circuits and Systems—I. 2007; 54: 99–110.
DOI: 10.1109/TCSI.2006.887456
[30] Duponta E. P. et al. Fluorescent magnetic bead and cell differentiation/counting using
a CMOS SPAD matrix. Sensors and Actuators B. 2012; 174: 609–615. DOI: 10.1016/j.snb.
2012.06.049
[31] Gulari M. N. et al. A compact, optofluidic system for measuring red blood cell concen‐
tration. 2013. IEEE Conference on Solid‐State Sensors, Actuators and Microsystems,
IEEE. 2552–2555.
[32] Nicholls J. G. et al. From Neuron to Brain, 3rd ed. Sinauer Assoc. Inc., Sunderland, 1992.
[33] Purves R. D. Microelectrode Methods for Intracellular Recording and Ionophoresis.
Academic, London, U.K., 1981.
[34] Eversmann B. et al. A 128 x 128 CMOS biosensor array for extracellular recording of
neural activity. IEEE Journal of Solid State Circuits. 2003; 38: 2306–2317. DOI: 10.1109/
JSSC.2003.819174
[35] Eversmann B. et al. CMOS sensor array for electrical imaging of neuronal activity. IEEE
International Symposium on Circuits and Systems (ISCAS 2005), Kobe, Japan. IEEE;
2005, 3479–3482.
[36] Rothberg J. M. et al. An integrated semiconductor device enabling non‐optical genome
sequencing. Nature; 2011: 475 (7356): 348–352. DOI: 10.1038/nature10242
[37] Heer F. et. al. CMOS microelectrode array for bidirectional interaction with neuronal
networks. IEEE Journal of Solid State Circuits; 2006: 41: 1620–1629. DOI: 10.1109/JSSC.
2006.873677
[38] Rothberg J. M. et al. An integrated semiconductor device enabling non‐optical genome
sequencing. Nature; 2011:475 (7356): 348–352. DOI: 10.1038/nature10242
[39] Soea A. K. et al. Neuroscience goes on a chip. Biosensors and Bioelectronics. 2012; 35:
1–13.
[40] Ghallab Y. H., Badawy W. Magnetic Field Imaging Detection Apparatus, US Patent,
2008: 7, 405, 562.
CMOS Circuits and Systems for Lab‐on‐a‐Chip Applications
http://dx.doi.org/10.5772/63303
33
[41] Ghallab Y. H., Abdelhamid H., Ismail Y. Lab‐on‐a‐chip based on CMOS technology:
system architectures, microfluidic packaging and challenges. IEEE Test and Design;
2015: 32: 20–31.
[42] Ghallab Y. H., Badawy W. A single CMOS chip for biocell tracking, levitation, detection,
and characterization. International Symposium on Circuit and System (ISCAS 06),
Greece. IEEE; 2006, 3349–3352.
Lab-on-a-Chip Fabrication and Application34
[41] Ghallab Y. H., Abdelhamid H., Ismail Y. Lab‐on‐a‐chip based on CMOS technology:
system architectures, microfluidic packaging and challenges. IEEE Test and Design;
2015: 32: 20–31.
[42] Ghallab Y. H., Badawy W. A single CMOS chip for biocell tracking, levitation, detection,
and characterization. International Symposium on Circuit and System (ISCAS 06),
Greece. IEEE; 2006, 3349–3352.
Lab-on-a-Chip Fabrication and Application34
Chapter 3
Magnetic Field-Based Technologies for Lab-on-a-Chip
Applications
Veronica Iacovacci, Gioia Lucarini,
Leonardo Ricotti and Arianna Menciassi
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/62865
Abstract
In the last decades, LOC technologies have represented a real breakthrough in the field
of in vitro biochemical and biological analyses. However, the integration of really complex
functions in a limited space results extremely challenging and proper working princi‐
ples should be identified. In this sense, magnetic fields revealed to be extremely promising.
Thanks to the exploitation of external magnetic sources and to the integration of magnetic
materials, mainly high aspect ratio micro-/nanoparticles, non-contact manipulation of
biological and chemical samples can be enabled. In this chapter, magnetic field-based
technologies, their basic theory, and main applications in LOC scenario will be descri‐
bed by foreseeing also a deeper interaction/integration with the typical technologies of
microrobotics. Attention will be focused on magnetic separation and manipulation, by
taking examples coming from traditional LOC devices and from microrobotics.
Keywords: Lab-on-chip, microrobotics, magnetic nanoparticles, magnetophoresis,
magnetic manipulation
1. Introduction
The need of reliable, precise, and fast techniques for biochemical and biological analysis has
fostered the search for miniaturized systems integrating multiple laboratory techniques, assays,
and procedures into a really small chip, up to few square centimeters in size. These small
platforms, named lab-on-a-chip (LOC) or, less frequently, micro total analysis systems (μTAS),
have historically  been fabricated in  silicon and/or  glass  using semiconductor  processing
techniques. More recently, polymer-based devices emerged, thanks to the introduction of soft
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
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lithography [1].  LOC devices can be considered as sophisticate microsystems embedding
mechanical, electronic, and fluidic functions [2], aiming at mixing, pumping, and manipulat‐
ing samples. It is possible to identify a wide literature concerning LOC systems, in which a
variety of applications ranging from biological assays, drug sorting and testing, DNA extrac‐
tion, cell manipulation, etc., have been explored.
The use of LOC devices for laboratory tasks execution offers several advantages: reduced
sample and reagent volumes, fast sample processing, high sensitivity and spatial resolution,
increased detection accuracy, low contamination, high throughput, and reliability thanks to
the possibility to automate some processes, without depending on human operator skills [3].
Due to the really small dimensions of LOC devices, the major role is played by surface effects
with respect to inertial ones. Consequently, traditional actuation strategies cannot be exploited
for actuation in LOCs. Fluidic actuation is the most commonly employed strategy, but
electrostatic, magnetic, and chemical motion has been reported as well.
LOC systems can be distinguished in continuous-flow and stationary devices, depending on
the role played by the fluidic actuation in the execution of the desired tasks. In continuous-
flow devices, microfluidic forces are responsible for the effects experienced by the sample (e.g.,
beads, liquids, or droplets). In static flow devices, although the working environment is still a
fluid, additional actuation strategies, such those based on magnetic fields, are exploited for
effectively executing the desired task.
Depending on the working environment and on the object lengthscale, the most effective
physical principle to be exploited in order to achieve the desired objective can change signif‐
icantly. Figure 1 shows the trend of different physical effects at varying of the manipulated
object dimension. At the microscale, due to the capillary forces and to low Reynolds numbers,
it is quite hard to manipulate or mix liquids and particles by exploiting only fluidic forces or
direct manipulation, and the exploitation of other actuation strategies showing high efficiency
at the microscale is required. In this sense, magnetic field-based strategies exploitation could
be a valid solution. In LOC scenarios, in fact, the magnetic field sources can be really close to
the working environment, thus compensating the rapid decay of magnetic force with the
distance between the source and the object [4]. Furthermore, the exploitation of magnetic fields
enables non-contact manipulation [5] also for biological samples, thus paving the way for a
wide variety of applications in biology and medicine. In this chapter, the force balance acting
on a micro-object in a LOC will be analyzed with a particular focus on magnetism basic theory.
The exploitation of magnetic fields for torque and force generation will be considered,
especially for magnetic separation and magnetic manipulation applications. Techniques
employed both to endow an object with magnetic properties and to characterize it will be
described. Finally, potential applications of magnetic field-based strategies in LOCs will be
reviewed. Throughout the chapter, technologies and examples not typical of LOCs but
deriving, for example, from the world of microrobotics will be introduced, thus foreseeing a
deeper and deeper interaction/integration between these two fields.
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Figure 1. Scaling of different forces in function of the size of the object.
2. Physics at the microscale: key principles
According to Newton’s second law, when considering a magnetic microcarrier with mass mp
and moving in a fluidic environment with velocity v, the following equilibrium equation
should be considered:
p m g d b
dvm
dt
= + + +F F F F (1)
Several physical effects, including the magnetic force Fm, the fluidic drag force Fd, the net
gravitational force Fg that take into account also the fluidic lift effect, and the Brownian
interaction force Fb contribute to the force balance of the moving object. In the following, the
Brownian force, representing fluid-object and inter-objects interactions, will be neglected as it
is really weak with respect to the other contributions. The other forces contributing to the
equilibrium will be analyzed more in detail.
2.1. Fluidic drag force
Navier–Stokes equations completely define a fluid velocity in space and time. From these
equations, it is possible to derive the Reynolds number (Re), a dimensionless quantity that is
proportional to the ratio between the fluid’s inertia and its viscosity and that allows to define
a fluid’s behavior when it flows around an object. Given the fluid density ρ, the dynamic
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viscosity η, the object maximum velocity with respect to the fluid v and a characteristic linear




Usually, in both microrobotics and LOC applications, a low-Re regime, typically defined for
Re < 10, applies. At low Re, surface and capillary forces play an important role compared to
inertia and temporal variations of the flow pattern. Due to the relative importance of surface
effects, flow at low Re-number strongly depends on object geometry. Thus, it is interesting to
derive the viscous drag force acting on the object. By approximating the object to a sphere with
radius r put in an infinite extent of fluid, the viscous drag force can be calculated as a linear
function of the sphere’s velocity through the fluid:
6 ( )d f prph= -F n n (3)
where vf and vp are the fluid and the sphere velocity, respectively.
2.2. Gravitational force
Inertial and gravitational forces play a minor role at low Re. When considering a micro-object
immersed in a liquid, usually net gravitational force is taken into account. In fact upthrust
forces, responsible for body buoyancy, should be considered in addition to gravitational force,
which acts in the opposite direction:
( )g p p fV r r= - -F g (4)
In Eq. (4), Vp and ρp are object volume and density, ρf is the fluid density, and g is the gravity
acceleration.
2.3. Magnetic force
The force acting on an object immersed in a magnetic field depends both on the field features
and on the object properties. The magnetic force acting on a magnetic microstructure can be
modeled by using the “effective” dipole moment method, in which a magnetic object is
replaced by an “equivalent” point dipole with a moment mp,eff [6]. The force on the dipole is
given by:
,( )m f p effµ= ×ÑF m B (5)
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where μf is the magnetic permeability of the medium, mp,eff is the “effective” dipole moment
of the object, and B is the magnetic field produced by an external source acting at the center of
the target object, where the equivalent point dipole is located.
The dipole moment m strictly depends on object volume and magnetic properties and it can
be defined as:
V= ×m M (6)
where M and V are the magnetization and the volume of the dipole, respectively.
As mentioned, the force exerted on such dipole varies upon the features of the magnetic field
sources. It also depends on the distance between the source and the target object. If considering










m r r mB (7)
with r being the distance vector connecting the field source and the point P.
3. Classification of magnetic materials, magnetization, and characterization
of micro-objects
One of the greatest advantages of magnetic actuation lies in the possibility to transfer powering
and actuation in a wireless fashion. Remote magnetic actuation relies on the coupling, namely
the creation and maintenance of a magnetic link, between two objects showing magnetic
properties. Typically, an external control platform, based on permanent magnets, electromag‐
nets, or a combination of them, and a micro-object, that could be a magnetic bead, a magnetized
cell, or a microrobot, constitute the key elements. Materials behavior in response to a magnetic
field depends on the material atomic organization. In particular, the spatial organization of
the material microscopic domains and the possible changes in this organization produced by
the presence of an external magnetic field determine the material response. Indeed, the
magnetization induced in a material is proportional to the ability of these domains to align or
to form cooperative structures when a magnetic field is applied. This ability can be described
by means of the magnetic susceptibility χ, a non-dimensional parameter defined by the ratio
of the magnetization M induced in the material and the applied magnetic field H.
c=M H (8)
Depending on this parameter, it is possible to classify magnetic materials in three main
categories: diamagnetic, paramagnetic, and ferromagnetic (Figure 2) [7]. Diamagnetic mate‐
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rials, such as bismuth or brass, have no net atomic or molecular magnetic moment and do not
retain magnetization when the external magnetic field is removed. When these materials are
subjected to an applied field, atomic currents generate and produce a bulk magnetization
antiparallel to the field H, thus resulting in negative and negligible susceptibility χ levels
(~10−6 to ~10−3). Paramagnetic materials have a net magnetic moment at the atomic level which
shows a random orientation when no magnetic field is acting. When the magnetic field H is
applied, the moment tends to align with it. The susceptibility of such materials is in the range
10−6–10−1. Ferromagnetic materials, such as iron, nickel, and cobalt, on the other hand, have a
net magnetic moment at the atomic level, but unlike paramagnetic materials, they show a
strong coupling between neighboring moments as they align all in the same direction and
parallel to each other to produce a larger magnetization state. This coupling gives rise to a
spontaneous alignment of the moments over macroscopic regions, called domains, which
undergo further alignment when the material is subjected to an applied field. Ferromagnetic
materials can be permanently magnetized since they are able to retain residual magnetization
after the removal of the applied magnetic field. They can be furtherly classified as soft or hard
materials: The first ones are featured by a high permeability and a low coercivity Hc (the
coercivity is defined as the magnetic field intensity needed to reduce the magnetization of a
ferromagnetic material from its complete saturation to zero). This makes them easy to be
magnetized and demagnetized. The second ones have a relatively low permeability and high
coercivity which make them more suitable for the fabrication of permanent magnets [8, 9].
Figure 2. Schematic representation of diamagnetic, paramagnetic, and ferromagnetic materials microscopic structures
at rest and in the presence of a magnetic field H.
To enable magnetic field-mediated task execution in a LOC, it is necessary to provide the
objects to be manipulated with magnetic properties. In some cases, magnetic manipulation
relies on the intrinsic magnetic properties of the sample, as in the case of red blood cells [10].
More frequently, labeling and internalization of magnetic material, or fabrication of magnetic
microcarriers, are required. To this aim, magnetic micro- and nanoparticles have gained
growing attention in LOC systems and in microrobotics in general. Usually, polymeric or silica
microparticles with embedded iron oxide nanoparticles are used. Simple iron oxide nanopar‐
ticles are also used, mainly magnetite (Fe3O4) and maghemite (γ-Fe2O3) ones. Due to the
reduced dimensions of the magnetic core (diameter <1 μm), these particles usually consist of
single magnetic domains showing a superparamagnetic behavior. The main advantages of
using magnetic particles are that they have a large surface-to-volume ratio; they can be
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conveniently biofunctionalized, thus favoring their coating or enabling labeling molecules. To
provide a micro-object with magnetic properties, two main strategies can be employed: (1)
labeling with magnetic particles or (2) particle internalization. In both cases, sample incubation
in the presence of a relatively high concentration of particles is required.
Sample magnetic labeling relies on the possibility to properly functionalize particle surface to
enable the binding with functional groups exposed on sample surface. This applies, for
example, for cell labeling: functional micro- or nanoparticles are conjugated with antibodies
corresponding to specific cell surface antigens [11].
In the case of internalization, the magnetic particles are included in the sample structure itself
by embedding the magnetic material during the micro-object fabrication process or exploiting
transfection and magnetofection techniques in the case of biological samples. In this case,
superparamagnetic iron oxide nanoparticles (SPIONs), usually properly modified to promote
internalization, for example, through polystyrene or dextran coatings, or exploiting other
transfection agents, such as peptides or antibodies [12], are widely employed.
An alternative to sample magnetization through labeling or internalization is the exploitation
of magnetic carriers or manipulation systems that avoid a direct contact between sample and
magnetic material.
In this case, magnetic properties can be imparted to a carrier, by simply including magnetic
materials in its structure. To this aim, not only SPIONs have been employed: the integration
of ferromagnetic materials, for example, in the form of powder, has been investigated in
applications in which high magnetic responsivity and residual magnetization were required.
Ferromagnetic materials, such as Ni, have been employed also in the form of surface coating,
obtained through sputtering or evaporation techniques, with the aim to provide micro-objects
showing complex geometries, fabricated, for example, through 2D or 3D lithography techni‐
ques, with magnetic properties [13].
Once identified the methods allowing to magnetize the samples to be manipulated, it can be
useful to briefly describe some techniques allowing to properly characterize a magnetic micro-
object. When designing the hardware for a magnetic manipulation or separation platform, it
is useful (in some cases even mandatory) to precisely know the magnetic properties of the
beads or structures to be manipulated. Particularly, interesting parameters, most commonly
evaluated, are the magnetic susceptibility χ, the saturation magnetization Ms and the coercivity
field Hc. Considering that small entities usually show weak magnetic properties, traditional
technologies employed at the macroscale, such as Hall sensor-based probes, do not result
suitable for their characterization. Microstructured magnetic materials can be properly
characterized through both inductive- and force-based techniques. Inductive methods, such
as the vibrating sample magnetometry (VSM) and the superconducting quantum interference
device (SQUID) magnetometry, are usually employed for magnetic characterization at the
micro-/nanoscale. In both cases, the measurement can be carried out at variable temperature
and by applying different magnetic fields, thus allowing to obtain the typical material
magnetization curves in a specific range of temperatures. In VSM, a magnetic sample is
vibrated within a uniform magnetic field: sample vibration induces a current in dedicated
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sensing coils; by measuring the resulting voltage induced into the coil, it is possible to obtain
sample magnetic moment and to magnetically characterize it. The sensitivity of this kind of
technique can reach 10−6 emu. When the samples are really diluted or show really weak
magnetic properties, thus claiming for higher sensitivities, SQUID-based magnetometry can
be a suitable solution, enabling to reach sensitivities up to 10−8–10−12 emu. The magnetic
properties of the material are measured by detecting quantum mechanical effects in conjunc‐
tion with superconducting detection coils. In both VSM and SQUID magnetometry, however,
the duration of a single measurement is in the order of some hours. This obviously represents
a strong limitation for all cases in which the characterization of a large number of samples is
needed. On the other hand, force-based methods, such as Gouy and Faraday balances, rely on
the change in weight of a magnetic material when it is subjected to a uniform magnetic field.
Commercial systems based on the Faraday method, such as the alternating gradient magne‐
tometer (AGM), provide sensitivities in the 10−8–10−9 emu range with really fast measurement
procedures [14, 15].
4. Magnetic actuation in LOC: principles and exploited hardware
Some applications of magnetic fields in LOCs have already been mentioned and range from
magnetic separation for chemical and biological analyses to sample manipulation for drug
screening and cell sorting. In terms of magnetic actuation of samples, it is possible to classify
the various applications in two main categories: (1) magnetic separation and (2) magnetic
manipulation. In the first case, two or more classes of objects are separated depending on their
magnetic properties, but without any need to properly drive them along complex paths or to
guarantee the execution of specific tasks; in this case, magnetic fields are responsible for
separation, but transportation is usually provided by fluidic forces. In the second case, a more
accurate control is required to enable a single magnetic object or a swarm of them to follow a
planned trajectory or to perform a specific task; larger magnetic fields and forces are required
in this case, as they are responsible also for object transport.
4.1. Magnetic separation
Magnetic separation, often defined as magnetophoresis, is widely exploited in LOC applica‐
tions. Magnetophoresis is a nondestructive method for the selective collection or separation
of magnetic particles, by moving them in a viscous medium under the influence of an applied
magnetic field [16]. Usually, in LOC applications, we refer to free-flow magnetophoresis, since
the separation of particles or magnetic objects takes place in a liquid environment where
magnetic particles are deflected from the direction of laminar flow by a perpendicular
magnetic field (Figure 3); the extent of the deflection depends mainly on flow rate and on the
susceptibility of the magnetic particle, or more precisely, on the susceptibility mismatch
between the particle and the fluid.
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The vector udefl, which represents the deflection of magnetic particles due to the applied
magnetic field, is the result of two contributions: the flow velocity induced on the particle by
the applied magnetic field umag, and the hydrodynamic flow velocity uhyd:
defl mag hyd= +u u u (9)
The magnetically induced flow velocity umag, can be expressed as the ratio of the magnetic force








In a magnetophoresis application, the magnetic force depends on the particle features, mainly
its volume Vp, on the mismatch in terms of magnetic properties between the particle and the






= ×ÑF B B (11)
Eq. (11) is suitable for both paramagnetic and superparamagnetic particles, since soft mag‐
netism approximation, and lack of magnetic memory is considered for the particles, and for
relatively high magnetic field strengths, able to induce in the particles a magnetization close
to the saturation one. To this aim, macroscopic permanent magnets and electromagnets can
be exploited, since they produce sufficiently strong fields (>0.5 T), able to saturate superpara‐
magnetic particles.
Figure 3. Typical schematization of a magnetophoresis scenario in which a magnetic field perpendicular to the flow
direction is exploited to deviate magnetic particles from the trajectory imposed by fluidic forces and thus to separate
them from the rest of the sample. Complete separation of the species can be obtained through some consecutive steps.
It is possible to distinguish between positive and negative magnetophoresis depending on the
sign of the susceptibility mismatch: if Δχ is positive, for example, in the case of magnetic micro-/
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nano-objects in a non-magnetic fluid, we talk about positive magnetophoresis and the particles
are attracted by the externally applied magnetic field. On the other hand, when the suscepti‐
bility mismatch Δχ is negative, for example, in the case of diamagnetic particles in a magne‐
tofluid, the particles are repelled from the magnetic field and negative magnetophoresis
occurs. When designing a magnetophoresis device, it is necessary to assure the dominance of
magnetic forces respect to the other physical contributions. Considering Eq. (11), Fm results
proportional to the magnetic field gradients and to the susceptibility mismatch. Several
strategies aiming at optimizing magnetophoresis have been investigated and proposed, and
they may be essentially classified in two categories distinguishing between those aiming at
maximizing the magnetic field gradients and those acting on the susceptibility mismatch [18].
In the attempt to increase the magnetic field gradient, many solutions have been proposed in
literature, all aiming at the generation of a nonuniform magnetic field distribution. In some
cases, uniform external magnetic field sources, such as permanent magnets, were combined
with wires [19], ferromagnetic strings [20], or magnetic microparticles embedded in the chip
structure itself [21], whereas in other cases, the integration of small electromagnets produced
intense magnetic field gradients [22]. Alternatively, permanent magnets can be actuated to
generate a time-dependent magnetic field, for example, through the use of a rotating magnetic
wheel [23], or arranged in an asymmetric configuration, thus generating spatial field variation
or multiple magnetic separation stages [24]. One of the most commonly employed magnet
configuration in magnetophoresis applications, able to maximize field distribution anisotropy,
is the quadrupolar arrangement which creates a magnetic gradient radially outward from the
center of the flow column [25]. In a variant of this, the fluid is static, while an applied magnetic
field is moved up the container [26]. The particles move in the resulting field gradient at a
velocity dependent on their magnetophoretic mobility. At the top of the container, they enter
a removable section and are held here by a permanent magnet. The bottom section of the
container moves to the next section where a magnetic field with different strength to the first
is applied and the process repeats. The result is a fractionation of the sample into aliquots
differing for magnetophoretic mobility [27].
The alternative strategy to enhance the magnetic separation capabilities of the device lies in
increasing the susceptibility mismatch by modifying either the susceptibility of the particle,
or the one of the surrounding fluid. This can be accomplished (1) by labeling the cells or the
desired microstructure with higher magnetic susceptibility beads (2) by internalizing higher
quantity of magnetic material, and (3) by using a ferrofluid medium, for example, by adding
gadolinium, and diamagnetic particles instead of the para/ferromagnetic ones [28].
4.2. Magnetic micromanipulation
Magnetic fields can be employed in LOC for the non-contact manipulation of biological
samples or other magnetically labeled substances/structures. Apart from applications in which
it is necessary to separate different types of samples or specific entities from the medium (tasks
that can benefit from techniques mainly based on magnetophoresis), in some cases, precise
manipulation or transport along defined paths is required. This kind of task is more complex
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in terms of extent of magnetic fields required and of control, considering that for 3D manip‐
ulation, torque equilibrium must be taken into account, in addition to force balance.
It has been demonstrated that biological systems or chemical samples labeled with magnetic
nanoparticles can be micro-/nano-manipulated or transported in three dimensions, by
exploiting combinations of electromagnets or permanent magnets, possibly moved or rotated
along three axes. Permanent magnets offer the advantage to produce large fields without the
need of any electrical current, thus avoiding powering, heating and control issues, which have
to be faced instead when using electromagnets. On the other hand, electromagnets offer the
possibility to tune magnetic field gradients and field intensities by simply varying the currents
across the coils. By properly combining electromagnets, it is possible to produce in the
workspace both varying magnetic fields, without the need of moving parts, and spatially
uniform magnetic fields and gradients. This makes possible to accomplish also quite complex
manipulation and locomotion paradigms. Several architectures have been proposed, present‐
ing different magnet and electromagnet arrangements. In LOC applications, due to the need
to finely control the locomotion of small-scale entities, electromagnets are the most commonly
employed solution.
Generally, when an electrical current flows in a wire, a magnetic field is generated according
to the Biot–Savart theory [9]. When considering a single circular coil in which a current with
magniture I is flowing, the magnetic field along the central axis of the coil can be defined as:
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where r is the radius of the coil, and z is the coordinate along the central axis.
Often, specific coil pairs arrangements, namely Helmholtz and Maxwell coils, are exploited in
micromanipulation applications. They consist of two identical circular magnetic coils sym‐
metrically placed along a common axis, one on each side of the workspace, and separated by
a distance d corresponding to coil radius (rH) in the case of Helmhotz coils and to √3rM in the
case of Maxwell coils. In Helmholtz arrangement, each coil carries an equal electric current in
the same direction, whereas in Maxwell coils currents flow in opposite directions. The
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NH, IH, rH, NM, IM, rM are the numbers of windings, current, and radius of Helmholtz and Maxwell
coils, respectively.
When considering a combination of Helmholtz and Maxwell coils (Figure 4A), the magnetic
field B and magnetic field gradient ∇B in the workspace can be derived analytically by Eqs.



















Equations (15) and (16) clearly show that Helmholtz coils are able to generate a uniform
magnetic field, whereas Maxwell coils produce a uniform magnetic field gradient along its
axis. For this reason, combinations of Helmholtz and Maxwell coils have been exploited to
obtain both a uniform field gradient and magnetic field uniformity [29].
Nonuniform field setups have been developed as well. Despite the major complexity both in
terms of design/fabrication and control, they enable an increase in the number of controlled
degrees of freedom. In this sense, a representative example is the OctoMag system [30, 31]
(Figure 4B), designed for the control of intraocular microrobots for minimally invasive retinal
therapy and diagnosis, but showing also potentialities for use as a wireless micromanipulation
apparatus. It consists of eight stationary electromagnets with soft-magnetic cores able to
generate predefined values of magnetic field and gradient, providing the manipulated object
with five degrees of freedom; this system can operate closed-loop position control by exploiting
computer-assisted visual tracking or in open loop by relying only on the operator microscope-
mediated visual feedback. Alternative approaches aim at exploiting other sources of nonuni‐
form magnetic fields: Martel et al. [32] demonstrated the effectiveness of using an MRI scanner
for the control of a swarm of magnetotactic bacteria in executing a manipulation task on micro-
objects. Micro-assembly of micro-objects using a cluster of microparticles (with average
diameter of 100 μm) and a magnetic-based manipulation system has also been shown in [33].
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Figure 4. Different magnetic field generation setup exploited for magnetic manipulation. (A) Combination of Helm‐
holtz and Maxwell coils; (B) OctoMag system [31].
5. Applications of magnetic fields in lab-on-a-chip
Once provided the reader with an overview of physics at the microscale, as well as of magnetic
materials properties and principles to be exploited, some real applications of LOCs will be
described, where using magnetic fields. Such applications range from biological samples
handling to chemical reactions and other manipulation tasks. As a consequence, in order to
better analyze the potential of using magnetic fields in this context, it is useful to classify the
applications in three main areas: (1) on-chip bioanalysis; (2) cell separation or manipulation;
and (3) non-conventional manipulation techniques.
5.1. On-chip bioanalysis
A vast number of reactions in genomics, proteomics, and clinical medicine need molecular
mixing of fluids or recognition events between single strands of DNA, between antibodies and
antigens, or between receptors and cells. Such reactions usually require a number of steps that
must be performed sequentially, such as isolation, washing, or purification. In this kind of
applications, the introduction of automation could lead to higher throughput and the use of
magnetic fields, commonly mediated by the use of magnetic particles, has revealed to be
extremely useful in some on-chip functions such as the mixing of fluids, selective capture of
analytes, later to be transferred for further analysis steps, or the performance of stringency and
washing. Usually two main properties of magnetic particles are exploited in analytical assays:
the possibility to biofunctionalize them, thus enabling selective binding and related applica‐
tions, and the capability to form supra-particle structures, such as chains, exploited mainly in
fluid mixing and analytes capture applications [5].
Usually, magnetic particles are labeled with molecules, for example, antibodies, showing high
affinity for the target species and able to mediate the binding with them. Often multistep
binding processes are carried out to bind the particle–analyte complex, for example to
fluorescent dies, thus to enable target detection [34]. In other cases, for additional purification
steps after labeling, magnetic separation, mediated by magnetophoresis phenomena, or
transfer processes are required to enable further purification/washing steps or analysis. This
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kind of procedures can be exploited both for the in vitro purification of nucleic acids or proteins
and for biomolecules separation, as well as DNA sequencing. For example, in case of DNA
extraction and separation processes, magnetic particles are firstly held in place by exploiting
external magnetic fields, thus exposing their functional groups to specific DNA strands.
Magnetic separation steps can consequently be performed to isolate the strands of interest from
the rest of the sample [35]. In other cases, the target-binding capabilities, with analytes showing
at least two epitopes, have been exploited to create large aggregates for albumin detection in
buffer [36]: The binding between particles is mediated by the target molecule and thus the
extent of the aggregate represents a measure of analytes concentration within the solution and
the magnetic properties of the aggregate allow their detection. In this case, non-specific particle
clustering should be avoided.
Another interesting application is in the field of biosensing or surface binding bioassays: In
this context, magnetic particles can be exploited as binding mediators between the target
species and a functionalized surface. The most common configuration in this field is the
sandwich one, in which the target molecule binds first the magnetic particles dispersed in the
solution. Later, by exploiting magnetic field gradients, the complex can be moved toward the
surface of the sensor where interactions at the molecular scale occur [37].
Whereas in detection applications, non-specific magnetic interaction within particles has to be
avoided, there are applications in which the capability of magnetic particles to interact each
other thanks to magnetic forces to form supra-particle structures can be advantageously
exploited. When working with really precious/expensive fluids, really small volumes and
microfluidic devices are employed. Due to the small scale and to the strong viscous force, fluid
mixing is not straightforward. In this case, magnetic particles can be exploited to steer fluids.
This is done specifically for supra-particle structures such as chains created by the dipole–
dipole interactions between magnetic particles, and actuated, for example, by means of
rotating magnetic fields [38].
5.2. Magnetic cell separation
Cell manipulation by means of magnetic fields relies on cells magnetic labeling or, alterna‐
tively, on magnetic particles internalization through magnetic field-mediated transfection
mechanisms (magnetofection). In a typical in vitro magnetofection system, target cells are
located at the bottom of a fluidic chamber well of a culture plate, and a permanent magnet
beneath the chamber provides a magnetic force that attracts the biofunctional particles toward
the cells.
Separation and isolation of rare cell populations from a heterogeneous suspension is essential
for many applications, ranging from disease diagnostics to drug screening. Various separation
techniques have been proposed, but magnetic fields emerged as very promising also in this
kind of application thanks to the exploitation of the magnetic separation principles presented
in the previous section.
Magnetic cell sorting can be operated in either a serial or a parallel manner, resulting in higher
throughput with up to 1011 cells processed in 30 min. This process can be operated in both
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batch and continuous flow mode. In batch processing, the hardware is very simple, including
a magnetic field source placed close to a column containing the cells to be separated. Several
architectures were developed to this aim both at large scales, exploiting for example ferro‐
magnetic columns [39] and at smaller scales with arrays of electrical wires exploited to produce
local magnetic fields [40]. In the case of continuous flow cell sorting, instead, typical magne‐
tophoresis principles are exploited.
Multicell sorting systems rely on the variation in the uptake of magnetic material between
different cell populations and thus on the different path deviation produced by magnetic field
gradients. They can be also used for the separation of different cell species from heterogeneous
samples [41].
The separation of a specific class of cells from a certain sample is extremely important for some
applications, for example, for the detection of pathology or for the testing of a therapeutic
strategy. For example, diagnosis and treatment of HIV disease rely on the efficient separation
of human T-lymphocytes from whole blood [42], whereas in the diagnosis and treatment of
malaria, the detection of infected red blood cells (RBCs) and their separation from healthy cells
is mandatory [43]. Separation of neuronal cells has gained interest for its potential applications
in cell replacement therapy of neurodegenerative disorders such as Parkinson’s disease,
multiple sclerosis, and Alzheimer’s disease [44]. Cell separation methods are also needed for
separating nucleated RBCs from the peripheral blood of pregnant women, for monitoring
maternal, fetal, and neonatal health [45].
Magnetic field-based cell counting techniques have also been developed. One method
estimates the location and number of cells tagged by measuring the magnetic moment of the
microsphere tags [46], while another uses a giant magnetoresistive sensor to measure the
location of microspheres attached to a surface layered with a bound analyte [47].
5.3. Non-conventional manipulation strategies based on magnetic fields
When high sensitivity, not compatible with magnetophoretic techniques is required, and
independence on the human operator are desirable, microrobotic manipulators acting at the
cellular scale can offer significant benefits. Wirelessly controlled (i.e., untethered) cell-sized
robots are highly noninvasive. At this length scale, where viscous fluid forces dominate inertial
ones, mobile microrobots cause very little mixing or agitation of the surrounding environment.
This is a significant advantage, for example, over suction pipetting for life scientists, since
pipettes cause relatively large fluid disturbances [48]. Magnetic control of microrobots and
microgrippers is gaining growing importance in micro-object manipulation: in addition to
increasing the manipulation accuracy, the exploitation of such micro-systems avoids some‐
times the direct magnetization of the sample, through internalization or labeling, thus helping
in keeping its integrity. Many challenges have to be faced to enable single cell manipulation.
When working with single cells or with really fragile samples, in fact, it is essential to have
microstructures with sizes comparable to those ones of the target, to be able to finely control
them within the workspace, and to avoid to affect cell viability or samples integrity due to the
microrobot exploitation.
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Some research groups focusing on microtechnologies have been working toward a high
efficiency in vitro fertilization (IVF) process [49] (Figure 5A). The IVF goal is to fertilize oocytes,
and it consists of several manually or teleoperated manipulation steps that require important
practical skills. Sakar et al. [50] developed microtransporters using a simple, single-step
microfabrication technique allowing parallel fabrication. They demonstrated that the micro‐
transporters can be navigated to separate individual targeted cells with micron-scale precision
and deliver microgels without disturbing the cells in the neighborhood and the local micro‐
environment. Yamanishi et al. [51] presented an innovative driving method, devised for cell
sorting, for an on-chip robot actuated by permanent magnets in a chip, where a piezoelectric
ceramic is applied to induce ultrasonic vibration to the microfluidic chip and the high-
frequency vibration reduces significantly the effective friction on a magnetically driven
microtool.
Other interesting magnetic microstructures, devised for cell manipulation in in vitro environ‐
ments for LOC applications, but finally eligible in the future for in vivo applications, have been
recently proposed. Examples are novel microgrippers, in which both the navigation and the
gripper actuation rely on magnetic fields [52] (Figure 5B), 3D laser lithography microcages
devised to act as cell carriers (Figure 5D) [53] or thin magnetic films working at the air fluid
Figure 5. Overview of non-conventional manipulation systems for microrobotics and LOC applications. (A) Conceptu‐
al overview of a microfluidic cell manipulation system based on magnetically driven microtools and exploited for oo‐
cytes handling [49] (reproduced with permission from Royal Society of Chemistry); (B) Schematic representation of a
remotely controlled microgripper exploiting magnetic fields both for navigation and for gripper actuation (adapted
from [52] and reproduced with permission from Royal Society of Chemistry); (C) SEM image of a magnetic thin film
devised for cell manipulation (left) and schematic representation of the film structure with microscope images showing
T24 cell compatibility with the magnetic structure (right) [13] (reproduced with permission from Springer); (D) SEM
image (above) and confocal microscope image of a magnetic microcage after cell culture [53]; (E) Experimental setup
for magnetic micromanipulation (left) and microscope images of the magnetic microrobot during christal manipula‐
tion tasks (adapted from [55] and reproduced with permission of the International Union of Crystallography).
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interface and exploiting surface tension phenomena together with magnetic navigation and
showing compatibility with cell manipulation applications [54] (Figure 5C). Interesting is also
the development of manipulation strategies for precise non-contact handling of small and
fragile samples based on complex control algorithms aiming at creating vortexes, as demon‐
strated for crystal harvesting applications (Figure 5E) [55].
6. Conclusions
LOC technologies represented a real breakthrough in the last decades for in vitro laboratory
analyses. However, the integration of really complex functions in a limited space results
extremely challenging and further efforts are required to make LOC systems accurate and
operating in an automated fashion. Magnetic fields exploitation revealed to be extremely
promising and effective in the execution of certain tasks, with the aim of overcoming some of
the limitations connected to human operators and enabling procedures impossible with
traditional laboratory techniques.
In this sense, the role played by magnetic nanoparticles is extremely important, but alternative
techniques providing the samples to be manipulated with magnetic properties have been
investigated and show great potentialities.
In some cases, magnetic field-based technologies appear more advantageous compared with
other LOC actuation strategies, first of all the fluidic one. However, in view of more reliable
systems, a possible future trend, already investigated in many applications focuses on
combining several effects, including chemical binding, microfluidic actuation, magnetic and
electric fields, to obtain more efficient analytical and biological testing platforms. A further
enhancement of LOC devices, and especially of those exploiting magnetic fields, may derive
from the integration of technologies that are typical of the microrobotics world. Some examples
have been reported in the Section 5.3 and an interesting contribution could derive from
microrobotics, both in terms of cell carriers and manipulation systems fabrication, and in terms
of control strategies.
The development of cheaper and more reliable LOCs could enable many steps forward in
really important fields, such as nanomedicine, personalized medicine, and cellular studies.
The advantages and technological progresses offered by magnetic technologies at all the scales
and in different fields could surely help to reach this goal.
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Abstract
Since the 1990s, centrifugal microfluidic platforms have evolved into a mature technol‐
ogy for the automation of bioanalytical assays in decentralized settings. These “Lab-on-
a-Disc” (LoaD) systems have already implemented a range of laboratory unit operations
(LUOs) such as sample loading, liquid transport, metering, aliquoting, routing, mixing,
and washing. By assembling these LUOs in highly functional microfluidic networks,
including sample preparation and detection, a sizable portfolio of common test formats
such as general chemistry, immunoassays/ protein analysis, nucleic acid testing, and cell
counting has been established. The availability of these bioanalytical assay types enables
a broad range of applications in fields such as life-science research, biomedical point-of-
care testing and veterinary diagnostics, as well as agrifood, environmental, infrastruc‐
tural, and industrial monitoring.
Recently, a new method of the so-called “event-triggered” flow control has been developed
which is independent of the spin rate. These valves, which function in a handshake mode
as opposed to the typically batchwise liquid transfers on the “Lab-on-a-Disc” (LoaD)
platform, assume a similarly pivotal role as relays and transistors in digital electronics,
allowing conditional, logical (flow) control elements. This chapter will describe the
modeling of this new generation of “digital” centrifugal microfluidic systems with low-
dimensional, lumped-element simulations which have already been instrumental to the
modern success story of modern microelectronics.
Keywords: lumped-element simulation, centrifugal microfluidics, lab-on-a-disc,
event-triggered flow control, valving
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1. Introduction
The centrifugal microfluidic platform has evolved into mature technology platform which has
already proven to open significant market opportunity [1–5]. A large number of groups groups
working on such LoaD systems in industry has already convincingly demonstrated the
capability to integrate, automate, parallelize, and miniaturize a wide range of common
bioanalytical test formats for detecting targets such as small molecules, proteins/antibodies,
nucleic acids, and cells. Applications span from decentralized biomedical point-of-care
diagnostics, veterinary medicine and agrifood, to the surveillance of the environment and
infrastructures.
Based on the recently introduced, event-triggered flow control scheme [6, 7], highly functional
microfluidic circuits can be assembled in a modular fashion from a limited set of LUOs to
implement a broad repertoire of multi-step, multi-reagent bioassay protocols in a sample-to-
answer fashion. Furthermore, it has been demonstrated that the chips could be progressively
miniaturized to significantly enhance integration density (i.e., the number of assay steps and/
or tests per disc) and thus boost the overall cost efficiency and functionality of the LoaD
platform.
Similar to integrated circuits in microelectronics, a microfluidic network can be modeled by
lumped-element descriptors. Instead of a finely meshed 3-dimensional lattice, the Lab-on-a-
Disc systems are described by a low number of parameters such as pressure head (voltage
source), flow resistance (electric resistance), and compressibility (capacitance). This reduced-
dimension method can be utilized for fast design and simulation of microfluidic systems that
are composed of a library of functional units.
After the introduction (Section 1), the hydrodynamic principles of centrifugal microfluidics
are presented (Section 2) before outlining digital flow control schemes (Section 3). Next, the
concept of lumped-element simulation in event-triggered centrifugal microfluidic networks is
developed (Section 4).
2. Centrifugal hydrodynamics
The rotationally controlled microfluidic “Lab-on-a-Disc” platform is based on (the volume
density of) the centrifugal force
2f rw r w= (1)
the Euler force
. /Ef r d dtr w= (2)
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and the Coriolis force [1]
2Cf vrw= (3)
where ρ is a fluid density on a rotating platform, ω = 2πv the angular velocity with the
frequency of rotation v, r is a distance from a central axis, and v represents the speed of flow.
All forces act in the plane of the disc and scale with the angular velocity ω directly impacts
these three forces.
The centrifugal force (Eq. (1)) translates into an equivalent centrifugal pressure
2p rrw r wD = D (4)









of the liquid in the channel [5] featuring the hydraulic diameter Dh = 4A/P with the A, P, and
L, its cross-sectional area A, wetted perimeter of the channel P, and length L. The fluid viscosity
is denoted by μ, the mean radial position by r̄ =(r2 + r1) / 2, and the radial length by ∆r = (r2 − r1).
Air pockets, which often arise accidentally or strategically during priming, can be compressed
by the hydrostatic pressure head of a liquid column (4) in a more central position. This









according to Boyle’s law [6] where Pc represents the pressure of the gas in the pneumatic
chamber, V is the total volume of the pneumatic chamber, and ∆V denotes a reduction of gas
volume due to filling of liquid in the pneumatic chamber.
3. Digital flow control schemes
Flow control is instrumental for orchestrating sequential liquid handling on the LoaD plat‐
forms where all volumes are subjected to the same centrifugal field (Eq. (1)). Such flow control
can be categorized into rotationally actuated and instrument-supported schemes.
Instrument-supported valves involve some stationary modules (other than the platform innate
spindle motor). To switch a valve, these “lab-frame” elements interact with the disc cartridge,
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either at rest or during spinning. The actuation can be powered by pneumatic pressure sources
[8–9], heating of phase-change materials [10–13], or even varying the chip orientation with
respect to the radial direction [14–16]. While these may provide enhanced and more flexible
control, these active valving mechanisms typically involve additional instrumentation,
maintenance, cost, and susceptibility to failure.
Rotationally actuated valves are far more common and are considered more suitable for
deployment of inexpensive point-of-use applications. Through varying the rotationally
induced fields relative to the statically defined forces such as interfacial or membrane tension,
the force equilibrium at a fluid element can be unbalanced. Such static forces can be imple‐
mented by capillary action [17–21], dissolvable films (DFs) [22- 23], burstable foils [24],
elastomeric membranes [25], dead-end pneumatic chambers [26], siphons [27]–29], and
pneumatically enhanced centrifugo-pneumatic siphons (CPSVs) [30–33].
In particular the popular, rotationally actuated capillary “burst” valves are strongly dependent
on physicochemical properties such as geometry, surface roughness, and contact angle; hence,
valve performance is intimately linked to manufacturing fidelity. The often rather poor
reproducibility and stability of these effects translate into a significant “smearing” of the burst
frequencies. For serial flow control which is common in bioanalytical protocols, rather wide,
non-overlapping bands of the spin rate have to be reserved for each assay step. As the
maximum spin rate is practically limited by the motor power and safety, this imposes a
practical limit on the number of sequential LUOs which can be rotationally controlled by a
spindle motor.
Event-triggered valving circumvents this restriction [6– 7]. Here, the arrival of liquid at defined
locations on the disc coordinates a sequential opening of valves; valve actuation is thus
decoupled from changes in the spin rate and support instrumentation. So far, event-triggered
valving has been based on dissolvable film (DF) membranes [22], [23], [34], [35] and, in
function, can be described akin to an electrical relay. The architecture of the disc determines
the order of valve actuation, while the timing is controlled by the dissolution of these mem‐
branes. It has been shown that event-triggered schemes can also implement logical flow control
elements such as AND and OR conditions [6], thus enabling a modular system design similar
to electronics. Developing the lumped-element tool for the simulation, digital centrifugal
microfluidic systems can generate a broad scope of applications, thus mitigating development
risks, upfront investment, and time to market.
The basic event-triggered valve is composed of a pneumatic chamber sealed by the restrained
liquid and two dissolvable films called the load film (LF) and the control film (CF). The
geometry of the pneumatic chamber is designed so that, at the spin rates typical for the
centrifugal platform, the restrained liquid cannot be pumped into contact with the LF or CF
by compressing the trapped air within the pneumatic chamber. Similarly, the section of the
chamber connecting the LF and CF extends radially inward of the restrained liquid. When the
CF is wetted and dissolved by an ancillary liquid, the pneumatic chamber is vented so the
main liquid contacts and thus opens the LF.
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deployment of inexpensive point-of-use applications. Through varying the rotationally
induced fields relative to the statically defined forces such as interfacial or membrane tension,
the force equilibrium at a fluid element can be unbalanced. Such static forces can be imple‐
mented by capillary action [17–21], dissolvable films (DFs) [22- 23], burstable foils [24],
elastomeric membranes [25], dead-end pneumatic chambers [26], siphons [27]–29], and
pneumatically enhanced centrifugo-pneumatic siphons (CPSVs) [30–33].
In particular the popular, rotationally actuated capillary “burst” valves are strongly dependent
on physicochemical properties such as geometry, surface roughness, and contact angle; hence,
valve performance is intimately linked to manufacturing fidelity. The often rather poor
reproducibility and stability of these effects translate into a significant “smearing” of the burst
frequencies. For serial flow control which is common in bioanalytical protocols, rather wide,
non-overlapping bands of the spin rate have to be reserved for each assay step. As the
maximum spin rate is practically limited by the motor power and safety, this imposes a
practical limit on the number of sequential LUOs which can be rotationally controlled by a
spindle motor.
Event-triggered valving circumvents this restriction [6– 7]. Here, the arrival of liquid at defined
locations on the disc coordinates a sequential opening of valves; valve actuation is thus
decoupled from changes in the spin rate and support instrumentation. So far, event-triggered
valving has been based on dissolvable film (DF) membranes [22], [23], [34], [35] and, in
function, can be described akin to an electrical relay. The architecture of the disc determines
the order of valve actuation, while the timing is controlled by the dissolution of these mem‐
branes. It has been shown that event-triggered schemes can also implement logical flow control
elements such as AND and OR conditions [6], thus enabling a modular system design similar
to electronics. Developing the lumped-element tool for the simulation, digital centrifugal
microfluidic systems can generate a broad scope of applications, thus mitigating development
risks, upfront investment, and time to market.
The basic event-triggered valve is composed of a pneumatic chamber sealed by the restrained
liquid and two dissolvable films called the load film (LF) and the control film (CF). The
geometry of the pneumatic chamber is designed so that, at the spin rates typical for the
centrifugal platform, the restrained liquid cannot be pumped into contact with the LF or CF
by compressing the trapped air within the pneumatic chamber. Similarly, the section of the
chamber connecting the LF and CF extends radially inward of the restrained liquid. When the
CF is wetted and dissolved by an ancillary liquid, the pneumatic chamber is vented so the
main liquid contacts and thus opens the LF.
Lab-on-a-Chip Fabrication and Application60
However, the connecting channel between the LF and CF acts as a geometric barrier which
prevents the liquid escaping through the disrupted CF. Thus, in this configuration, the CF acts
analogous to the control line of an electrical relay and the LF to the load line. This basic
configuration can then be arranged into a complex fluid network where valves sequentially
cascaded; the flow released from the first valve triggers the subsequent “ancillary liquid.”
Importantly, the interval between valve actuations is governed by the aggregate time of
membrane dissolution and liquid transfer.
Alongside the basic configuration (Figure 1), the conditions of valve actuation can be altered
by changing the arrangement of the CF. For example, locating the CF such that it can only be
wetted when two or more upstream “ancillary liquid’ volumes have been released (Figure 1)
establishes a Boolean AND condition. Similarly, by designing a valve with two CFs where
wetting one or the other will trigger the valve, we create a Boolean OR condition (Figure 2).
Finally, locating two CFs in close proximity so they can be reached by a single ancillary liquid
can simultaneously open two pneumatically connected valves and thus can represent parallel
valve actuation (Figure 3).
Figure 1. Schematic demonstrating the basic event-triggered configuration and also showing the Boolean AND release
mechanism (a) Valve closed, (b) upstream valve 1 opens (c) AND upstream valve 2 opens, (d) CF is dissolved, (e) LF is
wetted, (f) Valve opens.
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Figure 2. Schematic illustrating the OR conditional release mechanism. The top pane shows the valve actuation trig‐
gered by liquid movement to one chamber and the lower pane shows the valve actuation triggered. (a) Valve closed,
(b) CF wetted, (c) LF wetted, (d) Valve opens.
Figure 3. Schematic illustrating the OR conditional release mechanism. The top pane shows the valve actuation trig‐
gered by liquid movement to one chamber and the lower pane shows the valve actuation triggered. (a) Valve closed,
(b) CF wetted, (c) LF wetted, (d) Valve opens.
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4. The concept of lumped-element simulation in digital, event-triggered
centrifugal microfluidic networks
The rapid evolution of microelectronics (following Moore’s law) has been leveraged by the
trinity of miniaturization, fabrication, and, last but not least, large‐scale system integration
(LSI). The breathtaking progress within these tightly intertwined factors has tremendously
reduced production costs and seminally enhanced system performance. This is clearly visible
when looking back over the last decades when microelectronic devices took the road from very
clumsy, maintenance‐intensive, multi‐million dollar machines sparsely scattered around the
globe to the sleek, ubiquitous, and quite affordable digital gadgets people even carry in their
pockets. The unprecedented commercial success story of microelectronics has been enabled
by seminal advances in microfabrication as well as the capability to generate complex func‐
tional architectures from a limited set of base modules such as capacitors and transistors. These
simple modules are composed into sophisticated functional networks by lumped‐element
model software. We have developed a new type of “digital” LoaD platform which follows a
similar design paradigm to implement different types of bioanalytical tests, e.g., for small
molecules, proteins, antibodies, DNA, and cells [6].
Over the past decades, simulation has a key role in developing new products. The common
simulation methods are FEA (finite element analysis), CFD (computational fluid dynamic),
and MBS (multi-body systems). In principle, these mesh-based simulation methods are very
accurate. Nevertheless, these numerical tools display serious limitations, for instance, that they
tend to be very time-consuming; in particular for more complex networks, also the grid size
and proper boundary conditions impact the result (mesh dependency). Therefore, simplified
geometries are required for keeping computation times and common convergence issues at
bay; lumped-element simulation was proposed to simplify analysis based on electric circuit
elements; this method is quite fast and fit for swift parameter optimization; in addition, these
methods could simulate serial and parallel multi-element architectures [36].
The centrifugal flow control elements and their combination of complex microfluidic circuitry
translate into equivalent, lumped-element descriptors. Each lumped element exhibits certain
free parameters, for instance, corresponding to resistances or capacitances. In microfluidics,
these parameters typically relate to geometries, e.g., the channel cross section, as well as
hydrodynamic and mechanical properties such as the viscosity and compressibility of the
fluids and the flexibility of the ducts. Lumped-element analogies for the different environ‐
ments are listed in Table 1.
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Table 1. Physical lumped-element analogies in different environments.
For a given microfluidic network and spin rate protocol, the lumped-element simulation of
microfluidic systems allows to calculate pressure distribution, flow rate, and timing. Parallel
simulation and parameter sweep for efficient design generation of microfluidic systems
represent further advantages of lumped-element simulation. In addition, its computational
simplicity and fast convergence mean it can also be applied to “real-time” active control of
microfluidic processes. Utilizing this real-time graphical simulation to monitor filling level and
aliquoting timing along the LUOs in multi-step, multi-reagent bioassay protocols will consti‐
tute an important milestone because it would allow the evaluation of the functional operation
of the LoaD device without any further fabrication and experimental processes.
This lumped-element simulation in different environments is illustrated by the equivalent
electric circuit elements comprising a resistor, a capacitor, and a diode, and the required
relations for lumped-element simulation are presented in the following:
4.1. Kirchhoff’s current law (KCL) [37]
The material balance equation, flow-in equal flow-out at any given node in the microfluidic
network.
( ) ( ) ( ) ( )1 2 1 20 0 in in out out
i i
At each nodesIi qi q q q q= = ® + +¼= +¾¾¾¾¾® +¼å å (7)
4.2. Kirchhoff’s voltage law (KVL) [31]
The sum of pressure differences around a microfluidic loop must be zero.
0 0In closed loop
i i
Vi Pi¾¾¾¾¾= =®å å (8)
4.3. Capacitance
Increasing charge storage results in increasing voltage in an electrical capacitor and increasing
fluid leads to increase pressure in the reservoir (fluid capacitator).
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.LV C P= (9)
The force at the bottom of storage due to the weight is mg = ρVLg which constant earth
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The fluid capacitance in centrifugal system is C = Aρ r̄ω 2 .
4.4. Flow resistance
The flow resistance can be considered Ohm’s law ∆V = IR.
P qRD = (11)


















æ öæ öæ ö-ç ÷ç ÷ç ÷
è øè øè ø
å (12)
Lumped-Element Modeling for Rapid Design and Simulation of Digital Centrifugal Microfluidic Systems
http://dx.doi.org/10.5772/62836
65









where w is width and h height of the channel.
4.5. Inertance
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This relation is similar to inductor equation ∆V = L didt  and we could write where I = ρL/A and
p represents pressure difference.
4.6. Application example
In this work, we consider a single design which allows us to demonstrate how our lumped-
element approach can be applied to “digital” centrifugal flow control. Therefore, we model a
liquid handling protocol similar to that used by Nwankire et al. [35] to implement a nitrite/
nitrate panel for whole blood monitoring. To implement their assay, Nwankire et al. used DF
burst valves which were designed to open in sequence with increasing spin rate of the disc.
We present a lumped-element model to simulate the centrifugo-pneumatic chambers which
are the key enabling technology of the DF burst valves; a good understanding of these
chambers is also critical to the implementation of our event-triggered valving architecture [22].
The schematic view of the design is shown in Figure 4. This design shows three reservoirs,
labeled A through C and three pneumatic chambers which are sealed using DF burst valves.
The DFs are arranged to burst at a rotational frequency greater than 20 Hz and less than 40
Hz. These reservoirs feed a mixing chamber which is further sealed by two DFs which dissolve
= &P Iq
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chambers is also critical to the implementation of our event-triggered valving architecture [22].
The schematic view of the design is shown in Figure 4. This design shows three reservoirs,
labeled A through C and three pneumatic chambers which are sealed using DF burst valves.
The DFs are arranged to burst at a rotational frequency greater than 20 Hz and less than 40
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on contact with the liquid. Upon dissolution, an open path into two overflow reservoirs is
provided.
Figure 4. (a)The design of centrifugal microfluidic platform (b) Schematic view of Lumped element network.
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We model the system in four different conditions to demonstrate a parallel simulation defined
by different spin rates. These conditions share a spin profile (Figure 5a) which involves a rapid
acceleration to a maximum frequency, followed by rapid mixing, stopping the disc, and then
fast acceleration back to the maximum frequency. These spin protocols are identical except for
their magnitude; they have maximum spin rates of 20 Hz, 40 Hz, 60 Hz, and 80 Hz.
Figure 5. Lumped-element simulation graph for main atmospheric reservoir. (a) Angular frequency profile vs the time.
(b) Total inflow vs time. (c) Total net flow (flow-in-flow-out) vs time. (d) Filling level of the chamber due to the ingress
of liquid into the reservoir. (e) Pressure generated in the pneumatic and centrifugal valve (A) due to angular velocity.
To demonstrate the wide capability of this lumped-element model to predict on disc perform‐
ance, a number of parameters are shown in Figure 5 which have been calculated using the
simulation software based on a number of defined boundaries and initial conditions. These
parameters are the volume flow into the mixing chamber assuming no out volume flow
through the two exits (Figure 5b); the net flow into the mixing chamber, assuming outflow
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To demonstrate the wide capability of this lumped-element model to predict on disc perform‐
ance, a number of parameters are shown in Figure 5 which have been calculated using the
simulation software based on a number of defined boundaries and initial conditions. These
parameters are the volume flow into the mixing chamber assuming no out volume flow
through the two exits (Figure 5b); the net flow into the mixing chamber, assuming outflow
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through the exists (Figure 5c); and the liquid level in the mixing chamber, assuming outflow
through the exits (Figure 5d). Finally, Figure 5e shows the predicted pressure, during the spin
profile, in each DF burst valve with the assumption the DF does not dissolve.
Based on the lumped-element analysis, the critical burst frequencies of the DFs are between
25 and 30 Hz. Therefore, in Figure 5b, c, and d, it is predicted that, for the 20 Hz test condition,
the DFs do not dissolve and so there is no liquid flow. As stated above, Figure 5b shows the
total volume entering into the main chamber; this is defined as Vin = VA + VB + VC. Similarly, the
net flow rate in and out of the mixing chamber is shown in Figure 5c and is defined by
qnet = qA + qB + qC − qd − qf. In turn, and most importantly, the liquid level in the main chamber
can also be predicted in Figure 5d; this information is important as it can be used to inform
incubation times and washing protocols which are critical for Lab-on-a-Disc applications.
Finally, in Figure 5e, the pressurization of the centrifugo-pneumatic valves (Valve A) is
presented. Here, the increased centrifugal force pushes the liquids from the main reservoir
(Reservoir A) and into the dead-end pneumatic chamber which is sealed by a DF. The fluid
flow is stopped in the pneumatic chamber by a pocket of entrapped air which pushes back
against the centrifugally generated hydrostatic pressure; this equilibrium condition is reached
when the centrifugal pressure head, described previously in Eq. (4), balances with the pressure
of the trapped gas, defined by Boyle’s law in Eq. (6). In the real case, the DF membrane in the
pneumatic chamber is dissolved (valve opening) beyond the critical burst frequency when the
liquid ingress is sufficient to contact the film. Then, the liquid flows are directed into the main
(downstream) chamber.
Over the past three decades, a special breed of microfluidic systems is based on centrifugal
liquid handling for a wide spectrum of applications in biomedical point‐of‐care diagnostics
and the life sciences. Recently, event-triggered flow control was introduced on these LoaD
platforms to implement logical flow control which functions akin to digital microelectronics
[33]. Similar to the difference between an old‐fashioned office mainframe and a modern
smartphone, these breakthroughs may provide an unprecedented level of system integration
and automation which is needed to eventually implement complex, highly functional net‐
works representing a repertoire of bioanalytical assays on a user‐friendly, cost‐efficient,
portable, and still high‐performance microfluidic point‐of‐use “gadget.” We presented an
advanced lumped-element approach for the fast-generation and robust simulation for event-
triggered centrifugal microfluidic networks.
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Abstract
Lab‐on‐a‐chip (LOC) and microfluidics  are  important  technologies  with  numerous
applications  from drug delivery  to  tissue  engineering.  LOC integrates  fluidic  and
electronic components on a single chip and becomes very attractive due to the possibility
of  their  state‐of‐art  implementation  in  personalized  devices  for  the  point‐of‐care
treatments. Microfluidics is the technique that deals with small (10-9 to 10-18 L) amounts
of fluids, using channels with dimensions of 10 to 100 μm. These LOC and microflui‐
dics  devices  enable  the  development  of  next‐generation  portable  and  implantable
bioelectronics  devices.  Superior  chip‐based  technologies  are  emerging  with  the
advances in microfluidics and motivating various chip‐based methods for rapid low‐
cost analysis as compared to traditional laboratory method.An organ‐on‐chip (OOC) is
on‐chip  cell  culture  device  created  with  microfabrication  techniques  and  contains
continuously perfused chambers inhabited by living cells that simulate tissue‐ and
organ‐level physiology. In vitro models of cells, tissues and organ based on LOC devices
are  a  major  breakthrough  for  research  in  biologic  systems  and  mechanisms.  The
recapitulations of cellular events in OOC devices provide them an edge over two‐
dimensional (2D) and three‐dimensional (3D) cultures and open a gateway for their
newer applications in biomedicine such as tissue engineering,  drug discovery and
disease modeling. In this chapter, the advancement and potential applications of OOC
devices are discussed.
Keywords: lab‐on‐chip, MEMS, organ‐on‐chip, 3D cell culture, drug discovery
1. Introduction: why cell and organ on chip?
The field of microfluidics or lab‐on‐chip (LOC) technology aims to advance and broaden the
possibilities of bioassays, cell biology and biomedical research based on the idea of miniaturi‐
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
zation. Microfluidic systems allow more accurate modeling of physiological situations for both
fundamental research and drug development [1].
Drug discovery and research is the prime aspect of any pharmaceutical company. The past 50–
60 years have witnessed significant scientific and technological growth in entire field of
biotechnology, computational drug design and screening and advances in scientific knowl‐
edge, such as an understanding of disease mechanisms, new drug targets and biomarkers
discovery. In principal, these advancements should also be reflected in rise of new commercial
products and drugs, but unfortunately, the pharmaceutical industry is facing unprecedented
challenges owing to rising costs and the declining efficiency of drug research and development.
Modern drug development requires implementation of extensive preclinical testing, and
validation protocols before potential therapeutic compounds are approved to progress to
clinical evaluation. This process is costly and time‐consuming, as well as inefficient as for every
10 drugs entering clinical trials, only one or two will typically be licensed for eventual use in
humans [2]. The number of new drugs approved per billion US dollars spent on R&D has
halved roughly every 9 years since 1950, falling around 80‐fold in inflation‐adjusted terms.
The failures of drug clinical trial are primarily due to the poor predictive power of existing
preclinical models. The existing cell culture techniques often failed to mimic the complexity
of living systems and are incapable of modeling situations where organ‐organ or tissue‐tissue
communication are important. Moreover, cells maintained in standard in vitro culture
conditions often suffer from incomplete maturation or are held in a configuration that prevents
their full functional development, making predictions of in vivo tissue function more difficult
to extrapolate. Although animal models preserve the intricacy of living systems, due to the
inherent complexity of interconnected tissues, elucidation of specific mode of drug action is
often difficult that leads to confound observations. Furthermore, animal models have, on
multiple occasions, been predicated human responses to drug treatment in a rather harmful
way [3, 4]. The drug discovery community has identified the critical need for new testing
approaches and an intermediate human in vitro model in the early stage of drug development
to generate reliable predictions of drug efficacy and safety in humans that could mitigate the
side effects observed in clinical trials and LOC systems can play a pivotal role in this by
fulfilling this unmet need by microengineered cell culture models with miniaturized and
automated assays that will increase resolution and precision. These models leverage cutting‐
edge microfabrication and microfluidics technologies to control the cellular microenvironment
with high spatiotemporal precision and to present a variety of extracellular cues to cultured
cells in a physiologically relevant context [5–6].
This chapter deals with the cutting‐age research in the field of microfabrication technologies
and multiorgan microdevices that mimic key aspects of human metabolism. We discuss about
latest advancements and how this emerging field transforms the face of biomedicine.
1.1. Need of microfluidics technologies for global health: applications and limitations
Diagnostic applications for global health have seen a fast pace in recent years. LOC, micro total
analysis systems (μ‐TAS) or microfluidics systems are the major breakthrough in this regard
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and with their state‐of‐art technology, these miniaturized integrated devices have great
potential to change the face of healthcare sector globally. Basically, from industrial perspective
to develop a high‐throughput diagnosis system, it must utilize small chemical volumes to keep
the cost of development at an affordable level. The current trend of miniaturized and auto‐
mated assays can address these issues directly owing to their better resolution and accuracy.
Microfluidics devices are new and promising players in healthcare segments. These devices,
which scaled down analytical processes in conjugation with advances in microfluidics
technology, are the soul motivation behind various chip‐based methods of lower cost and rapid
analysis than the conventional laboratory bench‐scale methods. Although these microelectro‐
mechanical systems (MEMS) or miniaturized chip‐based systems have seen a fast pace in other
fields, such as electronics, aerospace and computer science, since their inception in early 1990s
and have witnessed many innovations based on these techniques, in this chapter, our prime
focus is how these technological advancements have been transformed into the face of
biomedical sciences with its wide range of biological applications, such as high‐throughput
drug screening, single cell or molecule analysis and manipulation, drug delivery and advanced
therapeutics, biosensing and point‐of‐care diagnostics, among others. [7]
Extracting new phenomena and elaborated information about the biologically active systems
is the basis of all innovations in the field of biomedical sciences. The complex live systems and
richness of biological processes are stimulating factors for new LOC approaches, and these
emerging technologies are gradually changing the scenario, and now, we can seek experi‐
mental answers at the molecular level.
1.1.1. Development of microfluidics technologies for different applications in healthcare segment
In a broader sense, microfluidics can be linked to the development of integrated circuit
technology and wafer fabrication facilities. They have unique ability to combine different
systems possessing high‐throughput capabilities, new data processing and storage strategies.
These miniaturized devices provide new tools for highly parallel, multiplexed assays with
better isolation, purification and handling of entities, cells or organisms for a simplified,
parallel analysis. Initially, silicon and related materials were the preferred choices to fabricate
miniaturized devices but now polymeric materials are also the stake holders for because of
ease of manufacturing by embossing or molding [8]. They are attached to other surfaces such
as silicon, and the formation of fluid channels and patterns on polymeric devices are relatively
easy. Other materials, such as semiconductors and metals, are other necessary components of
electrical detection schemes, and earlier reports are there where semiconductor nanowires and
carbon nanotubes are being studied as sensor components [9, 10]. Integration of mechanical
devices with fluid systems for biological implementation and to fabricate disposable systems
has been reported earlier and summarized in many reviews [7, 11, 12]. Figure 1 shows an on‐
chip disposable diagnostic card. In this segment, few latest applications of LOC devices are
discussed briefly [50].
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Figure 1. Example of an integrated disposable diagnostic card. (a) Image of a card. The red O‐rings are for interfacing
with off‐card components, valves and pumps, that will eventually be incorporated onto the card itself. (b) Schematic of
the card [49].
1.1.1.1. On‐chip DNA hybridization and PCR
An on‐chip deoxyribonucleic acid (DNA) hybridization assay refers to the bioassay conducted
on the microfluidic system/device based on the nucleic acid hybridization technique [13]. From
its earlier applications in 1980s, it has been evolved as a powerful tool to detect and identify
the presence of a specific DNA sequence. On‐chip DNA hybridization systems are amalga‐
mation of advantages of both microfluidics and hybridization.
In the past 20 years, microfluidics devices have been emerged as an important area of research.
As a combination, miniaturization eliminates the need of large reagent consumption, time‐
consuming labor‐intensive procedures and involvement of bulky or expensive equipment
while keeping its distinctive advantages of high sensitivity, selectivity and specificity of
conventional techniques. Additionally, these miniaturized devices can play a pivotal role in
healthcare sector of the Third World countries, by bringing cheaper and smaller, but still
sophisticated analytical tools to rural areas and resource‐poor regions [14]. This section focuses
on few recent application of on‐chip polymerase chain reaction (PCR) devices. There are few
criteria to be taken care of while designing on‐chip PCR systems such as high‐temperature
resolution and acquisition rate for precise thermal cycling in microfluidics. Apart from
traditionally embedded thermocouples and thermometers [15–17], Wu et al. [18] reported an
integrated PCR system with a temperature controller using platinum (Pt) thin film as heater
and temperature sensor, an optical detection system and an interchangeable (disposable or
modular) PCR chip, which was independent from the two functional systems as shown in
Figure 2. In this system, Pt thin‐film sensor was patterned to microsize and integrated to thin‐
film heater into the chip to provide rapid response and precise integration.
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Figure 2. Interchangeable PCR chip and temperature control device. (a) Top view of PCR chip. (b) Back side view of
heater chip, Pt heater and thermal sensor were integrated in one chip. (c) optical detection system in upper panel [18].
In another approach, Chia et al. developed fully integrated, portable PCR device that consists
of the following four major parts: a disposable chamber chip with microchannels and pumping
membranes, a heater chip with microheaters and temperature sensors, a linear array of
electromagnetic actuators and a control/sensing circuit. Apart from the small size (67 × 67 × 25
mm3) and less power consumption (5V DC) and reduced volume of DNA solution, this system
could effectively reduce the PCR process time into one‐third of the time required by typical
commercial PCR system [19]. In another approach, Steinbach et al. [20] came forward with
their K‐Ras mutation detection on chip. Figure 3 shows schematic of the on‐chip detection
device. They aimed to develop a fast and reliable chip‐based K‐Ras mutation based on existing
microfluidic chip platform for visual signal readout of K‐Ras mutation profiling. Successful
hybrid formation was monitored by streptavidin horseradish peroxidase binding, followed
by an enzymatic silver deposition. Silver spots represented robust endpoint signals that
enabled visual detection and grey value analysis. This study has the potential to replace
expensive detection devices. These few examples give a gist of microfluidics in DNA detection
and PCR. Many reviews are available on this topic [13, 21, 22].
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Figure 3. Assay design (a) The schematic workflow of the assay is pictured, starting from isolation of genomic DNA
from cells, DNA amplification and on‐chip hybridization, respectively. (b) The location of KRAS codon 12 mutations
within the amplicon and the corresponding capture probes is illustrated (ctr = positive control; wt = wild type; SNP =
single‐nucleotide polymorphism; SA‐HRP = streptavidin horseradish peroxidase) [20].
1.1.1.2. On‐chip biosensing and disposable point‐of‐care devices
Over the past decade, on‐chip diagnostic systems observed explosive growth and showed
significant potential for clinical diagnostics specifically for diseases, including toxicity. The
early, rapid and sensitive detection of the disease state is the prime objective for every on‐chip
clinical diagnosis. Initially, this field was focused on developing the concepts of LOC and later
evolved to applications in a number of biochemical analysis operations, such as clinical
analysis (blood gas analysis, glucose/lactate analysis, etc.) [23].
In on‐chip diagnosis devices, apart from pregnancy detection kit and glucometer, most
applications are based on genes and peptides detection for early indicators of disease [24–26].
For instance, Dinh et al describe a multifunctional biochip with nucleic acid and antibody probe
receptors specific to the gene fragments of Bacillus anthracis and Escherichia coli, respectively
[25]. These devices were based on the detection of specific diseases or biological warfare agents
by incorporating biomarkers specific to such agents. Monitoring of regular metabolic param‐
eters, such as glucose and lactate, was demonstrated by the I‐Stat analyzer that provides point‐
of‐care testing for monitoring a variety of clinically relevant parameters [26]. Immunosensing
applications as a part of clinical diagnostics have also been demonstrated [27, 28].
Recent years have witnessed a vast range of applications of LOC due to the significant benefits
of small sample and reagent volume utilization, economic and rapid analysis with less wastage
and possibility of developing disposable devices. Ahn et al. demonstrated a fully integrated
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module of wristwatch-sized analyzer that included a smart passive microfluidic manipulation
system based on the structurally programmable microfluidic system (sPROMs) technology,
for preprogrammed sets of microfluidic sequencing with an on‐chip pressure source for fluid
driving, sequencing and biochemical sensors [23]. Point‐of‐care testing (POCT) is one of the
most impressive developments of microfluidics in life sciences and can be defined as diagnostic
testing at or near the site of patient care to make the test convenient and immediate. In many
countries, DNA test kits for HIV are already available [29]. This is a rapidly growing field, and
more detailed information can be obtained from various reviews in this area [23, 31, 32].
Figure 4. (a) View of microfluidic chip featuring the two distinct hydrodynamic flow‐focusing regions and expanding
nozzle geometry with a narrow orifice. All channels have a rectangular cross section and a height of 25 μm. (b) View of
targeted lipospheres with gas in core and active ingredient in lipid oil complex [36].
1.1.1.3. Drug delivery applications
The major objective of drug delivery systems is to localize the pharmacological activity of the
drug at the site of action as targeted drug delivery systems directly deliver the payload to the
desired site of action with minimum interaction with normal cells. This phenomenon is
especially important for anticancer drugs, as their toxicity to healthy cells is a cause of concern
to improve therapeutic response and patient compliance. Last decade witnessed tremendous
growth in targeted dosage forms for controlled release [33–35].
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them unfortunately die due to lack of better treatment strategies. With the advancement in
diagnostic, therapy techniques and nanomedicine, now better understanding of disease onset
and treatment is possible, but still more will be offered by state‐of‐art microfluidic technology
in terms of control over particle size, composition, encapsulation rate and better performance
of nanoformulations, which have a great impact on the cancer survival rate.
In the series of microfluidics‐based delivery systems, a gas‐filled lipospheres was reported by
Hettiarachchi et al. for targeted delivery of doxorubicin, using polydimethylsiloxane (PDMS)‐
based microfluidic chip that contained two distinct hydrodynamic flow‐focusing regions for
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local administration into tumor tissues as shown in Figure 4a [36]. Generally, liposomal‐
encapsulated doxorubicin suffers from relatively nonspecific biodistribution due to size
selection and nontargeted accumulation [37]. As a solution, Hettiarachchi et al. prepared
multilayer lipospheres with oil layer of triacetin (capable of carrying bioactive molecule)
sandwiched between inner gas‐filled core and outer lipid layer (polyethylene glycol (PEG)
lipid conjugate DSPE‐PEG2000‐Biotin) with avidin as targeting moieties based on the fact that
multilayer gas‐filled lipospheres for high payload delivery at target sites could overcome the
limitations of liposomal preparation. Figure 4b is representation of the modified delivery
system.
Another strategy that is gaining importance in diagnosis and treatment of cancer is theranostic
nanomedicine that combines imaging, diagnostic agent and antitumor agent. Theranostic lipid
complex nanoparticles formed by bulk mixing do not give control over composition and size
which can be overcome with a microfluidic setup [37, 38]. A static micromixer‐coaxial
electrospray (MCE) for the single‐step synthesis of theranostic‐lipid complex nanoparticles
(cationic lipid‐nucleic acid complexes called lipoplexes) was designed by Wu et al. to overcome
this limitation. Multicriteria evaluation (MCE) technique produced monodispersed particles
with a diameter of ∼194 nm and high encapsulation efficiency compared to a more
conventional bulk process; the advantage of this process is shown in Figure 5a. Quantum dots
(QD605) and Cy5‐labeled antisense oligodeoxynucleotides (Cy5‐G3139) were encapsulated as
the model imaging reagent and therapeutic drug, respectively, with successful cytoplasm to
delivery of drug into cytoplasm of A549 cells (nonsmall‐cell lung cancer cell line) leading to
48 ± 6% down regulation of the Bcl‐2 gene expression [37].
Figure 5. (a) Schematic drawing of the static micromixer‐coaxial electrospray (MCE) showing its various components
[37]. (b) Schematic of microfluidic gradient generator [40].
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A microfluidic gradient generator (MGG) was developed by Abhyankar et al. [39, 40] for testing
drug response on a cellular basis. These devices offered unique features of, higher resolution,
real‐time observation, tunable drug concentration and reduced costs in comparison with their
conventional counterparts, Transwell and Dunn chambers. MGGs are based on two techniques
—gradient achievement through time‐evolving diffusion or parallel streams mixing. Fig‐
ure 5b shows a sink‐source flow‐free gradient generator. The absence of convection flow is the
key advantage of this system that eliminates the shear‐stress induced to cells.
Apart from nano‐based drug delivery techniques, administration of drug to the whole body
is another application of microfluidics where miniaturized needles can be designed (micronee‐
dles) for improved delivery effectiveness and reduce the pain related to drug administering.
Microneedles can be classified into the following four general types: (i) solid microneedles, (ii)
drug coated, (iii) polymeric microneedles with encapsulate drug that fully dissolve in the skin
and (iv) hollow microneedles for drug infusion into skin.
1.1.1.4. Microarrays technologies
A microarray is an analytical device that comprises an array of molecules (oligonucleotides,
cDNAs, clones, PCR products, polypeptides, antibodies and others) or tissue sections immo‐
bilized at discrete ordered [41]. In a general microarray device, sample solutions are confined
in microfabricated channels and flow through the probe microarray area. Enhanced sensitivity
is obtained due to high surface‐to‐volume ratio in microchannels of nanoliter volume and
advantages of both fields can be exploited simultaneously by combining DNA microarray with
microfluidics [42, 43]. Consumption of small volumes in microfluidic systems is an added
advantage to develop low‐cost, compact and portable LOC systems. Secondly, the surface
hybridization of target DNA can also be accelerated on microfluidics platform by electrokinetic
delivery of negative charged DNA molecules on to the probe area [44].
Lee et al. proposed a recirculating microfluidic device for the hybridization of oligonucleotides
to DNA microarray [45]. Peristaltic pump was connected to the both ends of the microchamber
to generate circulatory flow as shown in Figure 6a. With this device, hybridization time was
also shortened to 2 h and sample volume was 100 μL.
Many companies are involved in designing microfluidic technology for various high‐through‐
put applications, such as immunoassays, diagnostic devices, single molecule DNA and protein
detection as well [42]. Researchers from the University of Chicago, USA, and other laboratories
demonstrated the use of two‐phase droplet systems that generate droplets within microfluidic
channels to be used as microreactors for high‐throughput screening of compounds and
multiple chemical reactions [46, 47]. Recently, Huang et al. presented a microfluidic device
integrated with pneumatically controlled microvalves and micropumps for parallel DNA
hybridizations to analyze 48 different DNA targets (18‐mer oligonucleotides derived from the
Dengue viral genes) simultaneously. A schematic of device is shown in Figure 6b [48].
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Figure 6. (a) Diagram for sample recirculation system on the hybridization chamber and hybridization image of fluo‐
rescence‐labeled target nucleotide [45]. (b) Left: Photograph of the microfluidic chip containing shuttle‐flow channels,
microvalves and micropumps. The shuttle flow hybridization was realized by controlling the gas ports 1, 2 and 3 auto‐
matically. Right: Hybridization specificity assay using four serotypes of Dengue virus under shuttle flow conditions
(frequency 2 Hz) in channels. The duration of hybridization process was 90 s and washing time was 30 s [48].
The commercialization of microarray and microfluidic technologies is evolving very fast as
demonstrated by the emergence of many start‐up companies due to its state‐of‐art technology.
Affymetrix is an example where they generated a new market based on their GeneChip®
technology over a 12‐year period.
1.1.2. Challenges for lab‐on‐chip devices
Apparently, microfluidics devices have the potential to serve different scientific needs of
healthcare and biomedical sectors and as we discussed earlier, their several successful
applications have already been reported. The major advantages associated with miniaturized
systems are faster/more accurate diagnoses; better epidemiological data for disease modeling;
vaccine introduction; and utilization of minimally trained healthcare workers and better use
of existing therapeutics but still many hurdles are there in broader applications of microfluidics
systems.
However, there is always a silver lining and due to vastly increased interest in global health
issues, the current funding climate for the development of diagnostics kits is significantly good.
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Financial support for new and improved diagnostic tools for priority diseases, such as
tuberculosis and cancer, is there. The Gates Foundation's Grand Challenges in Global Health
initiative is supporting the development of prototypes of a disposable/hand‐held reader
system [49]. Thanks to increased attention on the global health issues and the motivation for
their better treatment, we are witnessing the beginning of microfluidics diagnostic devices for
early detection of these fatal diseases in coming few years.
We started our discussion on the issues of need of miniaturized devices for pharma industry
and biomedicine. After a brief overview on impact of existing LOC systems on global health,
we discuss how the new emerging cells and OOC techniques will have an everlasting effect
on different areas of human health. The latest progress in microfluidics has led to the devel‐
opment of OOC microdevices, which recapitulate the complex structure, microenvironment
and physiological functionality of living human organs. The practical implementation of these
miniature organ systems is revolutionary for the field of biomedical sciences and will play a
pivotal role for drug discovery and will improve our understanding for mode of action of
molecules of therapeutic potential—overall, this state‐of‐art technology is expected to be a
boon for pharma and healthcare sector.
2. Evolution of cells and organ on chip: from 3D culture to organ on chip
The process of growing eukaryotic cells in vitro was put forth by Harrison in 1907 to investigate
the origin of nerve fibers [50] and since then its almost 100 years, these 2D cell cultures have
greatly advanced our knowledge of cellular biology. They have been routinely and diligently
undertaken in thousands of laboratories worldwide. However, the 2D cell cultures are
arguably primitive and do not reflect the anatomy or physiology of a cell or tissue microen‐
vironment in true sense. Two‐dimensional (2D) cell cultures oversimplify the extracellular
matrix (ECM) and cell microenvironment and the processes, such as drug delivery, toxicolog‐
ical analysis, gene expression and apoptosis, may not be directly taken up for the in vivo
experiments from 2D analysis as ECM is completely different in in vitro and in vivo and cannot
be adequately mimicked by 2D cell systems [51, 52]. These limitations of 2D cell culture led to
the innovation of 3D cell culture methodologies; the concept that gave birth to the idea of OOC
devices. In 3D culture, cells are grown in extracellular matrix, that is, hydrogels, scaffolds or
on hanging drops. The cells, growing in third dimension, exhibit enhanced expression of
differentiated functions and improved tissue organization but require a multidisciplinary
approach and expertise [53, 54].
Generally, spheroids, cell aggregates and cell sheets are the common platforms for 3D culturing
[55–60]. Basic objectives for developing 3D cell culture systems vary from engineering tissues
for clinical delivery to the development of models for drug screening. It was observed that
certain cellular processes of differentiation and morphogenesis for tissue engineering occurred
preferentially in 3D instead of 2D.
In one study by Slamon et al., alteration of cellular architecture between 2D and 3D cells was
observed in the growth of SKBR‐3 cells that overexpress HER2, an oncogene found to be
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overexpressed in approximately 25% of breast tumors [61]. Cells grown as 3D spheroids using
p‐HEMA‐coated plates had HER2 homodimers form, while in 2D cultures, HER2 formed
heterodimers with HER3 [61]. Recently, Choi et al. [62] also reported that human neural stem
cells with familial Alzheimer’s disease mutations when grown in 3D culture recapitulate both
amyloid‐β plaques and neurofibrillary tangles. 3D cell culture more accurately simulates
normal cell morphology, proliferation, differentiation and migrations. Similarly, in chemo‐
therapy procedures, a difference in sensitivity to drug exposure was observed in cells grown
in 2D or 3D microenvironments [63]. A study by Tung et al. indicated that A431.H9 cells grown
in 2D and 3D show differences in viability when treated with the same concentrations of 5‐
fluorouracil (5‐FU) and tirapazamine (TPZ). In the case of 5‐FU, 2D cultures were reduced to
approximately 5% viability following a 96‐h treatment (5‐FU; 10 mM), whereas 3D cells treated
with the same concentration and duration, showed 75% viability; indicating that these 3D
spheroids were more resistant to the antiproliferative effects of 5‐FU [64].
In recent years, an increasing shift in research focus from 2D cells cultures to 3D cell cultures
occurred which in turn translated 2D in vitro research to 3D in vivo animal models.
2.1. Advantages and limitations of 3D cell culture
• Flexible synthesis approach in 3D cell culture allows facile manipulations for cellular
microenvironment modeling.
• With 3D cell culture systems, study at different states of disease models can be done in a
similar tissue microenvironment that may reduce the need of animal testing.
• 3D culturing is more authentic way of monitoring drug metabolism studies instead of 2D.
Due to the presence of layers of cells in 3D culture with tightly bind cells as compare to a
monolayer in 2D, drug diffusion to cells by blocking or slowing simulate the real barriers
for drug action.
• Scaffolds to support 3D cell with simultaneous growth factor, drug or gene delivery can also
be synthesized.
• 3D cell culture has direct applications in tissue engineering and regenerative medicine.
Figure 7 is schematic of various methods of synthesis of 3D culture, including hanging drop,
forced floating method, etc.
It is an evolving field and requires further research for its optimization, and therefore, it is
evident that some clarity is needed in selecting the best method for the generation of 3D cells
from individual cell lines. Additionally, the best established 3D culture methods currently
available produce avascular tumor models that failed to mimic the full architecture of in vivo
tissues and vascularization aspect of tumor development is left out, which is a huge significant
part of true tumorigenesis. These limitations are the prime hurdles in the application of 3D
culture as potential drug discovery tools.
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Figure 7. Schematic of 3D culture synthesis methods. These methods include forced‐floating of cells; hanging drop
methods; agitation‐based approaches; the use of matrices or scaffolds; and microfluidic systems [53].
2.2. From 3D culture toorgans on chips: a giant leap toward biomedicine revolution
In previous section, we discussed the role of 3D cell culture and its significant impact on
different fields. The next important step of 3D microfabrication is evolution of integrated OOC
microsystems with the ability to mimic key structural, functional, biochemical and mechanical
features as well as interactional effect of microenvironment on cell and tissues in vivo of living
organs in a single device [65]. By definition, OOC devices are microfluidic devices for culturing
living cells in continuously perfused, micrometersized chambers in order to model physio‐
logical functions of tissues and organs [66].
Cellular behavior and its interaction with in vivo microenvironment is still an unsolved
mystery. Advancements in the field of 3D OOC opened entirely new possibilities to create in
vitro models that reconstitute more complex, 3D, organ‐level structures, with integrated
chemical signals and important dynamic mechanical cues. OOC devices not only mimic the
cells biomechanical and biochemical behavior in in vivo tissue but also predict the interactional
effects of microenvironment on cells and tissue functions [58]. This unique ability of OOC
devices makes them a potential candidate for drug discovery programs and a boon for
healthcare segment. Though this state‐of‐art innovation is in its nascent state, preliminary data
obtained had shown promising future of OOC devices with wide applications in biomedical
sciences. As a proof of concept, researchers have fabricated two stacked PDMS cell culture
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chambers separated by permeable synthetic membrane to study polarized functions of various
epithelial cells of intestine [67, 68], lung [69], kidney [70], heart [71], etc.
2.3. Basic microfabrication techniques and material for OOC devices
To mimic in vivo organ‐specific microenvironment, OOC devices required high precision and
accuracy. Microfabrication techniques are the preferred methodologies to fabricate OOC
devices due to feasibility of constructing tissue‐specific environment at microscale. Typical
techniques include replica modeling, soft lithography and microcontact printing [52, 66, 72].
Figure 8 is a schematic representation of these techniques.
Figure 8. Schematic of microfabrication techniques. (a) Replica modeling. (b) PDMS stamp for formation of microchan‐
nels [158]. (c) Microcontact printed protein for cell pattering [159].
Replica molding techniques have been used to replicate complex surface relief patterns to
produce biomimetic structures that mimic organ‐specific microarchitecture. Lee et al. designed
the replica modeling techniques to recreate the artificial liver sinusoid and natural endothelial
barrier layer in liver. [73] This was an important breakthrough that successfully reconstituted
a tissue‐tissue interface that was a critical element of whole liver organ structure, and was not
possible in conventional 3D ECM gel cultures. In other report by Esch et al [74], photolithog‐
raphy was explored to recreate the key aspects of villi structure on microfluidic chambers
covered by 3D shaped, porous membranes for models of the gastrointestinal tract epithelium
by two‐exposure step fabrication process. As shown in Figure 9, complete crosslinking was
used to fabricate the chamber and partial with SU‐8 to form the porous membrane. This
microdevice could create better in vitro models of human barrier tissues, such as the gastroin‐
testinal tract epithelium, the lung epithelium or other barrier tissues with multiorgan “body‐
on‐a‐chip” devices for drug‐screening application.
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An array of PDMS microchambers interconnected by 1 μm wide channels was similarly used
to enable growth and in vivo‐like reorganization of osteocytes in a 3D environment that
replicated the lacuna‐canalicular network of bone [76]. In a similar approach, Sudo et al. came
up with the idea of a microdevice incorporating ECM gels microinjected between two parallel
microchannels to investigate vascularization of liver tissues in 3D culture microenvironments
[76], while a compartmentalized microfluidic system for coculturing of neurons and oligo‐
dendrocytes to study neuron‐glia communication during development of the central nervous
system was developed by Park et al. [77]
Figure 9. Porous SU‐8 membranes that are anchored to and span across microfluidic chambers. The membranes are
either flat (a and b), or they were dried over sacrificial silicon pillars and take on the shape of the pillars (c and d). (b) A
higher magnification scanning electron microscopy image of a flat membrane with 3 μm pores. (d) Close‐up of the 3D‐
shaped membrane imaged in (c). The image reveals the membrane's porous character. The sacrificial silicon pillars can
be removed via xenon difluoride etching 3D cell culture of gastrointestinal epithelial cells (Caco‐2) that were grown for
8 days (a, b, c) and 21 days (d, e, f) on porous SU‐8 membranes that were dried on silicon pillars (50 μm wide and 200
μm high) [74].
From their inception, production of these microdevices relied on silicon microfabrication and
micromachining techniques. Although widely explored and applied, silicon micromachining
is rather complex, costly with limited accessibility to specialized engineers. To overcome these
practical hurdles, researchers developed microfluidic systems made of the silicone rubber,
poly(dimethylsiloxane) (PDMS), that are less expensive and easier to fabricate, which opened
entirely new avenues of exploration in cell biology. [6]
PDMS has several unique properties that make it a perfect choice for the fabrication of
microdevices for the culture of cells and tissues. First, PDMS possesses superior gas
permeability and flexibility for adequate oxygen supply to cells in microchannels, which
eliminates the need for separate oxygenators, commonly required in silicon, glass and plastic
device and is particularly important to maintain differentiated function of primary cells of high
metabolic demand [54, 78]. PDMS microfluidic systems enabled the formation of viable and
functional human tissues.
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Excellent optical transparency is prime advantage of PDMS that enabled real‐time monitoring
of nitric oxide production and variation in pulmonary vascular resistance in a microfluidic
model and cell morphology, tissue repair and reorganization. [79–81]
Moreover, control of cellular parameters is another important phenomenon in designing OOC
devices and recent advances in microfabrication techniques have significant contribution
toward efficient monitoring and control of cellular responses and study of broad array of
physiological factors that wasn't possible with 3D static cultures. Electrical, chemical, me‐
chanical and optical probes for direct visualization and quantitative analysis of cellular
biochemistry, gene expression, structure and mechanical responses also can be integrated into
virtually any microfabricated cell culture devices and more relevant data can be obtained with
these advanced OOC devices. [54, 66]
3. Organ‐on‐chip devices: concept to application
In this section, various state‐of‐art existing OOC platforms and their structural features,
working principles, potential and feasibility for biomedical application are discussed. OOC
devices can be defined as microfluidics systems for living cells culturing in continuously
perfused, micrometersized chambers in order to model physiological functions of tissues and
organs [66]. The prime objective of this emerging technique is to fabricate minimal functional
units of an organ that recapitulate tissue‐ and organ‐level interactions. These devices have
great potential for investigating basic mechanisms of organ physiology and are well suited for
the study of biological phenomena that depends on tissue microarchitecture and perfusion
and last for relatively short span (< I month). These chips often consist of featuring multiple,
controllable parallel channels, splitting and merging channels, various pumps, valves and
integrated electrical and biochemical sensors. Some kind of microenvironment stimuli derived
from organ‐level functions can be applied to cells from certain organ.
3.1. Basic working mechanism of OOC devices
OOC systems are basically elaborated microengineered physiological systems that reconstitute
the key features of specific human tissues and organs and their interactions as depicted in
Figure 10 [82, 83].
Key factors in OOC designing include the following:
• Fabrication of OOC devices start with identifying the key aspects of biochemical, mechanical
environment of specific organ, including local factors from neighboring cells or tissues and
stretch of organ. [82].
• The final step is to measure the functional output parameters of the cultured cells.
Earlier, with 2D and 3D cell cultures, efforts were taken to control and regulate the cell growth,
shape and other cellular events but due to lack of precise 3D environment, these models
suffered with inaccuracy and reliability in recapitulating the issue‐ and organ‐specific systems
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[83]. But with the state‐of‐art OOC technology, new possibilities to create efficient in vitro
models with organ‐specific microenvironments, tissue microarchitecture reconstruction,
spatio‐temporalchemical gradients, tissue‐specific interfaces, crucial dynamic mechanical cues
and biochemical signals [54, 84]. In this section, we describe recent progress in this field and
currently reported OOC devices such as liver, kidney, intestine, kidney, heart, skin and blood
vessels.
Figure 10. Representation of organ‐on‐chip device and concept of modeling, a complex microenvironment and their
existing simulation of functional units [82].
OOC devices can be classified into three broad segments based on the working mechanisms:
[82]
i. Membrane‐based penetration and mechanical stimuli—blood‐brain barrier, lung,
kidney, gut, heart on chip.
ii. Organ function mimicking based on anatomy—arteries and spleen on chip.
iii. Perfusion‐based OOC devices—liver, brain and womb on chip.
3.2. Membrane‐based organ on‐chip devices
To study the drug response with respect to human biological barriers is a crucial step in drug
discovery. Researchers developed 3D compartmentalization with membrane‐based multilayer
compartments for mimicking biological barriers such as the blood‐brain barrier [85, 86, 99],
the kidney transport barrier [87, 71], and the lung's alveolar‐capillary interface [88, 89] that can
be considered a major breakthrough for biomedicine. In this segment, recent discoveries in
membrane and muscular thin films to recapitulate the physiochemical interface and mechan‐
ical cues are described.
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3.2.1. Lung on a chip
Lung is an important organ of respiratory system for the exchange of oxygen and carbon
dioxide in blood stream. The elementary tissue unit of the lung is the layer of epithelial and
endothelial cells over which the exchange of gases between air and blood takes place. The
geometry of the lung tissue contains the epithelial‐endothelial interface, epithelium‐air
interface, endothelium‐blood interface and periodic mechanical force with each respiratory
cycle. Understanding of cell‐cell interactions, cell‐blood and cell‐gas flow is utmost necessary
for drug discoveries and physiochemical research. Complex geometric and compositional
structure of lung is the great barrier to enable straightforward manipulation and observation
of cells.
Lung‐on‐chip is the microreplica of the lung on a microchip. This is used for nanotoxicology
studies of various nanoparticles that are introduced into the air channels and to understand
the pulmonary diseases where due to the formation of liquid plug that blocks small airways
and obstruct gas flow in alveoli [89]. To understand the mechanism of liquid plug propagation
and rupture, Huh et al. designed a microengineered system that consists of two PDMS
chambers separated by thin polyester membrane with 400‐nm pores. This system mimicked
an in vivo basement membrane for small airway epithelial cells (SAECs) attachment and
growth.
Figure 11. Schematic of lung on‐chip system. (a) PDMS‐based membrane to mimic alveolar capillary barrier and a vac‐
uum based deformation controller. (b) Size variation of lung during inhalation. (c) Bonding and alignment of three lay‐
er PDMS devices [70].
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Using this system, injurious response of SAECs to propagation and rupture of finite liquid
plugs at an air‐liquid interface afflicted with surfactant deficiency was demonstrated [88].
Another report by Huh et al. designed an alveoli‐on‐chip having alveolar and the capillary
interface. To mimic the breathing pattern, two chambers were constructed at the side through
which air is pumped in at certain required pressure, continuous increase and decrease of the
flow is done in order to accomplish the inhalation and exhalation pattern. A thin flexible layer
of PDMS was used in the central chamber where coculturing of human alveolar epithelial cells
and blood vessel wall cells on the opposite sides is done. The membrane stretches and relaxes
according to the flow of air. The culture medium is pumped through the lower microchannel
to mimic the blood flow and the sample is injected on the top layer that interacts with the
alveolar epithelial cells as shown in Figure 11 [70]. In another model to study alveolar cell
complexities, Douville et al. put forth their system consisting of two compartments—alveolar
chamber and actunation channel. These chambers were separated by a PDMS thin membrane
to create both cyclic stretch and fluid mechanical stresses. This in vitro model successfully
demonstrated the difference in morphological changes cells undergo when exposed to
combine stresses as compared to cells exposed solely to cyclic stretch [90].
These inventions reconstituted the critical lung functions and can be applied for in vivo models
in environmental toxins, absorption of aerosolized therapeutics and the safety and efficacy of
new drugs. Such a tool may help accelerate pharmaceutical development by reducing the
reliance on current models, in which testing a single substance can cost more than $2 million
[54, 66].
3.2.2. Kidney on chip
The word kidney‐on‐chip suggests that the kidney is mimicked on a chip. Here, the renal cells
or the nephrons are mimicked on the chip and this is used for checking the toxicity of drug
and its screening. This model helped to know more about the filtration, reabsorption of the
necessary molecules from the drug as kidney toxicity is a cause of concern during drug
development [91]. Nephron is the basic unit of kidney and mainly consists of glomerulus,
which acts as a filtering unit that helps in filtering unwanted toxic particle from the required
molecules and helps in throwing out these unwanted molecules. Nephron's glomerulus,
proximal convoluted tubule and loop of Henle are mimicked on the chip. As reported by
Weinberg et al., an artificial nephron function with three components on a single chip was
designed [92]. Jang at al developed an on‐chip kidney to reproduce cisplatin nephrotoxicity.
Their device contained two compartments, where top channel mimicked urinary lumen and
has fluid flow, whereas the bottom chamber imitate interstitial space filled with media. Kidney
cells have less shear stress than endothelial or lung cells. This device was operated with 1 dyn/
cm2 of sheer stress [93]. A modified version of same device using human proximal tubular cells
was also developed by the same group. The advantage of using proximal cells was there less
sheer stress ∼0.2 dyn/cm2 that is similar to that of the living kidney tubules surrounding as
shown in Figure 12 [94]. Better understating of filtration pattern and absorption behavior that
leads to toxicity was the prime aspect of this discovery.
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Figure 12. (a) Nephron on a chip: Schematic of the chip with cross sections of three functional units named glomerulus,
proximal convoluted tubule and loop of Henle, which are response for filtration, reabsorption and urea concentration,
respectively. (b) Kidney reabsorption functions using a microfluidic chip comprising of an apical channel separated
from a bottom channel by proximal tubular epithelial cells cultured ECM‐coated porous membrane [94].
3.2.3. Blood‐brain barrier on chip
To understand and treat neurological diseases, proper understanding of blood‐brain barrier
(BBB) is utmost important. By definition, BBB is a unique selective barrier membrane that
obstructs the passage of most exogenous compounds in blood to the central nervous system
(CNS) while permeable for essential amino acids and nutrients. It is made primarily of three
different cells: endothelial, pericytes and astrocytes, and the membrane is formed by firm
junctions between endothelial cells that control compound permeability with high values of
transendothelial electrical resistance (TEER) [82, 95]. Hatherell et al. designed a membrane‐
based system to replicate BBB by cultivating endothelial cells on the top side of a transwell
membrane while cultivating astrocytes with or without pericytes on the opposite side [88].
However, due to low porosity and uneven pore distribution, this artificial membrane failed to
recreate the close proximity to cell interaction. To address this issue, silicon nitride membrane
was developed by Ma et al. to increase the direct contact between the cells and astrocytes [96].
Another report by Shayan et al. also demonstrated a considerable reduction of the flow
resistance across a nanofabricated membrane with controlled pore size and low thickness (3
μm) and maintenance of metabolic activity and viability for at least 3 days [97]. A novel BBB
in vitro model was developed by Brown et al. for efficient cell‐to‐cell communication between
endothelial cells, pericytes, and astrocytes and independent perfusion with vascular chamber
and brain chamber separated by a porous membrane (Figure 13a) [98]. Booth and Kim also
developed a BBB that impersonated the dynamic cerebrovascular environment having fluid
shear stress and a comparatively thin culture membrane of 10 μm (Figure 13b). This system
has two components called lumenal and ablumenal on which endothelial and astrocytes were
cultured to form the neurovascular unit [99].
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Figure 13. Schematic view of the neurovascular unit (NVU) indicating major components, cell types and their spatial
arrangement. (a) Illustration of key properties should be included in an effective in vitro microfluidic blood‐brain barri‐
er (μBBB) models (left). (b) Structure of microdevice consisting of two channels for astrocytes and endothelial cells cul‐
ture with electrodes for transendothelial electrical resistance (TEER) measurement [98, 99].
These novel systems are the promising tools of future due to their unique characteristics of
feasible real time, TEER and selective permeability to study barrier function and delivery of
drugs to CNS.
3.2.4. Heart on chip
Heart on chip was developed to imitate the contractility and electrophysiological response of
heart in in vitro condition. Microfluidics has previous applications in vitro on cardiomyocytes,
which generates the electrical impulse that controls the heart rate. However, these previous
experiments could not fully reconstruct the tissue microenvironments, such as the propagation
of an action potential (AP) or generation of contractions. To fulfill specific needs of heart‐on‐
chip studies, a biohybrid construct was designed based on muscular thin films (MTFs); a tissue‐
engineered myocardium consist of anisotropic cardiomyocytes cultured on a deformable
elastic thin film with various geometries [100, 101].
Grosberg et al. was pioneer in developing MTF‐based “heart‐on‐a‐chip” system that success‐
fully measured the contractility of neonatal rat ventricular cardiomyocytes exposed to various
doses of epinephrine [100]. Eight separate MTFs were framed the skeleton of their system and
was fabricated in batches enabling them to collect data from multiple tissues simultaneously
in the same experiment. This heart‐on‐chip system mimicked the hierarchical tissue architec‐
ture of laminar cardiac muscle, and measurements of structure‐function relationships,
including contractility, AP propagation and cytoskeletal architecture. In another approach,
Agarwal et al. explored an optimized semiautomated microdevice to test the positive inotropic
effect of different dosages of isoproterenol on cardiac muscle contractility. They achieved an
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increased drug‐screening throughput with their device having 35 separate thin films
(Figure 14a) [102]. Basic components of this device includes a semiautomatic microdevice
integrated an MTF chip, an electrode for electric field simulation, a metallic base on a heating
element as temperature control unit and a transparent window for cantilever deformation
monitoring. As these models were based on animal tissues and cannot recapitulate human
system with precision. To overcome this limitation, Mathur et al. designed cardiac microphy‐
siological system (MPS) that could imitate the human myocardium and envisage the cardio‐
toxicity of drugs accurately, by merging hiPSC‐derived (human‐induced pluripotent stem cells
(hiPSC)) cardiomyocytes with an appropriate microarchitecture and “tissue‐like” drug
gradients (Figure 14b) [103]. These hiPSC‐derived cardiac MPS predicted drug response and
toxicity in vitro and showed a wide applicability for disease modeling and drug screening [82,
103]. Few reports are also available to tackle this complex yet vital organ of our system [104].
Figure 14. (a) Graphical illustration of the fabrication process flow for muscular thin film (MTF) and the semiautomatic
microdevice integrated a MTF chip [102]. (b) Schematic of the microphysiological system (MPS) with nutrient channels
(red), cell‐loading channel (green) and 2 μm endothelial‐like barriers. Optical and confocal fluorescence imaging of 3D
cardiac tissue aligned with multiple hiPSC cardiac cells layer [103].
3.2.5. Stem cells on chip
Human stem cells are a critical component for OOC devices. Few reports are available where
stems cells were grown in scaffolds and microarrays. These controlled conditions make it
possible to mimic the complex structures and cellular interactions within and between
different cell types and organs in vivo and keep the culture viable over long periods of time. It
was reported that neurogenesis of human mesenchymal stem cells can occur in the absence of
chemical stimuli, simply through the substrate stiffness [105]. Figure 15a is illustrating a PDMS
membrane‐based platform for stem cells growth.
In principle, all cell sources, whether primary cells (directly taken from an organ or tissue, e.g.,
by means of a biopsy needle), or cells or in the form of cell lines, from animal or human origin,
can be useful for the OOC approach. The basic criterion for selecting the stem cells for OOC is
target disease. For the diseases with well‐known gene mutation, the DNA, specific disease‐
causing DNA mutation can be introduced into a stem cell line by the technique of homologous
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recombination, resulting in two human cell lines with one having disease‐causing DNA
mutation in one of them. For this purpose, both hES (human stem cells) and iPSC (induced
pluripotent stem cells) sources can in principle be used. On the other hand, for diseases caused
by a whole spectrum of mutations in any part of the disease‐causing gene, or diseases
associated with a more complex genetic background, iPSC cell line or adult stem cells derived
from a patient with the disease need to be used to recreate “the patient”—on a chip. iPSC cells
are the first choice in contrast to adult stem cells, due to ease of regeneration [106].
Figure 15. (a) PDMS based on‐chip platform for stem cells. (b) Crypt‐villus structures grown from single LGR5 positive
adult stem cells from the intestinal crypt [106].
Three‐dimensional “organoid” stem‐cell culture technology was developed in the laboratory
of Hans Clevers at the Hubrecht Institute. In this approach, intestinal stem cells were isolated
from the intestinal epithelial tissue by separating tissue cells from each other. Subsequently,
few stem cells within the cell mixture were identified by coupling them to a specific fluorescent
antibody, followed by isolation with a fluorescence‐activated cell sorter. 3D environment was
created by the gel surrounding the cells to make them feel comfortable in their new “niche.”
In this process of cell growth, the stem cells were bound to their “mate,” which is necessary to
provide the essential cell‐cell contact to start the self‐renewal process. Once in the dish, each
cell combination starts to self‐assemble, a new crypt‐villus structure in three dimensions forms
called organoids (Figure 15b).
3.3. Anatomy‐based organ function mimicking
As described in previous section, microengineering platforms evolved as critical methods for
the fabrication of various models of organs in the biomedical sciences. Newer inventions in
this filed are reported to generate patterns of complex microstructures with precise control of
fluid dynamics and incorporation of specific biological element that simulates organ functions
directly. In this segment, few OOC devices based on anatomical mimicking will be described.
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3.3.1. Spleen on chip
Spleen is a secondary lymphoid organ for selective filtration of damaged RBCs and infectious
microbes including Plasmodium parasites [107]. Keeping in mind its special role in filtration
and to understand its functionally in deeper sense, it was critical to design an OOC with high
precision and accuracy. Spleen consists of white pulp, red pulp, and the marginal zone and
slow blood microcirculation through the reticular meshwork of the splenic red pulp with
increasing hematocrit is the prime reason of its unique filtering capacity that facilitates
specialized macrophages in recognizing and destroying unhealthy RBCs [108]. Rigat‐Brugar‐
olas et al. designed a novel microdevice to copy the physical properties and hydrodynamic
forces of the splenon; the minimal functional unit of the red pulp able to maintain filtering
functions (Figure 16a) [108]. Their design consists of two main microfluidic channels for flow
division to mimic the closed fast and the open slow microcirculations of spleen. The junction
between slow‐flow and fast‐flow channel was arranged with parallel 2 μm microconstrictions
resembling the IES to constrain cells. This device could precisely reproduce the natural
physiochemical conditions of spleen and the unique characteristic of distinguishing different
RBCs based on their mechanical properties.
Figure 16. Splenon on a chip: (a‐left) Diagram of the human splenon showing the closed‐fast and open‐slow microcir‐
culations as well as the interendothelial slits (IES); (a‐right) Schematic representation of flow division zone, the pillar
matrix and microchannels within slow‐flow channel to mimic IES, respectively [108], (b) Artery on a chip: Schematic
representation of a resistance artery segment on a chip contains a microchannel network, an artery loading well and an
artery inspection area. ECs and SMCs represent the endothelial cells and smooth muscle cells, respectively [110].
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3.3.2. Blood vessel on chip
Arteries or blood vessels transport the blood in human body. Geometry of vasculature and
accumulation of particles inside the vessels varies with the pathological changes in the
structure and function of small blood vessels, which leads to cardiovascular diseases [109].
Scalable approaches to assess the structure and function of intact cardiovascular tissues in
health and disease will be crucial for developing better treatment strategies. Fluid sheer stress
and cyclic stretch are other parameters that should be taken into account while designing in
vitro vessels on‐chip systems.
Typically, most of the current systems contain small arteries mounted on two wires or perfused
with glass micropipettes that suffer from the disadvantages of nonscalability and need of a
skilled person to operate. To overcome this barrier, Gunther et al. presented a scalable organ‐
based microfluidic platform for loading, precise placement, fixation as well as controlled
perfusion and superfusion of a fragile resistance artery segment (Figure 16b) [110]. This device
was comprised of three parts: the artery‐loading area, a microchannel network and a separate
artery inspection area, connected to a thermoelectric heater and a thermoresistor to maintain
the temperature at 37°C. Resistance arteries had specialized structures with 30–300 μm
diameters to regulate the flow and redistribution of blood in organs. As depicted, the setup
was located in the terminal sections of the arterial vascular tree, and their walls are composed
of a single layer of lining endothelial cells (ECs) and several layers of circumferentially
arranged smooth muscle cells (SMCs). This device although could not replicate the full
functionality but showed a unique property to analyze small artery structure and function
through exposure to a well‐defined heterogeneous spatiotemporal microenvironment.
In another approach by Zhang et al., cyclic stretching of vesicular endothelial cells can be
studied. They designed a two‐layered microsystem with upper microfluidics layer and bottom
groove layer separated by an elastic membrane to provide cyclic stretch (Figure 17). A vacuum
pump was integrated with the device to apply suction pressure on membrane resulting in
cyclic stretch [111].
3.4. Perfusion‐based on‐chip systems
Cell‐cell interactions are vital for maintaining tissue structure and function, and many cells
respond to both homotypic and heterotypic interactions. Combining fluid flow and mechanical
forcing regimens as in in vivo cellular environment can improve tissue‐ and organ‐specific
functions [66]. In this section, we describe few microengineering systems for liver, brain and
womb that were designed for better understanding of mechanism of cellular interactions [82].
3.4.1. Liver on chip
Liver is considered to be one of the versatile organ performing thousands of functions that
include detoxification, protein synthesis, hormone production, glycogen storage, etc. It is also
a key player in human drug interaction and a trivial target for drug‐induced toxicity.
Liver possess a complex structure and hepatic lobule is its prime functional unit consisting of
hepatocytes, blood vessels, sinusoids and Kupffer cells. [112]. Hepatocytes are crucial con‐
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tributors to liver functions and necessary for understanding the metabolism of xenobiotics and
possible hepatotoxic effects in pharmacology. However, hepatocytes lack proliferative
properties and biological interactions, which makes it rather difficult to maintain the liver‐
specific function of these cells in vitro. As a solution to this barrier, Kane et al. demonstrated a
microfluidic array with wells capable of supporting micropatterned primary rat hepatocytes
in coculture with 3T3‐J2 fibroblasts [113]. In this process, under continuous perfusion with
medium and oxygen, the synthetic and metabolic capacity of hepatocytes were preserved as
evidenced by the continuous and steady synthesis of albumin and production of urea.
In other approach by Du et al., encapsulated hepatocytes that were produced with recombinant
protein, with endothelial cells, differentiating them from hiPSCs within specific niches in
multicomponent hydrogel fibers and further assembled into 3D‐patterned endothelialized
liver tissue constructs [114]. Endothelial cells significantly improved the function of hepato‐
cytes in vitro and when tested on a mouse model of partial hepatectomy, an improved
vascularization of the fiber scaffold was observed.
A miniaturized, multiwall coculture system for human hepatocytes surrounded by fibroblasts
with optimized microscale architecture that maintained the typical phenotypic functions of
the hepatocytes for several weeks was reported by Bhatia et al. Another device comprised of
three sections, including a central channel for heptocytes, a microfluidics convection channels
and a microfluidics sinusoid barrier with a set of narrow channels to model epithelial cells as
Figure 17. Schematic of blood vessel on chip. (a) PDMS chambers connected by a membrane, (b) Fabricated device, (c)
Microfluidic channel for consecutive flow, (d) Stretching and relaxed elastic membrane [111].
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show in Figure 18a [115]. This model succeeded in mimicking the transportation between
blood flow and hepatocytes and the sheer stress experienced by hepatocyts.
Figure 18. (a) Schematic of soft lithographic process to fabricate microscale multiwell format for primary hepatocytes
that selectively adhere to matrix‐coated domains and coculture with fibroblasts seeded on bare areas [115]. (b) Config‐
uration of one basic unit of liver tissue, the classic hepatic lobule and lobule‐mimetic‐stellate‐electrodes array. (c) The
configuration and operation principles of DEP‐based heterogeneous lobule‐mimetic cell patterning [116].
Another research, also based on hepatocytes‐based model, was done by Ho et al., where they
designed an array of concentric‐stellate‐tip microelectrodes to mimic the lobular structure of
liver tissues (Figure 18b, c) [116]. This device was comprised of vertical microelectrodes or
lobule‐mimicking stellate electrode arrays, to achieve 3D liver cell patterning by separately
snaring hepatocytes and endothelial cells that were manipulated under patterned electric
fields via dielectrophoresis (DEP). Few other researchers (i.e., Feng et al. [117], Wong et al.
[118], Lee et al. [119]) have also put forth their proof of concepts based on hepatocytes. Wong
et al. developed a concave microwell‐based size controllable spheroidal “hepatosphere” and
“heterosphere” models by monoculturing primary hepatocytes and by coculturing primary
hepatocytes and hepatic stellate cells (HSCs), respectively, to monitor the effect of HSCs in
controlling the formation of tight cell‐cell contacts and final organization of the spheroidal
aggregates [118, 82].
Some other reports are also there where researcher came forward with their ideas to design
efficient liver on‐chip devices for drug screening and toxicity analysis [98, 120–122].
Recently, Lee et al. have designed a novel liver on‐chip system based on liver microsomes that
were encapsulated in 3D hydrogel matrix to mimic the metabolism reactions and the transport
phenomena in the liver. Photopolymerization of poly(ethylene glycol) diacrylate (PEG‐DA)
allowed controlling the mass transfer with matrix sizes. To reproduce the blood flow through
liver, gravity‐induced passive flow was explored. They measured the reaction kinetics of P450
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enzymes in the device and simulated the convection‐diffusion‐reaction characteristics inside
the device with a mathematical model [123]. Figure 19a is illustrating the schematic and design
of on‐chip liver platform. Although there were several factors to be modified for improved
reaction kinetic data such as diffusion limitation, optimization of convection and mixing,
reducing the nonspecific binding to PDMS surface, preliminary analysis shows great potential
and this device will be further explored for the metabolism of various compounds in liver [123].
Figure 19. (1) Schematic of PDMS chip fabrication method and picture of fabricated chip (size of the glass slide was 25
mm by 75 mm) [123]. (2) Schematic diagram illustrating the sequential procedure for constructing the biomimetic mi‐
crotissue [124].
Most of the on‐chip liver platforms are based on hepatocytes, and generally, these in vitro
hepatocyte culture systems imitated the structure of the hepatic cord or can applied for
studying specific aspects of toxicity. However, to imitate advanced liver architectures (i.e.,
hepatic sinusoids) that could preserve cell‐cell and cell‐ECM interactions, these existing
devices did not solve the purpose. To overcome this limitation, Ma et al designed a microflui‐
dics‐based biomimetic method for in vitro fabrication of a 3D liver lobule such as microtissue.
Their system was composed of a radially patterned hepatic cord‐like network and an intrinsic
hepatic sinusoid‐like network as shown in Figure 19b. This device showed that the 3D
biomimetic liver lobule‐like microtissue retained higher basal liver‐specific functions in Phase
I/II (i.e., CYP‐1A1/2 and UGT activities) and more sensitive response was obtained for
pharmacological inducers/inhibitors than the 2D and 3D monocultures of HepG2 cells. This
device was tested for three model drugs—acetaminophen, isoniazid and rifampicin and a high
hepatic capacity for drug metabolism was exhibited by biomimetic microtissue that indicated
that microtissue, designed by Ma et al. can be explored as a promising platform for in vitro
toxicity of drugs [124].
3.4.2. Brain on chip
Human brain is the most complex structure and the quest to understand how it stores and
processes information leads researches to the application of new microengineering technolo‐
gies to design in vitro model of brain. Unraveling the basic concepts could be beneficial for
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neural diseases, development of improved brain‐machine interfaces and domain of machine‐
learning will be totally revolutionized. A brain‐oriented paradigm shift has occurred with the
advances in neuroscience and OOC systems [131, 132].
Figure 20. (A) The microfluidic‐based culture platform directs axonal growth of CNS neurons and fluidically isolates
axons [125]. (B) Schematic diagrams of normal brain mimicking microfluidic chip (a) and Alzheimer’s disease brain
mimicking microfluidic chip [127].
We discussed earlier various other OOC but owing to its structural and functional hierarchy,
high specialization and constant metabolic demand to design a complete in vitro brain model
is difficult. The prime limiting factors are used to identify the smallest structural and functional
unit, ion channels or synapses in the microenvironment [126]. Researchers from all over the
world give different experimental models of circular microfluidic compartmentalized cocul‐
ture platforms to study brain development and degeneration based on physiological neuron
connection architecture. A microfluidic culture platform was demonstrated by Taylor et al,
consist of a relief pattern of somal and axonal compartments connected by microgrooves that
function in directing, isolation and biochemical analysis of CNS axons (Figure 20a) [125]. In
another work, Park et al describe a microfluidic chip based on 3D neurospheroids that more
closely mimics the in vivo brain microenvironment and provides a constant flow of fluid similar
in the interstitial space of the brain. Concave microwell arrays were explored for the formation
of uniform neurospheroids, with cell‐cell interactions and contacts in all directions while
osmotic micropump was used to maintain the slow interstitial level of flow. Using this
platform, effect of flow on neurospheroid size, neural network and neural differentiation was
investigated via this in vitro platform. Larger sizes of neurospheroids were obtained and
formed more robust and complex neural networks than those cultured under static conditions.
This finding proved the effect of the interstitial level of slow and diffusion‐dominant flow on
continuous nutrient, oxygen and cytokine transport and removal of metabolic wastes [127].
This chip was designed to detect the toxic effect of β‐amyloid; a major contributor of Alz‐
heimer's disease. Figure 20b is showing the schematic of this unique platform for neurodege‐
nerative disease diagnostic. Kato‐Negishi et al. came up with a millimeter‐sized neural
building block to reconstruct 3D broad neural networks connecting with different neurons
[128]. Peyrin et al. also described a microfluidic system involving several different neuron
subtypes separated into two individual chambers with asymmetrical connection architecture
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of funnel‐shaped microchannels to reconstruct oriented neuronal networks [129]. This device
was a kind of diode that operated as direction selective filter where axonal projections can be
penetrated by axons in a single direction and as an impermeable barrier for cell bodies. In this
point, Kunze et al. demonstrated a 3D microfluidic device for creating physiologically realistic,
micrometer scaled neural cell multilayers in an alginate‐enriched agarose scaffold [82, 130].
A method to fabricate neurospheres networking with nerve‐like structure using concave well
arrays connected by the hemicylindrical channels was illustrated by Jeong et al. This method
provides the topological effect of the concave‐well hemicylindrical‐channel‐networking,
which is crucial in guided outgrowth of neuronal network [131]. Similar hemicylindrical
systems were also explored to generate 3D nerve‐like neural bundles between neural spheroids
and neighboring satellite spheroids in concave channels [132].
3.4.3. Breast and womb on chip
Breast cancer is still the cause of concern and with the advancement of microfabrication
techniques, improved detection and therapy of breast neoplasia can be obtained via nanode‐
vices traveling inside mammary ducts. However, the decreasing size of branched mammary
ducts prevents access to remote areas of the ductal system using a pressure‐driven fluid‐based
approach. Magnetic field guidance of superparamagnetic submicron particles (SMPs) in a
stationary fluid might provide a possible alternative but it is critical to first reproduce the breast
ductal system to assess the use of such devices for future therapeutic and diagnostic (“thera‐
nostic”) purposes. Graften et al. came up with an idea of to engineer a portion of a breast ductal
system using polydimethylsiloxane (PDMS) microfluidic channels of decreasing sizes with a
total volume of 0.09 mL. A magnet was used to move superparamagnetic/fluorescent SMPs
through a static fluid inside the microchannels [133]. Figure 21a is the schematic of PDMs on
chip assembly. This device can be explored for the early detection of ductal breast cancer and
consisted of basoapically polarized monolayer of luminal cells only as the device imitated the
luminal portion of the ductal breast system only and myoepithelial cells at the basal side of
the luminal cells and terminal ductal lobular units at the ends of the narrowest channels were
not included. Apart from breast on chip, womb OOC was also developed by Chang et al. with
the objective to deal with infertility.
In recent years, a genuine increase in infertility has been observed due to diverse factors,
including stress, environmental pollution and increase in age, smoking, consumption of
alcohol, sexually transmitted diseases, etc. In vitro fertilization (IVF), a state‐of‐the‐art tech‐
nology, enhances the rate of pregnancy. As a procedure, fertilized eggs in the blastocyst stage
are transferred to the woman's uterus for implantation and further development and efforts
are made to improve the culture environment of the preimplantation embryos and developing
specialized culture surfaces to enhance the success rate of this technique [134, 135].
Due to the failure of static culture systems to mimic the dynamic fluid environment in the
fallopian tube [136], dynamic culture platforms that explored shaking/rotation [137], control‐
led fluid flow [138] and vibration [139] models were studied for use in embryonic development
where method of coculturing embryos with endometrial was done to overcome developmental
arrest of early embryos in single culture. Although these methods showed enhanced perform‐
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ance and beneficial effects of coculturing on the development of mammalian, they could not
be considered as a complete on chip system for womb. Recently, Chang et al. also designed an
autologous 3D perfusion platform as a necessary approach to deal with IVF and partly mimic
the physiological function of the reproductive system [140]. This device as shown in Fig‐
ure 21b is comprised of an upstream concentration gradient generator (width: 250 μm, height:
230 μm) was integrated with a diamond‐shaped passive micromixer (width: 200 μm, height:
230 μm) that could generate six different homogeneous concentrations of progesterone.
Micromixer was used to increase the contact area between liquid molecules and to provide
enhanced mixing efficiency by its continuous splitting and mixing of liquids. The main
specifications and goals of this microfluidic channel design was as follows: (i) Gradient
distribution for specific concentrations of steroid hormones in six culture chambers, (ii)
Maintaining homogenous concentrations of steroid hormones in individual chamber, (iii)
Preserve uniform culture conditions with respect to the flow speed/rate by constant flow
speed/rate for the chambers.
This womb‐on‐chip platform showed the ability to replace the present embryo culture
platforms used for assisting in vitro fertilization.
3.5. Human on chip
Organ‐on‐chip concept is in its nascent state and despite of the substantial advances in the
creation of microengineered tissue and organ models, a lot is left to explore for recreating
complex 3D models that could reconstitute the whole organ metabolism and physiology. With
the recent advances in tissue engineering, microfabrication techniques, researchers are now
focusing on multiorgan‐on‐chip devices that could imitate complete human on chip up to some
extent if not fully [141, 142]. Figure shows a body‐on‐chip systems.
Figure 21. (a) Schematic of breast on chip [133], (b) PDMS‐based embryo coculture microchip, where the concentration
gradient generator is integrated with a mixer and a cell culture chamber on the top [140].
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Although complete functional body‐on‐chip devices are still far from reach but the latest
development in this field has given a glimpse of promising future of this revolutionary field
of biomedicine. Figure 22 shows the concept of body‐on‐chip microsystem [4].
Figure 22. Schematic of a body on chip system. (a) A microdevice containing interconnected cell culture microcham‐
bers integrated with microfluidic culture of intestinal epithelial, hepatocytes and breast cancer cells. (b) A micro cell
culture analog (μCCA) representing a colon tumor, the bone marrow and liver [4].
4. Pharmaceutical applications and future prospects of organ‐on‐chip
devices
The field of OOC devices is still in its infancy, although it is a rapidly growing research arena
with lots of future potential in biomedicine from understanding the mechanism of complex
organ architectures to drug discovery. Earlier studies revealed that while 3D cell cultures were
far more superior planar than conventional 2D models due to their better control over cell
differentiation, ECM mechanical compliance and a much better response was obtained in
terms of tissue‐ and organ‐level functionality by combining microengineering with cell
biology. Fortunately, with the recent advances in microfabrication strategies and microfluidics,
precise dynamic control of structure, mechanics and chemical delivery at the cellular size scale
can be achieved. Microengineered 3D cell culture models, and particularly more sophisticated
OOC microdevices, have many potential applications, including disease research and drug
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discovery, but in this section, we mainly focus on OOC application relevant to pharmaceutical
industry.
The pharmaceutical industry is under intense pressure economically, ethically and scientifi‐
cally to find ways to accelerate the drug‐development process, and to develop drugs that are
safer and more effective in humans at a lower cost. Traditional animal testing approaches are
expensive and often fail to predict human toxicity or efficacy of drugs; in fact, nowadays,
questions are arising with regard to the significance of animals testing if they cannot reliably
predict clinical outcomes [4, 143]. As correctly suggested by Dr. Ingber, Founder Director‐
Harvard's Wyss Institute for Biologically Inspired Engineering that chips respond to drugs
like human organs do—–and have the potential to replace animal testing for safety and efficacy
early in the drug‐development process.
4.1. Bottlenecks in drug discovery process
4.1.1. High cost of compound testing
Modern drug development requires implementation of extensive preclinical testing and
validation protocols before getting the formal approval to progress to clinical evaluation of the
compound. This process is tedious and costly and a single compound can cost more than $2
million. Moreover, every 10 drugs entering clinical trials, generally only one or two would be
licensed for eventual use in humans [2].
4.1.2. Lack of exact simulation of human systems in static 2D cells culture
The lack of preclinical model systems to provide accurate predictions of human responses to
novel therapeutic drugs is another critical limiting factor in drug discovery. The current gold
standard for laboratory‐based preclinical evaluation is based on in vitro cell culture assay and
in vivo animal model experimentation and assessment. Although cell culture assays have
advantage of controlled environments where cellular maturation and activity are easily
observed and tested, they lack the complexity of living systems and are incapable of mimicking
the conditions of organ‐organ or tissue‐tissue communication. This simplicity is a major
drawback in drug‐development studies since drug metabolism and the effect of metabolite
activity on nontarget tissues cannot be predicted [3].
4.1.3. Time period of animal studies and loss of numerous animal lives
Another crucial limiting factor is time involved in in vivo studies. Although animal studies can
somehow better predict the drug metabolism and response as animal models maintain the
intricacy of living systems and assessment of organ‐organ crosstalk and nontarget organ
toxicity is possible , these models on multiple occasions, been proven to be wrong predictors
of human responses to drug treatment. Human system is more complex and developed than
laboratory animals and the response and mechanisms are different for many therapeutic
agents. The hypothesis that favorable outcomes observed in animals will translate to human
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patients has led to clinical situations where treatments have proved futile or even detrimental
to patient well‐being and recovery [3, 144].
4.1.4. Lack of accurate prediction of clinical response and diminished number of new drugs for patients
As discussed earlier, due to inadequate in vitro data and practical difficulties of in vivo studies,
the clinical response is not always as expected. Eroom's law (Moore's law backwards) states
that “the number of new medicines halves every nine years,” despite an “astronomical”
increase in research funding from government and industry. This situation exists in large part
because the traditional journey from drug discovery to drug development still occurs mostly
in 2D static cell cultures and animal studies, which are not the true predictors of response of
new compounds in the human body resulting in failure of approximately 85% of therapies in
clinical trials and of those that make it to advanced phase III, generally the last step before
regulatory approval, only half are actually approved. This data itself ignite are concerns for
the pharma industry and how to expedite the current drug discovery scenario [149].
Microengineered cell culture systems that mimic complex organ physiology have the potential
to be used for the development of in vitro human‐relevant disease models. These are more
predictive of drug efficacy and toxicity in patients and can provide better insight into drug
mechanism of action. OOC devices provide compelling advantages over other in vitro cell
culture models for the evaluation of drug safety and metabolism. In broader sense, in vitro
assays incorporating cultured human cells can act as savior in identifying environmental toxins
and providing better understanding of their mechanisms of action, as well as improving our
ability to predict risks for specific compounds. In addition, the ability to integrate functional
organ mimetics, such as gut, liver, lung and skin‐on‐chips within a “human‐on‐a‐chip,” the
interplay of different organs in determining pharmacokinetic properties of compounds can be
monitored [3, 145].
4.2. Role of organ‐on‐chip devices in drug discovery
4.2.1. Reduction in cost
The drug‐development process is costly in the phases of clinical trials, which can cost millions
of dollars. However, despite extensive animal testing of drugs before starting a clinical trial
with humans, many drugs fail because of low efficacy or unexpected toxic side effects not
predicted with earlier trials. In this regard, the most promising advantage of body‐on‐a‐chip
devices is that the devices can mimic both animal and human metabolism and predict
differences between them that will allow for a higher level of accuracy when predicting the
outcome of clinical trials. Moreover, any toxicity observed before human trial with in vitro on
chip systems can prevent unsuitable drug candidates from entering the expensive phase of
clinical trials that limit costs and unrealistic expectations.
Body‐on‐a‐chip devices are low‐cost platforms that can substantially reduce the cost of drug
testing.
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4.2.2. Drug‐target identification
Organs‐on‐chips have the potential to serve as a new enabling platform to identify and validate
the effectiveness, safety of potential targets early in the pipeline to increase the likelihood of
success in clinical trials [4]. Song et al has recently a microengineered model of vasculature to
mechanistically examine chemokine‐mediated interactions between circulating breast cancer
cells and the microvascular endothelium that induced site‐specific basal stimulations and
activation of the microfluidic endothelium by introducing chemokines into the lower cham‐
bers. Through quantitative analysis of cancer cell attachment to the endothelium and the levels
of cell surface receptor expression, this system predicted that endothelial recruitment of breast
cancer cells induced by a chemokine‐CXC‐chemokine ligand 12 (CXCL12), involved in cancer
metastasis, is mediated by the endothelial receptor CXCR4 and this response is independent
of the expression of CXCL12 receptors on circulating cancer cells. These findings gave a new
insight into critical role of the vascular endothelium in the metastatic behavior of circulating
tumor cells and how to control and manipulate a biological target to analyze a functional
outcome of target modulation. This discovery related with OOC model was an important
breakthrough in indentifying a valid therapeutic target for preventing cancer metastasis
[146].
Other studies on OOC platforms for understanding of molecular mechanisms of cell‐cell
interactions, mitochondrial cardiomyopathy of Barth syndrome, and drug‐induced toxicities
in pulmonary edema have also been successfully performed [147–149].
4.2.3. Toxicity and drug efficacy evaluation
This a very important aspect of drug research as toxicity analysis is utmost important for any
new therapeutic agent. Liver and kidney tissues are of great interest to drug developers due
to their predominant role during the absorption, distribution, metabolism and excretion
(ADME) process of a drug [3]. Physiologically, drug is metabolized mainly in the liver while
kidney deals with their elimination. These two critical processes make these two organs highly
susceptible to drug injury. In a coculture bio‐analytical microplatform of liver‐kidney, toxicity
of anticancer drug ifosfamide illustrated the importance of the liver‐kidney interaction.
Ifosfamide is a prodrug, activated in body system by CYP450 enzymes in the liver, but some
of its metabolites, such as chloracetaldehyde, are nephrotoxic. With this model of highly
differentiated liver cells (HepaRG), perturbation of cell proliferation and calcium release in the
kidney tissue could be monitored that was not possible with the single culture. Previously, the
same group simulated the performance of hepatocytes on‐chip system coupled with NMR for
toxicity analysis of flutamide [149, 150].
These contributions signify the role of on‐chip systems for toxicity analysis of drug in vitro that
is an important step for clinical trials.
Multiorgan interactions in drug testing and their importance were highlighted by Sung et al.
also. They studied the dose response and efficacy of 5‐fluorouracil (5‐FU) on a system con‐
taining system that contained liver cells (HepG2/C3A), colon cancer cells (HCT‐116) and
myeloblasts (Kasumi‐1) [151]. They monitored the degradation phenomenon of 5‐Fu and effect
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of its pro drug Tegafur and uracil‐a competitive inhebitor of 5‐Fu for the dose response and
bioavailability.
Predicting the bioavailability of a drug accurately can be difficult with animal models.
Multiorgan microdevices that contain a combination of the gastrointestinal tract epithelium
and the liver at the appropriate sizes and with realistic liquid‐to‐cell ratios have the potential
to predict the bioavailability of ingested drugs [152].
4.2.4. Drug screening
The absence of predicted therapeutic effects of a drug or increased dose levels is the major
cause of drug toxicity. The failure of existing methods to accurately predict in vivo drug efficacy
before clinical trials give rise to the undesirable outcomes. Human OOC models can become
instrumental in addressing these existing imitations [4].
The potential of OOC approaches for testing drug efficacy was recently explored by Aref et al.
in a microengineered 3D assay of epithelial‐mesenchymal transition (EMT) during cancer
progression [153]. By culturing lung cancer spheroids in a 3D matrix gel adjacent to an
endothelialized microchannel, this model recapitulated EMT‐induced tumor dispersion and
phenotypic changes in cancer cells in an endothelial cell‐dependent manner. Twelve drugs
ranging from prospective drugs to US Food and Drug Administration (FDA)‐approved drugs
were screened into the vascular channel, and their ability to inhibit EMT was analyzed by
direct visualization of the cancer spheroids.
The results obtained for drugs efficacy in cancer treatment by on‐chip systems, significantly
varies from 2D static culture and were in close proximity with human clinical trials. This study
concluded that such OOC systems will be developed as a more realistic platform for efficacy
and to decide for advanced trails, a major step toward drug discovery.
4.2.5. Response of combination of drugs
Since microdevices are relatively inexpensive, and many such devices will be operated in
parallel, it is possible to test many drugs and combinations of drugs at different concentrations
with devices. Testing combinations of drugs is useful to monitor drug interactions and cross
talks. Synergistic interactions are of particular interest. Another benefit of such studies is that
the drugs having similar functions, but different side effects could potentially be combined at
reduced dosages to achieve the needed tissue response. These multiorgan on‐chip systems can
play a major role to design individualized therapy regimen for patients that do not respond
to routinely used drug combinations as a synergistic effect and dose of different drug combi‐
nation can be predicted.
4.2.6. Pharmacokinetics and body on‐chip systems
Physiologically based pharmacokinetic models (PBPKs) are mathematical models that are
used to extrapolate data from animal experiments and predict human response to a drug. These
models mainly rely on existing understanding and knowledge of a drug's metabolism from
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ranging from prospective drugs to US Food and Drug Administration (FDA)‐approved drugs
were screened into the vascular channel, and their ability to inhibit EMT was analyzed by
direct visualization of the cancer spheroids.
The results obtained for drugs efficacy in cancer treatment by on‐chip systems, significantly
varies from 2D static culture and were in close proximity with human clinical trials. This study
concluded that such OOC systems will be developed as a more realistic platform for efficacy
and to decide for advanced trails, a major step toward drug discovery.
4.2.5. Response of combination of drugs
Since microdevices are relatively inexpensive, and many such devices will be operated in
parallel, it is possible to test many drugs and combinations of drugs at different concentrations
with devices. Testing combinations of drugs is useful to monitor drug interactions and cross
talks. Synergistic interactions are of particular interest. Another benefit of such studies is that
the drugs having similar functions, but different side effects could potentially be combined at
reduced dosages to achieve the needed tissue response. These multiorgan on‐chip systems can
play a major role to design individualized therapy regimen for patients that do not respond
to routinely used drug combinations as a synergistic effect and dose of different drug combi‐
nation can be predicted.
4.2.6. Pharmacokinetics and body on‐chip systems
Physiologically based pharmacokinetic models (PBPKs) are mathematical models that are
used to extrapolate data from animal experiments and predict human response to a drug. These
models mainly rely on existing understanding and knowledge of a drug's metabolism from
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traditional 2D static cultures and animal studies and as we discussed, these methods are not
the accurate predictors. This is the reason for the equations used in a PBPK are not complete
and the models are not accurate. Multiorgan microdevices can be modeled more precisely with
PBPKs and divergence between the model's prediction and experimental data obtained with
the devices can enhance our understanding of human response to a wide variety of combina‐
tion of inputs with higher accuracy than before.
To generate a precise PBPK model, for pharmacokinetics and pharmacodynamics studies,
recapitulating human physiology at the whole‐body level is the most crucial aspect. Research‐
ers have begun to pursue the development of multi‐organ models, and in one such study,
combined models of breast cancer, the intestine and liver were designed to create a network
of interconnected microfabricated cell culture chambers that exhibited the sequential absorp‐
tion, metabolism and efficacy of four anticancer drugs [154]. Shuler et al [155] applied
pharmacokinetic and pharmacodynamic modeling (PKPD) principles to micro cell culture
analog comprising interconnected microchambers representing a colon tumor, the liver and
bone marrow, which imitated the in vivo distribution, retention and recirculation of drug‐
containing blood in these organs. Hepatic metabolism‐mediated cytotoxicity of the prodrug
tegafur to colon cancer, liver cancer and bone marrow cells was investigated by this system.
These multiorgan on‐chip systems are better than the existing models and can expedite the
drug discovery process by increasing the efficiency and mitigating the high cost associated
with drug‐development process.
4.3. Future prospects of organ‐on‐chip devices
As an alternative to conventional cell culture and animal models, human OOC could transform
many areas of basic research and drug development. They have wide applications in research
on molecular mechanisms of organ development and disease, organ‐organ coupling and the
interactions of the body with stimuli, such as drugs, environmental agents, consumer, products
and medical devices. Due to complexities involved, OOC have limited or no applications in
certain areas of biomedical research, such as chronic diseases, adaptive immune responses or
complex system‐level behaviors of the endocrine, skeletal and nervous systems. As described
previously, OOC are effective for investigating physiological and disease processes that occur
in a relatively short‐time frame (less than ∼1 month) and depend on relative cell positions
within an organ‐ or tissue‐specific microarchitecture [66].
OOC technology has certain technical and entrepreneurial challenges also. One of the critical
technical challenges is material for fabrication—such as poly(dimethylsiloxane) (PDMS) that
have gained widespread use in rapid‐prototyping of OOC microdevices as most of the OOC
models rely mostly on synthetic materials (e.g. PDMS, polycarbonate and polyester), the
physicochemical properties of which are not appropriate for mimicking extracellular matrices
in vivo. It is utmost important to identify new cell culture substrates to produce devices for
more accurate predictions. For successful translation of OOC from proof of concept in the
laboratory to commercial screening platforms, identification and optimization of new low‐cost
materials and fabrication strategies suitable for their mass production and integration into
existing infrastructures in the pharmaceutical industry is call of time.
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More reliable and sustainable sources of human cells, especially disease‐specific cells that are
acquiescent to in vitro culture in OOC and phenotypically are true representative of their in
vivo counterparts are required. To overcome this hurdle, human embryonic stem cells and iPS
cells can be engineered to suit specific needs in the development of OOC [3, 156]. The OOC
models with stem cells can generate and control physiologically relevant structural, biochem‐
ical and mechanical cues required for stem‐cell differentiation and maturation.
With the new avenues opened by OOC in drug development, there is a need of fabricating
human on‐chip or multiorgan on‐chip devices and to maintain a balance between the com‐
plexity and practicality will play an important role in their wide applications. With the
improvement in physiological relevance, complexity in the model is obvious that presents
major challenges to practical operation and management of the system. Accurate identification
of minimal subset of cells and microenvironmental factors will be helpful to create a balance
and designing a simplest model possible that recapitulates physiological responses of interest.
Integration of laboratory on‐chip platforms with miniaturized analytical systems is also
important for better detection sensitivity despite of low culture volumes and cell numbers [1].
OOCs are not universal solutions, and alternative tools will continue to be better solutions for
modeling certain in vivo processes as animal offer whole‐organism toxicity testing and this
parallel analysis will be required until the current OOC scenario attains the maturity and refine
human on‐chip systems come into existence.
Despite their limitations, OOCs have the potential to play a transformative role across drug
discovery and development. Eventually, OOC models may play a pivotal role in streamlining
the clinical trial process. Due to the complexities of organ function and regulatory require‐
ments, it is unlikely that OOCs will replace animal testing anytime soon [66].
However, with the scientific advancements, this field is evolving at a fast pace and these
hurdles could be surmountable with tri‐lateral partnerships between academic institutions,
industry and regulatory agencies. The paradigm‐shifting potential of OOC technology has
been recognized by funding agencies integrated microphysiological systems [157, 158].
Pharmaceutical companies are also coming forward to establish industry‐ academia partner‐
ships to jointly explore this emerging research arena and to establish themselves at the forefront
of expected OOC advances. In nut shell, it is concluded that despite of several limitations,
achievements in this revolutionary field of biomedicine, OOC technology present exciting new
avenues for drug discovery and development and a perfect picture of a promising future.
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Abstract
Microfluidic lab-on-a-chip (LOC) technologies have been developed as a promising
alternative to traditional  central  laboratory-based analysis  approaches over several
decades  due  to  the  capability  of  realizing  miniaturized  multiphase  and multistep
reactions. In the field of nucleic acid (NA) diagnosis, digital NA detection (dNAD) as a
single-molecular-level detection is greatly attributed to the perfect combination of NA
amplification and microfluidic LOC techniques. In this chapter, the principle, classifi‐
cation, advances, and application of dNAD will be involved. In particular, the focus will
be on chip-based dNAD for giving a deep interpretation of the analysis and evalua‐
tion of digital detection. The future prospect of dNAD is also anticipated. It is sure that
dNAD by means of microfluidic LOC devices as the promising technique will better
serve the ambitious plan of precision medicine through absolute quantitation of NA
from individuals.
Keywords: digital nucleic acid detection, lab-on-a-chip, microfluidic chip, digital
PCR, quantitation
1. Introduction
It has been clearly investigated that nearly all of the diseases possess a series of biomarkers
associated with nucleic acid (NA) molecules during the development of biological researches
[1–5]. Determining these NA molecules and their intercellular and extracellular changes is a
well-worked strategy for estimating therapy efficacy, monitoring minimal residual diseases,
unveiling the mechanisms of cellular signal transduction, and so on [6–8]. To reflect individu‐
al genetic differences, single-molecule level quantitation of NAs has been increasingly con‐
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
cerned recently due to its superiority on analytical sensitivity and accuracy [9, 10]. Furthermore,
single NA molecule detection is also highly preferred as the calibration strategy for next-
generation sequencing (NGS) to better serve recently proposed ambitious plans of precision
medicine [11–13]. Thus, testing NAs, especially in single-molecule level, plays an essential role
in modern biological researches and diagnosis fields.
At present, the widely used approaches in detecting NA molecules are quantitative polymer‐
ase chain reaction (qPCR) and quantitative reverse transcription-PCR (qRT-PCR). Apart from
the capability of real-time monitoring the amplification, they can be applied to quantify the
target NA molecules through two common strategies: relative quantification and absolute
quantification. The former is based on internal reference genes (namely, housekeeping genes)
to normalize and reflect fold differences in expression levels of mRNA, which is commonly
interpreted as cDNA [14, 15]. The latter can provide the exact number of targeted molecules
using an established standard curve of the change in quantification cycles with known
molecule number of NA standards [16–19]. However, qPCR is compromising the ability of
single-molecule quantitation analysis [20, 21]. Alternatively, when PCR meets microfluidic or
nanofluidic chips, a highly sensitive NA quantification technique [digital PCR (dPCR)]
emerges, estimating NAs advantageously at a single-molecule analysis level [22].
At the end of 20th century, the first concept of dPCR was proposed by Vogelstein and Kinzler
[23]. Since the concept was proposed, many dPCR platforms have been launched for several
Figure 1. Some vendors and their launched microfluidic chips and dPCR devices. The pictures are all from the web‐
sites of the corresponding companies or reprinted with permission from Ref. [59]. © Copyright 2011 American Chemi‐
cal Society.
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cal Society.
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decades based on differently designed microsystems, including femtoliter array, spinning
disk, SlipChip, droplet, microfluidic formats, and so on [24–30]. Some even have been
successfully paced into industrial phase because of the superiority of testing and the promising
application. Currently, several vendors in the biological industry, such as Fluidigm, Bio-Rad
Laboratories, Life Technologies (ThermoFisher), RainDance Technologies, and Formulatrix,
have launch individually their commercialized dPCR devices (Figure 1).
Apart from dPCR, digital isothermal NA amplification (dINAA) devices also arouse great
concern. Unlike dPCR, dINAA leans on the isothermal NA amplification, which can be carried
out at a consistent temperature, obviating the requirement of highly stable thermocycling
devices. Thus, when targeting practical point-of-care testing (POCT) devices, dINAA is
superior to dPCR. However, viewed from the principle of realizing digital detection, the
concept of dINAA is the same as that of dPCR, just replacing PCR with isothermal amplifica‐
tion. In particular, due to loop-mediated isothermal amplification (LAMP) displaying as the
best promising method among a lot of isothermal NA amplifications, digital LAMP (dLAMP)
is the first dINAA developed [31, 32]. Later, other dINAAs have been reported, such as digital
multiple displacement amplification (dMDA), digital isothermal multiple-self-matching-
initiated amplification (dIMSA), digital recombinant polymerase amplification (dRPA), and
so on [33–38]. However, the development of dINAA devices is still in the research stage, as
the commercial products have not been launched yet.
As of now, more and more researchers are enthusiastic about the potential of digital NA
detection (dNAD) based on microfluidic Lab-on-a-Chip (LOC) devices, since an increasingly
significant role has been played in single-cell analysis, early diagnosis of cancer, prenatal
diagnosis, and so on. In this chapter, we will concentrate on the principle, classification and
advances, analysis and evaluation, application, and future prospects of dNADs that are
accomplished either through commercialized LOC devices or the devices our laboratory or
other laboratories have established.
2. Principle of dNAD
According to the strategies of amplifying NA, dNAD or single-molecule NA detection can be
divided into dPCR and dINAA. However, both of them share the same principle.
Generally speaking, the principle of dNAD is composed of three core steps [39]. First, the
original sample should be partitioned into thousands or hundreds of thousands of individual
microreactions, endeavoring to make each contain nearly one target molecule. Second, the
number of “positive” microreactors indicated either in a real-time reaction or in an endpoint
reaction is counted and analyzed. Third, the concentration of nonpartitioned sample is
calculated using certain statistical methods. In theory, if the number of microreaction is more
enough or the number of target molecules is less enough, one reaction unit with positive signal
represents one target molecule. However, in fact, a positive partition may contain more than
one molecule. Therefore, in calculating the target’s true concentration, a Poisson distribution
is adopted in hope to correct the results. Therefore, dNAD can be considered as a binary output
(present or absent like “1” or “0” in computer science) measurement, giving a direct and high-
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confidence NA molecule’s measurement method [10, 40]. Compared to conventional tube-
based NA detection, digital analysis is superior in realizing the absolute quantification with
high sensitivity, high precision, and low ambiguity, avoiding the requirement of establishing
a standard curve.
3. Classification and advances of dNAD
In the early stage of digital detection, the used materials are 96- and 384-microwell plates. Then,
due to the rapid development of microfluidic chip techniques, an increasing number of digital
detection devices emerge. Also, a variety of materials have been used individually or jointly,
such as silicon wafer, quartz, glass, polydimethylsiloxane (PDMS), polymethyl methacrylate,
and so on. According to the approaches to partition reaction mixture, the currently launched
dNAD methods can be roughly grouped into three categories: plate-based dNAD (pdNAD),
droplet-based dNAD (ddNAD), and chip-based dNAD (cdNAD). On structural design, each
classified dNAD has the advantages and disadvantages, and the corresponding commercial
devices are also developed. In this subchapter, we are going to narrate their features and recent
advances in either commercial or research aspects.
3.1. pdNAD
At present, most of the pdNADs are established as dPCR devices, but they are not hard to be
developed as dINAA platforms. As the first generation of dNAD, plate-based dPCR (pdPCR)
was first conducted using plenty of commercially available 96- and 384-microwell plates [23,
41]. The biggest benefit for this kind of digital platform is saving to create the plates that have
been widely used in conventional PCR. Each microwell undertakes each microreaction;
therefore, the high sensitivity and accuracy of detection lean entirely on the enough number
of microwells. However, actually, the number is hard to be reached just using microwell plates.
Another problem causing the embarrassment is the volume of reagents required [42]. For each
microwell, more than 5 μL are needed, and the cost of reagents inevitably daunts most
researchers, let alone the application for POCT. To break the barriers, some researchers made
modification. As shown in Figure 2, Morrison et al. deceased the volume of microreaction into
33 nL using a stainless steel plate (25 mm in width and 75 mm in length) in which up to 3072
microholes (320 μm in diameter) were created [43]. In contrast, the required volume was
reduced to 1/64, and the throughput was increased by 24-fold, although it had the comparable
sensitivity to the past. At present, this technique has been applied to commercial devices in
2009, the OpenArray RealTime PCR System from Life Technologies. However, as the number
of reaction units increases, the problem turns into how to efficiently load the reagents.
Consequently, it has to use some ancillary equipment-like microarray spotter or mechanical
arms, which in turn raises the cost and is cumbersome.
Considering the embarrassing situation, in the second half of 2013, Life Technologies launched
the next-generation digital detection device, the QuantStudio 3D dPCR system [42, 44]. It is a
simple and affordable platform to provide the reliable and robust dPCR. The device used a
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confidence NA molecule’s measurement method [10, 40]. Compared to conventional tube-
based NA detection, digital analysis is superior in realizing the absolute quantification with
high sensitivity, high precision, and low ambiguity, avoiding the requirement of establishing
a standard curve.
3. Classification and advances of dNAD
In the early stage of digital detection, the used materials are 96- and 384-microwell plates. Then,
due to the rapid development of microfluidic chip techniques, an increasing number of digital
detection devices emerge. Also, a variety of materials have been used individually or jointly,
such as silicon wafer, quartz, glass, polydimethylsiloxane (PDMS), polymethyl methacrylate,
and so on. According to the approaches to partition reaction mixture, the currently launched
dNAD methods can be roughly grouped into three categories: plate-based dNAD (pdNAD),
droplet-based dNAD (ddNAD), and chip-based dNAD (cdNAD). On structural design, each
classified dNAD has the advantages and disadvantages, and the corresponding commercial
devices are also developed. In this subchapter, we are going to narrate their features and recent
advances in either commercial or research aspects.
3.1. pdNAD
At present, most of the pdNADs are established as dPCR devices, but they are not hard to be
developed as dINAA platforms. As the first generation of dNAD, plate-based dPCR (pdPCR)
was first conducted using plenty of commercially available 96- and 384-microwell plates [23,
41]. The biggest benefit for this kind of digital platform is saving to create the plates that have
been widely used in conventional PCR. Each microwell undertakes each microreaction;
therefore, the high sensitivity and accuracy of detection lean entirely on the enough number
of microwells. However, actually, the number is hard to be reached just using microwell plates.
Another problem causing the embarrassment is the volume of reagents required [42]. For each
microwell, more than 5 μL are needed, and the cost of reagents inevitably daunts most
researchers, let alone the application for POCT. To break the barriers, some researchers made
modification. As shown in Figure 2, Morrison et al. deceased the volume of microreaction into
33 nL using a stainless steel plate (25 mm in width and 75 mm in length) in which up to 3072
microholes (320 μm in diameter) were created [43]. In contrast, the required volume was
reduced to 1/64, and the throughput was increased by 24-fold, although it had the comparable
sensitivity to the past. At present, this technique has been applied to commercial devices in
2009, the OpenArray RealTime PCR System from Life Technologies. However, as the number
of reaction units increases, the problem turns into how to efficiently load the reagents.
Consequently, it has to use some ancillary equipment-like microarray spotter or mechanical
arms, which in turn raises the cost and is cumbersome.
Considering the embarrassing situation, in the second half of 2013, Life Technologies launched
the next-generation digital detection device, the QuantStudio 3D dPCR system [42, 44]. It is a
simple and affordable platform to provide the reliable and robust dPCR. The device used a
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special plate (10 mm in width and 10 mm in length) where a total of 20,000 hexagonal micro‐
wells are fabricated. The volume of each microwell is 0.8 nL, and each reaction well is isolated
absolutely from its neighbors. At present, the system has been applied to the absolute quan‐
tification of viral load, low-level pathogen detection, sensitive genetically modified organism
(GMO) detection, differential gene expression, copy number variation (CNV), NGS library
quantification, and rare mutation analysis [45–50]. Although the cost of reagents is reduced,
the system still calls for supporting instruments to load the reagents, amplify the sample, and
read the results.
For high-throughput sample analysis, 96- and 384-microplate formats are still of use. Formu‐
latrix introduced a new commercial high-throughput pdPCR device termed as constellation
dPCR. The device brings the digital analysis to a 96-sample microplate format, and the so-
called high-throughput results from the preformation of dPCR on 96 samples at once and up
to 384 samples per hour. As required, the number of partitions for each microwell in the plate
can be easily increased, and it reaches 496 for the 96-microplate format.
3.2. ddNAD
ddNAD can go back to emulsion PCR (ePCR) [51–54]. ePCR is widely used for NGS (Figure
3) [55]. After generating a DNA library, the fragments of genomic DNA are attached to the
beads, because their surface is modified with oligonucleotide probes whose sequences are
complementary to the sequences of the fragments. When the beads are compartmentalized
into water (the PCR reagent)-oil emulsion droplets, plenty of microreactors are produced. Since
each bead captures single-stranded DNA fragment, in theory, ePCR can amplify it down to
one DNA molecule. However, it is not easy to partition the fragments and beads into one
Figure 2. Plate-based chip used for the OpenArray RealTime PCR System. A rectilinear array of 3072 microholes with
320 μm in diameter was fabricated in a stainless steel plate (25×75×0.3 mm). The volume of each hole was approximate‐
ly 33 nanoliers, and to match the pitch of the wells in a 384-well microplate, the 48 groups of 64 holes are spaced at 4.5
mm. Reprinted with permission from Ref. [43]. © Copyright 2006 Oxford University Press.
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droplet simultaneously, and then the performance of ePCR suffers from variety. Benefitting
from the rapid development of microfluidic LOC techniques, ddNAD also enjoys a huge boom
in recent years. dPCR is still the main part in ddNAD, but droplet-based dINAAs including
dLAMP, dRPA, digital rolling circle amplification (RCA), and digital hyperbranched RCA
(HRCA) are showing up more and more [34–37, 56].
Figure 3. ePCR used for NGS. Top left: The genomic DNA is isolated, fragmented, ligated to adapters, and separated
into single strands. Top right: Fragments are bound to beads that are captured in the droplets of a PCR mixture-in-oil
emulsion. Then, ePCR occurs within each droplet. Bottom right: After breaking emulsion and denaturing the DNA
strands, beads with single-stranded DNA are deposited into wells of a fiber-optic slide. Bottom left: Pyrophosphate
sequencing is initiated within each well after depositing smaller beads carrying immobilized required enzymes. Re‐
printed with permission from Ref. [55]. © Copyright 2005 Nature Publishing Group.
Beer et al. successfully created picoliter-scale water-in-oil droplets by using a shearing T-
junction in a fused-silica device in 2008 [57]. The NA used for the device was RNA; therefore,
an off-chip valving system was integrated to stop the droplet motion, because a different
thermal cycling was required for reverse transcription and subsequent PCR amplification.
Each droplet contained the PCR mixture of single-copy template, primers, and reaction buffer,
which was really termed as digital detection. One year later, Mazutis et al. developed a method
for high-throughput dINAA platform in a 2 pL droplet-based microfluidic system [35]. The
isothermal HRCA was used to perform the DNA amplification in droplets. This platform was
demonstrated to allow fast and accurate digital quantification of the template. In 2011, Zhong
et al. reported another picoliter-scale droplet-based multiplexing dPCR platform, breaking the
one target per color barrier of qPCR [58]. The number of droplets generated reached more than
106, which was enough for enhancing the likelihood that only one DNA molecule was
amplified in each droplet. Given its great potential in application, RainDance Technologies
launched the commercial digital detection system with the highest droplet throughout, the
RainDrop dPCR system. Unfortunately, the system may consume up to 50 μL reagents per
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droplet simultaneously, and then the performance of ePCR suffers from variety. Benefitting
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in recent years. dPCR is still the main part in ddNAD, but droplet-based dINAAs including
dLAMP, dRPA, digital rolling circle amplification (RCA), and digital hyperbranched RCA
(HRCA) are showing up more and more [34–37, 56].
Figure 3. ePCR used for NGS. Top left: The genomic DNA is isolated, fragmented, ligated to adapters, and separated
into single strands. Top right: Fragments are bound to beads that are captured in the droplets of a PCR mixture-in-oil
emulsion. Then, ePCR occurs within each droplet. Bottom right: After breaking emulsion and denaturing the DNA
strands, beads with single-stranded DNA are deposited into wells of a fiber-optic slide. Bottom left: Pyrophosphate
sequencing is initiated within each well after depositing smaller beads carrying immobilized required enzymes. Re‐
printed with permission from Ref. [55]. © Copyright 2005 Nature Publishing Group.
Beer et al. successfully created picoliter-scale water-in-oil droplets by using a shearing T-
junction in a fused-silica device in 2008 [57]. The NA used for the device was RNA; therefore,
an off-chip valving system was integrated to stop the droplet motion, because a different
thermal cycling was required for reverse transcription and subsequent PCR amplification.
Each droplet contained the PCR mixture of single-copy template, primers, and reaction buffer,
which was really termed as digital detection. One year later, Mazutis et al. developed a method
for high-throughput dINAA platform in a 2 pL droplet-based microfluidic system [35]. The
isothermal HRCA was used to perform the DNA amplification in droplets. This platform was
demonstrated to allow fast and accurate digital quantification of the template. In 2011, Zhong
et al. reported another picoliter-scale droplet-based multiplexing dPCR platform, breaking the
one target per color barrier of qPCR [58]. The number of droplets generated reached more than
106, which was enough for enhancing the likelihood that only one DNA molecule was
amplified in each droplet. Given its great potential in application, RainDance Technologies
launched the commercial digital detection system with the highest droplet throughout, the
RainDrop dPCR system. Unfortunately, the system may consume up to 50 μL reagents per
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sample. Considering this point, the system may be not proper for rare sample detection. At
the same year, Hindson et al. also established a high-throughput droplet-based dPCR (ddPCR)
platform [59]. A total of 2 million droplets were generated, and the droplets were then
transferred into a 96-well plate for TaqMan probe-based PCR. Finally, to read out the results,
a flow cytometry-like double-channel fluorescence detection device was used in a microfluidic
chip, in which droplets went through one by one. The platform was confirmed to realize the
accurate measurement of germ-line CNV, discriminate the mutant molecules from the wild
molecules with 105-fold excess, and absolutely quantify circulating fetal and maternal DNA
from cell-free plasma. Based on the platform, the first commercial ddPCR system was launched
by QuantaLife in 2011, but in the end of that year Bio-Rad Laboratories purchased the company
and launched the QX100 ddPCR. Recently, the new version, QX200 ddPCR system, is also
available.
Apart from the process of droplet generation and subsequent NA amplification, other
approaches to generate droplet are also reported. As shown in Figure 4, Shen et al. described
a SlipChip to create droplet array [26]. The SlipChip was composed of two glass plates, in
which elongated wells were designed to overlap and form the fluidic path for reagent loading.
After sample loading, the simple slipping of the two plates broke the path, removing the
overlap among wells and generating 1280 droplet array (2.6 nL for each). The device had a
reservoir preloaded with oil, so each microreactor was absolutely isolated from each other
Figure 4. Design and mechanism of the SlipChip for dPCR. The top plate is outlined with a black solid line, the bottom
plate is outlined with a blue dotted line, and red represents the sample. (a) Schematic drawing shows the design of the
entire assembled SlipChip for dPCR after slipping. (b) Schematic drawing of part of the top plate. (c) Schematic draw‐
ing of part of the bottom plate. (d–f) The SlipChip was assembled such that the elongated wells in the top and bottom
plates overlapped to form a continuous fluidic path. (g–i) The aqueous reagent (red) was injected into SlipChip and
filled the chip through the connected elongated wells. (j–l) The bottom plate was slipped relative to the top plate such
that the fluidic path was broken up and the circular wells were overlaid with the elongated wells, and aqueous drop‐
lets were formed in each compartment. (d, g, and j) Schematic of the SlipChip. (e, h, and k) Zoomed-in microphoto‐
graph of the SlipChip. (f, i, and l) Microphotograph of the entire SlipChip. Reprinted with permission from Ref. [26]. ©
Copyright 2010 Royal Society of Chemistry.
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during thermal cycling. Finally, the results were read out using endpoint fluorescence
intensity. The biggest advantage of SlipChip is the capability of realizing multistep manipu‐
lation of plenty of microvolumes to form droplet array in parallel. Attributed to the remarkable
feature, until now, the SlipChip has been applied to perform immunoassays, protein crystal‐
lization, multiplex PCR, dPCR, dLAMP, dRPA, and so on [26, 34, 60–64].
To make the droplet more stable and to easily collect the amplified products, Leng et al.
invented an agarose droplet-based single-molecule ePCR device [51]. The agarose performed
the unique thermoresponsive sol-gel switching property, and a microfluidic chip was designed
to produce uniform agarose solution droplets. Schuler et al. applied centrifugal step emulsi‐
fication to the fast and easy generation of monodisperse droplets [37]. Only by adjusting the
nozzle geometry (depth, width, and step size) and interfacial tensions droplets with desirable
diameters could be produced. Using this droplet device, dRPA was successfully established
for the absolute quantification of Listeria monocytogenes DNA concentration standards within
30 min.
In ddNAD, the microreactors are generated by carefully titrating emulsions of water, oil, and
chemical stabilizer; therefore, there is no requirement of the walls of microwells to separate
the microreactors. Compared to pdNAD, ddNAD can easily achieve higher throughput via a
microdroplet generator to produce hundreds of thousands of droplet reactions per sample.
However, the workflow of ddPCR is complicated, referring to generating droplet, transferring
droplet, sealing microplate, conventional PCR, and reading out the signal by other devices.
3.3. cdNAD
The development of cdNAD is greatly attributed to the rapid progress of microfluidic
techniques, which can realize the low cost, low volume, and high-throughout paralleled NA
detections. In the last several decades, microreactors in cdNAD are mainly formed either by
the mechanical compartmentalization of PDMS or by the succeeding isolation via immiscible
liquid phase. In particular, for PDMS-based chips, the establishment of multilayer soft
lithography (MSL) techniques developed by Unger et al. in 2000 also gives a huge boost,
making the high-density microwells, micropumps, and microvalves easily fabricated [65].
Based on different power sources to partition reagents, cdNAD can be divided into three
categories: integrated fluidic circuit (IFC) cdNAD, self-priming compartmentalization (SPC)
cdNAD, and localized temporary negative pressure (LTNP)-assisted cdNAD as well as other
cdNADs.
3.3.1. IFC cdNAD
The outstanding feature of IFC chip is the special design of separated and interlaced liquid
and gas channels, as shown in Figure 5. Taking advantage of the high elasticity of PDMS,
hundreds or thousands of microreaction units are formed rapidly when gas channels are added
with pressure.
In 2006, Ottesen et al. used the IFC chip to achieve dPCR analysis [66]. A total of 1176 micro‐
reaction units were produced by controlling accurately the integrated microvalves and
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for the absolute quantification of Listeria monocytogenes DNA concentration standards within
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the microreactors. Compared to pdNAD, ddNAD can easily achieve higher throughput via a
microdroplet generator to produce hundreds of thousands of droplet reactions per sample.
However, the workflow of ddPCR is complicated, referring to generating droplet, transferring
droplet, sealing microplate, conventional PCR, and reading out the signal by other devices.
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The development of cdNAD is greatly attributed to the rapid progress of microfluidic
techniques, which can realize the low cost, low volume, and high-throughout paralleled NA
detections. In the last several decades, microreactors in cdNAD are mainly formed either by
the mechanical compartmentalization of PDMS or by the succeeding isolation via immiscible
liquid phase. In particular, for PDMS-based chips, the establishment of multilayer soft
lithography (MSL) techniques developed by Unger et al. in 2000 also gives a huge boost,
making the high-density microwells, micropumps, and microvalves easily fabricated [65].
Based on different power sources to partition reagents, cdNAD can be divided into three
categories: integrated fluidic circuit (IFC) cdNAD, self-priming compartmentalization (SPC)
cdNAD, and localized temporary negative pressure (LTNP)-assisted cdNAD as well as other
cdNADs.
3.3.1. IFC cdNAD
The outstanding feature of IFC chip is the special design of separated and interlaced liquid
and gas channels, as shown in Figure 5. Taking advantage of the high elasticity of PDMS,
hundreds or thousands of microreaction units are formed rapidly when gas channels are added
with pressure.
In 2006, Ottesen et al. used the IFC chip to achieve dPCR analysis [66]. A total of 1176 micro‐
reaction units were produced by controlling accurately the integrated microvalves and
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removing the conventional microarray spotter and plates. Now, the IFC chip-based dPCR (IFC
cdPCR) platform is successfully established for commercial purpose by Fluidigm. As the first
vendor to commercialize dPCR device, Fluidigm provides two IFC-based systems, the
BioMark HD and EP1 systems. In the two systems, the PCR reagents are mixed and partitioned
automatically, the thermocycling is integrated, and the results can be read out after reaction.
The BioMark HD system can offer real-time detection for each tiny reaction and eliminate false
positives according to the data, so the system is also available to qPCR. Compared to BioMark
HD, EP1 is just an endpoint detection machine, giving the binary output-like data whether or
not the microreaction occurs. Recently, Fluidigm also combines with Olink to detect human
protein biomarkers based on proximity extension assay (PEA) technology. Until now, the
dPCR device from Fluidigm has been applied to single-cell analysis, early diagnosis of cancer,
and prenatal diagnosis.
In 2011, Heyries et al. developed a megapixel dPCR platform in which 106 microunits were
fabricated, and the microreaction’s volume reached down to 10 pL (Figure 6) [67]. The density
of the microreactors reached up to 440,000/mm2, which was the highest density for IFC
platform. On detection performance, this device was able to discriminate one mutant molecule
from 105 wild molecules and achieve the discrimination of a 1% difference in chromosome
copy number. After the platform, in 2012, Men et al. published anther dPCR platform pos‐
sessing the lowest volume (36 fL) of microreactors until now. Its density of microreactors was
more than 20,000/mm2 [24]. After loading the reagents into all microreactors simultaneously,
the deformation of a PDMS membrane was used to completely seal the filled microreactors.
Due to the femtoliter-level microreactors fabricated, the device can greatly reduce the con‐
sumption of reagent and sample.
Figure 5. An IFC chip-based 12×765 digital array from the Fluidigm. Left: Schematic diagram of a part of the IFC chip
in which microchambers were connected and isolated by fluidic channels and pressure lines. Right: Optical microscop‐
ic images of the part. Reprinted with permission. © Copyright 2009 Springer.
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Figure 6. Schematic of megapixel dPCR device (a) and the layered device structure (b). Reprinted with permission
from Ref. [67]. © Copyright 2011 Nature Publishing Group.
For dINAA, IFC chip is also combined with isothermal MDA to develop dMDA for enumer‐
ation of total NA contamination [33]. On detection of microbial genomic DNA fragments,
dMDA performs higher sensitivity with orders of magnitude than qPCR.
By making the microchamber smaller or increasing its number, IFC cdNAD has a potential to
be developed into a digital detection platform with higher throughout, higher density, and
higher discrimination ability, but this platform still relies on the control system of integrated
microvalves and micropumps to load and partition the reagents, which is hard to be applied
towards POCT. Furthermore, narrowing the size of microchamber endlessly may have an
impact on the efficiency of NA amplification.
3.3.2. SPC cdNAD
Targeting practical POCT devices, currently proposed plate-based, droplet-based, and IFC
cdNADs are confronted with the huge challenge of demand for peripheral control instrument,
for instance, external syringe pumps, droplet generation devices, and plenty of integrated
microvalves and micropumps. Upon this challenge, the built-in power-driving, self-partition‐
ing, easy-to-use, and low-priced SPC cdNADs were developed by our laboratory. The built-
in power results from the gas solubility and permeability of PDMS, because PDMS remains
absorbing gas and letting gas go through them, although PDMS is in a solid state in chips [68].
The chip possesses the prominent feature of SPC, resulting from the used material of silicone
elastomer PDMS, a relatively cheap material, which possesses high gas solubility and perme‐
ability. When the fabricated chips are evacuated, a negative pressure environment is formed
due to the gas solubility of PDMS, which can service as a self-priming power to let the sample
solutions be sucked into each reaction chamber and sequentially the biocompatible oil to seal
and separate each filled chamber. Thus, in realizing dNAD, thousands of independent
microwells can be created automatically, avoiding the external control system, which is
superior to IFC cdNAD. Currently, SPC cdPCR and dINAAs [SPC chip-based dLAMP
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For dINAA, IFC chip is also combined with isothermal MDA to develop dMDA for enumer‐
ation of total NA contamination [33]. On detection of microbial genomic DNA fragments,
dMDA performs higher sensitivity with orders of magnitude than qPCR.
By making the microchamber smaller or increasing its number, IFC cdNAD has a potential to
be developed into a digital detection platform with higher throughout, higher density, and
higher discrimination ability, but this platform still relies on the control system of integrated
microvalves and micropumps to load and partition the reagents, which is hard to be applied
towards POCT. Furthermore, narrowing the size of microchamber endlessly may have an
impact on the efficiency of NA amplification.
3.3.2. SPC cdNAD
Targeting practical POCT devices, currently proposed plate-based, droplet-based, and IFC
cdNADs are confronted with the huge challenge of demand for peripheral control instrument,
for instance, external syringe pumps, droplet generation devices, and plenty of integrated
microvalves and micropumps. Upon this challenge, the built-in power-driving, self-partition‐
ing, easy-to-use, and low-priced SPC cdNADs were developed by our laboratory. The built-
in power results from the gas solubility and permeability of PDMS, because PDMS remains
absorbing gas and letting gas go through them, although PDMS is in a solid state in chips [68].
The chip possesses the prominent feature of SPC, resulting from the used material of silicone
elastomer PDMS, a relatively cheap material, which possesses high gas solubility and perme‐
ability. When the fabricated chips are evacuated, a negative pressure environment is formed
due to the gas solubility of PDMS, which can service as a self-priming power to let the sample
solutions be sucked into each reaction chamber and sequentially the biocompatible oil to seal
and separate each filled chamber. Thus, in realizing dNAD, thousands of independent
microwells can be created automatically, avoiding the external control system, which is
superior to IFC cdNAD. Currently, SPC cdPCR and dINAAs [SPC chip-based dLAMP
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(cdLAMP) and SPC chip-based dIMSA (cdIMSA)] have been developed by our laboratory [30,
31, 69, 70].
3.3.2.1. SPC cdPCR
The chip shown in Figure 7 is composed of three PDMS layers, two glass coverslips, and a
waterproof layer [30]. The three PDMS layers include an inlet and outlet layer, a microwell
array layer, and a blank layer. In the microwell array layer, a total of 5120 reaction microwells
(150 μm in width, 150 μm in length, and 250 μm in height) are equally distributed in four
separate panels. Each microwell contains down to 5 nL solution. The inlet and outlet layers
have four 0.5-mm holes and four 2.5-mm holes in diameter punched as injection ports and
suction chambers when aligning to the outlet of the microwell array layer, respectively. For
mechanical stability, the blank layer coats the microwell array layer with the waterproof layer
embedded. The waterproof layer is made of low permeability fluorosilane polymer, which
beneficially prevents the evaporation during the step of denaturing template DNA at 95°C in
PCR. One of the glass coverslips with plasma pretreated are used to seal the microwell array,
and the other one is pressed on the upper surface of the SPC chip for mechanical stability at
the end of microchip operation.
MSL techniques are used to fabricate the SPC chip. The chip patterns are designed by a software
of CorelDRAW X4 and printed on transparency films using a high-resolution printer to create
Figure 7. (A) Schematic diagram of the layered device structure of the SPC chip. (B) Photograph of the prototype SPC
cdPCR device. The size of the chip is 50×24×4 mm. (C) Principle and operation procedure of the SPC microfluidic de‐
vice. The red cuboids (150×150×250 μm) stand for the microwells. Reprinted with permission from Ref. [30]. © Copy‐
right 2014 Royal Society of Chemistry.
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the masks of channels and microwells. The photoresist material used are SU8 serials, which
are a high-contrast, epoxy-based negative photoresist. Several 4-inch silicon wafers are
adopted as the mold substrate. The PDMS to replicate the SPC chip is the silicone elastomer
PDMS, which is composed of PDMS base (A) and catalyst (B) at certain ratios. Because dPCR
is an endpoint detection, the reaction components including PCR buffer, primers, labeled
probes, and templates have to be mixed before loading into the chip. Each diluted template in
the mixture is individually injected into the three panels of the chip, allowing the samples to
be compartmentalized completely and each chamber contains down to 5 nL solution. A
Maestro Ex In-Vivo Imaging System (CRI Maestro, USA) is used to capture the fluorescent
image of the microchip after dPCR. As a new generation of microfluidic chips, SPC cdPCR has
been successfully applied to the absolute quantification of β-actin DNAs and the lung cancer-
related genes.
3.3.2.2. SPC chip-based dINAAs (cdINAAs)
Although PCR is widely adopted and used as a standard analytical technique in molecular
diagnosis, it is remarkably confined when applied to field and POCT due to the facts that it
requires nonportable thermocycling facilities, its process of obtaining results is cumbersome,
and the whole amplification takes 2 h or more. Also, SPC cdPCR confronts the same defects.
Accordingly, SPC cdLAMP and SPC cdIMSA are established by our laboratory. As simple and
easy world-to-chip fluidic devices, SPC cdINAAs have the great potential in POCT for the
developing countries.
Similar to SPC cdPCR, SPC cdLAMP is also the completely valve-free and SPC device (Figure
8) [31]. It is also made mainly of PDMS and fabricated by MSL techniques. In size, the SPC
chip used for dLAMP is the same as the dPCR-used chip; however, in composition, it does not
contain a waterproof layer because of the absence of the DNA denaturing step in LAMP. For
the microwell array PDMS layer of dLAMP-used SPC chip, a total of 4800 microwells (150 μm
in width, 150 μm in length, and 300 μm in height) are fabricated and they are also equally
distributed into four panels (each contains 1200 chambers), and the interval for two closed
chambers is 150 μm. The big difference from the dPCR-used SPC is that the rectangular
chambers are located vertically on the main channels and the branch channels link to chamber
without orthogonal turning points. On performance, the SPC cdLAMP can precisely calculate
the absolute DNA concentration. To conduct the data acquisition and analysis of SPC cdLAMP,
the Maestro Ex In-Vivo Imaging System is employed. However, the imaging system is too
cumbersome and expensive to allow the e POCT, especially in the less developed regions.
Herein, an easy-to-use and cost-efficient smartphone-based dLAMP POCT device platform is
also established by our laboratory.
SPC cdIMSA is an updated version of SPC cdLAMP, in which the LAMP is replaced by IMSA
and a mixed dye is used to establish a label-free and sensitive dual-fluorescence detection for
on-chip IMSA [70, 71]. The used SPC chip for dIMSA is the same as that for dPCR without any
modifications. The SPC cdIMSA with the mixed dye for the detection of hepatitis B virus (HBV)
is conducted. In contrast, the mixed dye indicating two different colors makes it easy to count
the positive chamber number by visual inspection regardless of the cutoff values. Also, there
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is a linear response of the counted positive chamber number to the dilution ratios of templates.
Moreover, the dual fluorescence is capable of indicating more positive chamber number in
contrast to single fluorescence by SYBR Green I. The mixed dye-loaded SPC cdIMSA possesses
the advantage of enlarging the color changes over other currently used dyes or indicators.
Similarly, the mixed dye-based dual-fluorescence detection has a potential in the POCT
application of SPC cdLAMP and other SPC chip-based dINAAs.
3.3.3. LTNP cdNAD
As another POCT-oriented LOC device, LTNP chip resembling SPC chip also uses the gas
solubility of PDMS to load solution into chambers (Figure 9) [29]. However, the measure of
evacuating the LTNP chip is different from the SPC chip. For the former, the gas solubility and
permeability of the chip itself and another PDMS layer coating on the chip services simulta‐
neously as the real-time power source of evacuating with a syringe filter. For the latter,
preevacuating by a vacuum pump is indispensable, which calls for robust and efficient
approaches of sealing and packaging chips [30].
The LTNP cdPCR has been already exploited [29]. The chip consists of three parts, which are
a lamina-chip layer (LCL), a vaporproof layer (VPL), and a syringe filter-like microfluidic
device (μfilter) with helical channels. The μfilter has two parts. One is designed for generating
the LTNP through pulling the plug of the syringe connected at one end of helical channels.
The helical channel in the μfilter is 200 μm in width and 40 μm in depth. The other is used for
Figure 8. (a) Schematic diagram of the SPC chip for cdLAMP. (b) Schematic of the whole microchip and the enlarged
schematic diagram of the part of the chip, with insets showing the array and microwell geometries. It contains four
separate panels, each of which has an individual inlet and outlet. The blue lines (8×50 μm) are the flow channel. The
red spots (150×150×300 μm) stand for the microwells. Each microwell was partitioned by oil. (c) Photograph of the pro‐
totype SPC cdLAMP device. Reprinted with permission from Ref. [31]. © Copyright 2012 Royal Society of Chemistry.
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sample and oil loading via the punched ports (0.5 mm in diameter) aligning at the ones in the
LCL. The area diameter of the region of helical channel in the two μfilters is 20 mm, covering
entirely the area of the whole chambers in the LCL. Sandwiched by the two parts of the μfilter,
LCL contains 650 chambers in a square array. The chamber is cylindrical with 200 μm in
diameter and 200 μm in depth, and the distance between two closed chambers is also 200 μm.
VPL on the LCL is also a thin circular layer with chambers at 100 mm in diameter, and its area
is 17.0 mm in diameter, entirely mulching the LCL.
Figure 9. (A) Schematic diagram of the LTNP chip. (B) Schematic of the reagent-loaded chip. It contains reagent-loaded
lamina chip (red), water-loaded VPL (blue), PDMS on the coverglass, and optical adhesive cover. (C) Digital image of
the prototype LTNP cdPCR device. Reprinted with permission from Ref. [29]. © Copyright 2015 Royal Society of
Chemistry.
Currently, LTNP cdPCR has been used for the detection of keratin 19 in A549 lung carcinoma
cells [29]. Additionally, the integrated LTNP chip with NA enrichment, isolation, and digital
detection functions has been developed and successfully applied to detect bovine DNA in
ovine meat for food adulteration detection [72, 73].
3.3.4. Other cdNADs
Gansen et al. described a self-digitization (SD) cdLAMP device shown in Figure 10 [32]. In this
device, the reagents were partitioned into the microchambers based on an inherent fluidic
phenomenon that the interplay between fluidic forces and interfacial tension could cause the
self-dispersion of an income aqueous fluid into an array of chambers prefilled with an
immiscible fluid. Therefore, the sample loading could be realized with manual or automated
syringe pumps or external air pressure, removing the hydraulic valves or mechanical action.
Less than 2 μL sample was used for the accurate quantification of relative and absolute DNA
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concentrations. To improve the efficiency of partitioning samples, a new generation of SD chip
was invented with close to 100% efficiency in 2013 [74]. In 2014, based on the SD chip, digital
RT-PCR was developed to absolutely quantify mRNA from single cells [75]. Due to the
simplicity and robustness of the SD chip, the SD cdNAD is an inexpensive and easy-to-operate
digital detection device.
Figure 10. Design of the SD cdLAMP device. (A) Schematic diagram of the individual components of a fully assembled
chip. Air pressure was delivered via a removable adapter, which was connected to an external pressure source. (B)
Layout of the microfluidic network. A dense array of rectangular side chambers was connected to a thin main channel.
The whole array was surrounded by a separate water reservoir to saturate the PDMS during incubation at 65°C. Scale
bar, 5 mm. (C) Geometry of the side chamber array and main channel. All dimensions are in micrometers. (D) Sequen‐
tial images showing the initial filling of the side-chamber array with aqueous solution. (E) Sequence of images show‐
ing the SD of aqueous sample in the side chambers. Reprinted with permission from Ref. [32]. © Copyright 2012 Royal
Society of Chemistry.
In 2010, Sundberg et al. designed a spinning disk platform to achieve dPCR [25]. The disk was
an inexpensive and disposable plastic disk-like chip. Differing from other approaches, 1000
nL microwells were generated by passive compartmentalization through centrifugation, and
the volume of each well was 33 nL in average. The whole process, including disk loading,
thermocycling, and fluorescent imaging, only costs less than 35 min. However, this kind of
cdNAD performed some defects, such as the tedious plastic disk manufacturing and the
probable NA adsorption to the disk.
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4. Analysis and evaluation of cdNAD
This part focuses on the analysis and evaluation of cdNAD. The contents involve four aspects,
which are the dehydration of microreaction, the dynamic range, the response of cdNAD, and
the precision of cdNAD.
4.1. Dehydration of microreaction
In PCR, dehydration is attributable to the repeated denaturing steps, whereas, for isothermal
NA amplification, reacting at a consistent temperature (e.g., 63°C) for at least 1 h results in
dehydration. Also, the influence of dehydration is different according to the different material-
based chips for cdNAD.
As we know, the microfluidic PDMS chips suffer from dehydration heavily. Actually, the
dehydration degree is determined by the thickness of the PDMS layer between the top of the
chamber and the waterproof layer. If v f is the total volume fraction of reaction reagent, v f is




A hv A h
×=
×
where A and h refer to the designed area and height, respectively. Using the formula of C
sat_25°C×P vap_70°C/P vap_25°C, a saturated concentration of water vapor in PDMS at 70°C (C sat_70°C) can
be calculated as 400 mol/m3. Then, the maximum fractional loss of water (fl max) from the reaction
chambers is defined by
where ρwater is the density of water and M water is the molar mass of water.
4.2. Dynamic range
When high concentration targets are loaded, the chip panel can be completely saturated,
whereas, for low targets, the chip panel still possesses the capability of realizing digital
detection. Therefore, the theoretical dynamic range is determined by the high concentrations
that make the chip completely saturated.
In this situation, the occurrence of an empty chamber is a small probability event, and due to
statistical independence between the chamber number and the total empty chamber number,
the event can be modeled as a random Poisson process. Then, the occurrence probability of t
empty chamber number, P (n=t, λ), is defined by P(n = t , λ)=λ
t e −λ
t !
. In the function, λ equals to
the mean number of empty chambers in panels. For each empty chamber in each panel, namely,
a chamber containing 0 molecule, the probability P(n=0,λ)=e-λ=e-m/N, where λ is the ratio of the
loaded molecule number (m) to the chamber numbers (N). Therefore, λ is equal to the product
of the probability P(n=0,λ) and the N chamber numbers, namely, λ=Ne-m/N. Finally,
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−m/N / t !. If λ is more than 10, the probability of the chip
panel is completely saturated, P(n=0,λ)=e-10, which is less than 10-4 and can be as the accept‐
able failure rate. Then, λ=N e-m/N>10, and the maximum loaded molecular number (mmax) can
be calculated.
4.3. Response of cdNAD
According to the distribution of molecules across the chip, the Poisson distribution is adapted
to calculate the original concentration of target stock solution.
For each chip panel, the probability (P) of having the number (n) of NA molecules per chamber
is P(n,λ)=(λ n e -λ)/n!, where λ is the ratio of loaded molecule number to chamber number of
each panel. For λ, it is equal to the average molecule number per chamber, which can be
expressed by the equation of λ=C 0 X dil V, where C 0 is the target’s original concentration, V is
the volume of each chamber, and X dil is the dilution factor of diluted targets used in the panel.
If the stock solution is diluted in k fold, the X dil=1/k, and particularly, the X dil of stock solution
is 1. When a chamber contains 0 molecule, the probability P(n=0,λ)=e -λ. As for a chamber
capturing one or more molecules, the probability P(n≧1,λ)=1-P(n=0,λ)=1-e -λ. After dPCR, a
chamber with observed positive signal suggests that at least one target molecule is captured.
Therefore, the ratio (f) of observed positive chamber number to chamber number of each panel,
namely, the observed fraction of positive chambers, equals to the probability P(n≧1,λ), which
is f=P(n≧1,λ)=1-e -λ. Then, λ=ln(1-f)=-C 0 X dil V, and a linear variation relationship is exhibited
in terms of the regression curve equation between ln(1-f) and X dil, because C 0 and V are constant
values. Then, the target’s original concentration C 0 can be calculated based on the slope of the
curve (-C 0 V).
In addition, because the Poisson distribution is a particular case of a binomial distribution, the
distribution of the positive chamber number (x) in each panel is classified as the binomial
distribution. The probability distribution P(x) is therefore influenced by the probability
p=P(n≧1,λ)=1-P(n=0,λ)=1-e -λ. Based on the nature of binomial distribution, x is equal to the
mean, namely, x=Np=N(1-e -λ) (N, the total chamber number in each panel). Then, the average
molecule number per chamber, λ=ln{N/(N-x)}, through which the loaded molecule number
(N e) for each panel can be estimated by the equation N e=Nλ=Nln{N/(N-x)}.
4.4. Precision of cdNAD
When the chamber number in each panel is very large, the Poisson distribution is approximate
to normal distribution, which is also called Gaussian distribution. Use the parameters in the
discussion of response and dynamic range above, and let y be a random variable representing
the number of positive chambers that capture at least one molecule. Also, we can know that
its mathematical expectation or mean μ is N (1-e -λ), and its variance σ 2 is Ne -λ (1-e -λ). Then,
the probability density function associated with y is as follows:
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If the precision of cdNAD is defined as the minimum difference in concentration (∆λ/λ) that
is reliably detected with more than 99% true positive and more than 99% true negative rate,
this situation corresponds to 4.6σ separation in the mean (μ) for two Gaussian distributions.
That is to say, in the case with small ∆λ, ∆μ/∆λ=4.6σ. Then, ∂[N(1-e -λ)]∆λ/∂λ=Ne -λ∆λ=4.6[Ne -
λ (1-e -λ)]1/2, and ∆λ/λ=4.6(e λ-1)1/2/(λN 1/2). For different total chamber numbers (N) in chip panel,
the precision (∆λ/λ) to expected molecules per chamber (λ) could be plotted.
5. Application of dNAD
Compared to conventional NA detection methods, dNAD provides better sensitivity, better
precision, higher tolerance, and the NA’s absolute quantification. Until now, dNAD has been
applied to a variety of research fields, including pathogen detection, food safety, clinical
diagnosis (genetic instability estimation and early cancer), prenatal diagnosis, quantitative
analysis of gene expression, and NGS library quantification. Although dPCR is still the most
widespread type of dNAD, in resource-limited regions, it is confined due to the requirement
of thermal cycling and robust temperature control. To overcome this awkwardness, dINAAs
without thermal cycling are of great interest, which also enlarge the application of dNAD,
especially for POCT. For this subchapter, the recent advances on application of dNAD will be
narrated.
5.1. Pathogen detection
Honestly speaking, on pathogen detection, the advantages of most conventional NADs on both
analytical sensitivity and specificity are inherited by the corresponding digital formats. In
addition, dNAD has the capability of realizing NA’s absolute quantification. Therefore, dNAD
can be used as the ultrahigh sensitivity and more accurate method for viral load determination
or bacterial quantification. Kelley et al. established a duplex ddPCR assay for high-precision
methicillin-resistant Staphylococcus aureus (MRSA) analysis [76]. By assaying 397 clinical
samples, a good agreement with the reference assay for both qPCR and ddPCR assays was
indicated. Strain et al. demonstrated and estimated the application of ddPCR for a highly
precise measurement of HIV DNA [77]. Total HIV DNA and episomal 2-LTR (long terminal
repeat) circles in cells that were all isolated from infected patients were targeted. Compared
to qPCR, ddPCR performed a significantly increased precision (5-fold for total HIV DNA and
>20-fold for 2-LTR circles), making it an alternative for the measurement of HIV DNA from
clinical specimens.
dNAD also enables the direct detection without NA extraction due to the ability of partitioning
target NA and nontarget components (e.g., inhibitors) into different microwells. Pavšič et al.
employed two dPCR platforms (QX100 ddPCR system from Bio-Rad Laboratories and the
BioMark HD IFC cdPCR system from Fluidigm) for the direct quantification of two whole-
virus materials of human cytomegalovirus (HCMV) without DNA extraction [78]. It was
demonstrated that direct quantification by both dPCRs could provide repeatable measure‐
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ments of viral DNA copy numbers, giving a closer agreement with the actual viral load than
that with either dPCR or qPCR of extracted DNA.
Although dNAD certainly possesses the superiority of absolute quantitation, some reports fail
to demonstrate the advantage, which calls for the requirement of optimization when estab‐
lishing dNAD. For instance, Boizeau et al. used ddPCR to provide an absolute quantitation of
HBV genome molecules [79]. However, the results indicated that qPCR assays remained more
sensitive than ddPCR when used for low HBV DNA levels, suggesting that optimization of
ddPCR was still necessary, especially on accurately differentiating the positive from negative
in samples with very low levels of target DNA molecules.
5.2. Food safety
Food safety mainly refers to two parts: the minoring of foodborne pathogens and the detection
of GMO. For example, human noroviruses (NoV) and hepatitis A virus (HAV) are two
foodborne enteric viruses that have caused the vast majority of nonbacterial gastroenteritis or
some fatal infectious hepatitis. Coudray-Meunier et al. conducted a comparative study of IFC
RT-cdPCR and conventional RT-qPCR when quantifying the NoV and HAV from lettuce and
water samples, proving that the IFC RT-cdPCR assay was more tolerant to inhibitory sub‐
stances from lettuce samples [80]. Also, the IFC RT-cdPCR may be useful for standardizing the
quantification of enteric viruses in bottled water and lettuce samples. Fu et al. used the BioMark
HD system equipped with a 48.770 digital array to develop cdPCR for GMO detection without
pretreatment [81]. The CaMV35s promoter and the NOS terminator were selected as the
targets, and nine events of GMOs (MON810, MON863, TC1507, MIR604, MIR162, GA21, T25,
NK603, and Bt176) were collected to determine the specificity. The results showed that the
cdPCR could achieve a discrimination of down to 0.1%, lower than the labeling threshold level
of the EU, allowing highly sensitive, specific, and stable GMO screening detection. Dalmira et
al. developed a duplex ddPCR assay to characterize the certified reference materials (CRMs)
in terms of T-nos/hmg copy number ratio in maize [82]. After optimization using a central
composite design, the duplex ddPCR method realized the absolute limit of detection (LOD)
and limit of quantification (LOQ) of 11 and 23 copy number T-nos, namely, relative LOD of
0.034% and relative LOQ of 0.08%, respectively. The dynamic range of T-nos/hmg ratio ranged
from 0.08% to 100%. The results indicated that the duplex ddPCR assay was useful for
characterizing CRM candidates on T-nos/hmg ratio.
The bias caused by reliance on quantitative standards may have an impact on the results of
qPCR, which is not beneficial for water monitoring and microbial source identification.
Therefore, Cao et al. employed a duplex ddPCR to simultaneously quantify Enterococcus spp.
and the human fecal-associated HF183 marker for evaluating the water quality [83]. The results
demonstrated that ddPCR performed greater tolerance of inhibition than qPCR, with one to
two orders of magnitude higher at inhibitor concentrations. Also, ddPCR brought about
remarkably improved precision, although a lower upper LOQ than qPCR was indicated.
For food safety, it is indispensable to identify and quantify the meat products for unveiling
species fraud and product mislabeling during food processing. Tian et al. used LTNP cdPCR
to detect bovine meat in ovine meat [72]. Floren et al. successfully applied two-step ddPCR for
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precise quantification of cattle, horse, and pig in processed meat product, with the nuclear F2
gene targeted [84].
5.3. Clinical diagnosis
At present, clinical diagnosis including genetic instability estimation and early cancer is also
the main application field for dNAD. It has been clearly confirmed that the genetic instability
of human cells is one of the causes of cancer, including somatic mutation, allelic imbalance,
loss of heterozygosity, CNVs, and single nucleotide variations (SNVs). Accordingly, how to
discriminate the rare mutant gene from abundant normal NAs attracts great concerns of
researchers. Interestingly, it is also the question that initiates the concept formation of dNAD.
As de novo CNV may be caused by reprogramming somatic cells into induced pluripotent stem
cells, Abyzov et al. used qPCR and ddPCR to detect and estimate this phenomenon. The results
showed that, in parental fibroblasts, at least half of the CNVs are indicated as low-frequency
somatic genomic variants [85]. Boettger et al. successfully applied a ddPCR approach to
analyze father-mother-offspring trios from HapMap at specific sites within region 1 on the
investigation of inference of complex CNV and single nucleotide polymorphism (SNP)
haplotypes at the human 17q21.31 locus [86].
Detecting biomarkers associated with tumor formation, development, and drug evaluations
on gene expression is the useful approach for early cancer diagnosis. Up to now, various
biomarkers have been identified, and dNAD reflects the unique advantage of absolute
quantitation of their gene expression [87]. Zhu et al. applied SPC cdPCR to the detection of
three lung cancer-related genes (PLAU, ENO2, and PLAT). cdPCR yielded comparable results
to qPCR, illustrating that the established platform had the ability of realizing absolute
quantitation for gene expression [30]. Floren et al. employed ddPCR to detect the BRAF-V600E
and V600K mutations in melanoma circulating tumor with high sensitivity [84]. The study
demonstrated that ddPCR performed 200-fold increased sensitivity than competitive allele-
specific PCR (castPCR), giving an LOD of 0.0005% when combined with whole-genome
amplification (WGA). Through noninvasive analysis of circulating free plasma DNA, Geven‐
sleben et al. determined the presence of oncogenic amplification by developing a plasma DNA
ddPCR assay targeting HER2 [88]. In the independent validation cohort, ddPCR could reach
a positive and negative predictive value of 70% and 92%, respectively. The results suggested
that ddPCR had the potential to the analysis of any locus amplified in cancer, not only in
metastatic breast cancer. Beaver et al. also employed a ddPCR assay for the detection of
circulating plasma tumor DNA (ptDNA) in patients with early-stage cancer [89]. A total of 30
tumors were first analyzed by Sanger sequencing for common PIK3CA mutations, and ddPCR
was then used to analyze their extracted DNA for the same mutations. This ddPCR-based
accurate mutation detection platform was demonstrated to be of great use for early-stage breast
cancer.
As a new generation of cancer biomarkers, abnormally DNA methylation in the gene’s
regulatory regions can affect identical residues that may cause the cancer. The analysis of
methylated genes therefore becomes more and more important in cancer research. For
example, Li et al. developed a sensitive bead-based ddPCR for the quantification of DNA
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discriminate the rare mutant gene from abundant normal NAs attracts great concerns of
researchers. Interestingly, it is also the question that initiates the concept formation of dNAD.
As de novo CNV may be caused by reprogramming somatic cells into induced pluripotent stem
cells, Abyzov et al. used qPCR and ddPCR to detect and estimate this phenomenon. The results
showed that, in parental fibroblasts, at least half of the CNVs are indicated as low-frequency
somatic genomic variants [85]. Boettger et al. successfully applied a ddPCR approach to
analyze father-mother-offspring trios from HapMap at specific sites within region 1 on the
investigation of inference of complex CNV and single nucleotide polymorphism (SNP)
haplotypes at the human 17q21.31 locus [86].
Detecting biomarkers associated with tumor formation, development, and drug evaluations
on gene expression is the useful approach for early cancer diagnosis. Up to now, various
biomarkers have been identified, and dNAD reflects the unique advantage of absolute
quantitation of their gene expression [87]. Zhu et al. applied SPC cdPCR to the detection of
three lung cancer-related genes (PLAU, ENO2, and PLAT). cdPCR yielded comparable results
to qPCR, illustrating that the established platform had the ability of realizing absolute
quantitation for gene expression [30]. Floren et al. employed ddPCR to detect the BRAF-V600E
and V600K mutations in melanoma circulating tumor with high sensitivity [84]. The study
demonstrated that ddPCR performed 200-fold increased sensitivity than competitive allele-
specific PCR (castPCR), giving an LOD of 0.0005% when combined with whole-genome
amplification (WGA). Through noninvasive analysis of circulating free plasma DNA, Geven‐
sleben et al. determined the presence of oncogenic amplification by developing a plasma DNA
ddPCR assay targeting HER2 [88]. In the independent validation cohort, ddPCR could reach
a positive and negative predictive value of 70% and 92%, respectively. The results suggested
that ddPCR had the potential to the analysis of any locus amplified in cancer, not only in
metastatic breast cancer. Beaver et al. also employed a ddPCR assay for the detection of
circulating plasma tumor DNA (ptDNA) in patients with early-stage cancer [89]. A total of 30
tumors were first analyzed by Sanger sequencing for common PIK3CA mutations, and ddPCR
was then used to analyze their extracted DNA for the same mutations. This ddPCR-based
accurate mutation detection platform was demonstrated to be of great use for early-stage breast
cancer.
As a new generation of cancer biomarkers, abnormally DNA methylation in the gene’s
regulatory regions can affect identical residues that may cause the cancer. The analysis of
methylated genes therefore becomes more and more important in cancer research. For
example, Li et al. developed a sensitive bead-based ddPCR for the quantification of DNA
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methylation, which could detect down to one methylated DNA molecule in approximately
5000 unmethylated DNA molecules from plasma or fecal samples [20]. Weisenberger et al.
developed an improved DNA methylation detection with single-molecule high-resolution
based on IFC cdPCR and successfully identified the breast cancer-specific hypermethylation
phenomenon in the CpG islands of RUNX3, CLDN5, and FOXE1 [90].
5.4. Prenatal diagnosis
Prenatal diagnosis is usually carried out by invasive or noninvasive approaches [91]. The
invasive method (e.g., amniocentesis) refers to inserting needles into the uterus, which is time-
consuming (several weeks required) and risky to the fetus [92]. In contrast, noninvasive
method seems to be more rapid and safer. Currently, noninvasive prenatal diagnosis mainly
involves ultrasonography of the womb or detecting cell-free fetal DNA (cffDNA) in maternal
serum and plasma. The latter is also termed as noninvasive prenatal testing (NIPT). Appling
dNAD to NIPT is the emerging noninvasive approach with high sensitivity and high precision
[93–97]. Gu et al. employed the QX100 ddPCR system from Bio-Rad Laboratories to detect
cffDNA for the risk of methylmalonic acidemia, confirming that ddPCR is a cost-effective and
noninvasive prenatal method when diagnosing known mutations associated with Mendelian
disorders [98]. Pornprasert and Prasing implemented a ddPCR for the deletion of α(0)-
thalassemia Southeast Asian (SEA)-type deletion [99]. The study showed that ddPCR might
be an alternative technology to routine clinical diagnosis. Barrett et al. adopted 12×765 digital
array chips to establish an IFC cdPCR to analyze the cffDNA for NIPT of sickle cell anemia [94].
The results suggested that the built IFC cdPCR is a useful method to determine the genotype
of fetuses at risk for sickle cell anemia. Meantime, the report also illustrated that it was essential
to optimize the fractional fetal DNA concentration.
Because most cffDNA fragments were approximately 200 bp in size and, in the early gestation,
the cffDNA occupies low percentage (mostly <10%) in maternal plasma, efficient methods for
the extraction of cffDNA are in great need. Holmberg et al. thereby estimated two commercial
platforms to extract cffDNA: the Akonni Biosystems TruTip technology and the Circulating
Nucleic Acids Kit from Qiagen [100]. Determined by QX100 ddPCR system and qPCR, the
extracted products from two platforms performed similar results.
5.5. NGS library quantification
As known to all, the establishment of NGS libraries still leans mainly on manual bench-top
procedures, which is slow and inefficient [101]. To solve it, Kim et al. invented an automated
digital microfluidic LOC-based sample preparation for the NGS. Compared to the conven‐
tional methods, digital microfluidic LOC platform is cost-efficient and has high throughout
[102]. Similarly, Thaitrong et al. integrated a droplet-based microfluidic LOC system with a
unit of capillary-based reagent delivery and the quantitative CE module to develop an
automated quality-control platform for NGS [103]. Besides, White et al. confirmed that dPCR
is able to provide sensitive and absolute calibration for NGS, enabling direct sequencing
without titration runs and with sufficient precision [11]. Fu et al. developed a picoliter-scaled
droplet digital WGA (ddWGA) platform for realizing uniform and accurate single-cell
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sequencing, bringing about significantly improved amplification evenness and accuracy for
the simultaneous detection of CNVs and SNVs in single-cell level [104]. Weisenberger et al.
applied the Fluidigm BioMark Digital Array to establish digital bisulfite genomic DNA
sequencing with high resolution and high sensitivity [105]. The results showed that IFC cdPCR
was a fast and reliable method for the single-molecule-scaled detection of DNA methylation
information.
6. Conclusion and future prospects
Undoubtedly, there is growing interest in dNAD, because it allows the more precise NA
quantification, the higher discrimination of rare NA mutants, and the more reproducible and
less susceptible to inhibitors than the traditional NA methods. Consequently, dNAD has full
potential to influence the development of biology research, clinical diagnosis, the safety of food
and environment, and other research fields.
To enhance the impact of this promising technique and push it towards clinical application,
the MIQE for dNAD (dMIQE) was also published [106]. Based on dMIQE, the experimental
protocols are standardized, the efficient utilization of resources is maximized, and the data are
adequately assisted. However, the promising technique of dNAD still confronts some
shortcomings. On one hand, although the development of microfluidic LOC offers a lot of
dNAD device platforms, these devices perform low functional integration, and the supporting
detection approaches lean primarily on real-time fluorescence scanning or the endpoint
analysis of CCD camera-captured images, which, to some extent, adds the real cost and also
has impacts on the true detection accuracy. Therefore, in the future, it will become a general
trend that dNAD devices are highly integrated with multiple functions including cell or single-
cell capture, cell lysis, and NA enrichment and purification, employing more advanced
supporting detection technology. Particularly, for ddNAD, the strategy of droplet generation
is one of the developing directions. For instance, Tanaka et al. currently created a hands-off
autonomous preparation method of monodisperse emulsion droplets using a degassed PDMS
chip [107]. Jeong et al. used a specially designed three-dimensional monolithic elastomer
device to create a kiloscale droplet generation [108]. According to the snap-off mechanism,
Barkley et al. also invented a novel technique to generate monodisperse droplets [109].
On the other hand, dNAD is actually the digital version of NAD, thereby possessing the same
disadvantages (e.g., bias or nonspecific amplification) as most sequence-based NA amplifica‐
tion methods. Based on this point, how to improve or guarantee the NA amplification fidelity
in microreactors is one of the future prospects of dNAD. It should be noted that the optimized
reaction conditions for NA amplification in microreactors might be different from those in bulk
state, meaning that the optimization of reaction system is indispensable. Furthermore, the
precision of dNAD is greatly influenced by the number and size of microchambers (for
cdNAD) or droplet (for ddNAD), which in turn challenges the fabrication of microfluidic chip
and the uniformity of partitioning. Accordingly, we also anticipate that, in the future, there
will be some novel strategies developed to realize digital detection not only based on parti‐
tioning reagents.
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sequencing, bringing about significantly improved amplification evenness and accuracy for
the simultaneous detection of CNVs and SNVs in single-cell level [104]. Weisenberger et al.
applied the Fluidigm BioMark Digital Array to establish digital bisulfite genomic DNA
sequencing with high resolution and high sensitivity [105]. The results showed that IFC cdPCR
was a fast and reliable method for the single-molecule-scaled detection of DNA methylation
information.
6. Conclusion and future prospects
Undoubtedly, there is growing interest in dNAD, because it allows the more precise NA
quantification, the higher discrimination of rare NA mutants, and the more reproducible and
less susceptible to inhibitors than the traditional NA methods. Consequently, dNAD has full
potential to influence the development of biology research, clinical diagnosis, the safety of food
and environment, and other research fields.
To enhance the impact of this promising technique and push it towards clinical application,
the MIQE for dNAD (dMIQE) was also published [106]. Based on dMIQE, the experimental
protocols are standardized, the efficient utilization of resources is maximized, and the data are
adequately assisted. However, the promising technique of dNAD still confronts some
shortcomings. On one hand, although the development of microfluidic LOC offers a lot of
dNAD device platforms, these devices perform low functional integration, and the supporting
detection approaches lean primarily on real-time fluorescence scanning or the endpoint
analysis of CCD camera-captured images, which, to some extent, adds the real cost and also
has impacts on the true detection accuracy. Therefore, in the future, it will become a general
trend that dNAD devices are highly integrated with multiple functions including cell or single-
cell capture, cell lysis, and NA enrichment and purification, employing more advanced
supporting detection technology. Particularly, for ddNAD, the strategy of droplet generation
is one of the developing directions. For instance, Tanaka et al. currently created a hands-off
autonomous preparation method of monodisperse emulsion droplets using a degassed PDMS
chip [107]. Jeong et al. used a specially designed three-dimensional monolithic elastomer
device to create a kiloscale droplet generation [108]. According to the snap-off mechanism,
Barkley et al. also invented a novel technique to generate monodisperse droplets [109].
On the other hand, dNAD is actually the digital version of NAD, thereby possessing the same
disadvantages (e.g., bias or nonspecific amplification) as most sequence-based NA amplifica‐
tion methods. Based on this point, how to improve or guarantee the NA amplification fidelity
in microreactors is one of the future prospects of dNAD. It should be noted that the optimized
reaction conditions for NA amplification in microreactors might be different from those in bulk
state, meaning that the optimization of reaction system is indispensable. Furthermore, the
precision of dNAD is greatly influenced by the number and size of microchambers (for
cdNAD) or droplet (for ddNAD), which in turn challenges the fabrication of microfluidic chip
and the uniformity of partitioning. Accordingly, we also anticipate that, in the future, there
will be some novel strategies developed to realize digital detection not only based on parti‐
tioning reagents.
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Certainly, the application of dNAD will be enlarged by combining with other molecular assays,
especially for single-cell analysis and single-cell genomic sequencing. For example, dNAD can
combine with proximity ligation or PEAs to achieve single-molecule protein biomarker
detection. Additionally, in the future, ongoing comparison tests of dNAD and qPCR will
roundly prove the detection superiority of dNAD in many research fields. Also, dNAD will
become the promising POCT-oriented research area for the ambitious plan of precision
medicine.
Conclusively, dNAD based on microfluidic LOC devices will continue to provide further
opportunities for determining NA molecules, protein molecules, and other biomolecules
towards deep analysis with high sensitivity and precision.
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Abstract
In this chapter, a novel microfluidic device (MagneChip) is described which comprises
microliter  volume reaction chambers filled with magnetically fixed enzyme-coated
magnetic nanoparticles (ecMNPs) and with an in-line UV detector. In the experiments,
MNPs with  phenylalanine  ammonia-lyase  (PAL)—an enzyme which  catalyzes  the
deamination of l-phenylalanine (Phe) to (E)-cinnamate in many organisms—immobi‐
lized on the surface were applied as biocatalyst  to study the characteristics of  the
MagneChip device. In the reaction chambers of this microfluidic device, the accurate in
situ quantization of the entrapped MNPs was possible using a resonant coil magneto‐
meter integrated below the chambers. Computational fluid dynamics (CFD) calcula‐
tions were used to simulate the flow field in the chambers.  The enzyme-catalyzed
biotransformations could be performed in the chip with excellent reproducibility and of
repeatability. The platform enabled fully automatic multiparameter measurements with
a single biocatalyst loading of about 1 mg PAL-ecMNP in the chip. A study on the effect
of particle size and arrangement on the catalytic activity revealed that the mass of ecMNPs
fixed in the chamber is independent of the particle diameter. Decreasing the particle size
resulted in increasing catalytic activity due to the increased area to volume ratio. A binary
mixture of particles with two different particle sizes could increase the entrapped particle
mass and further the catalytic activity compared to the best uniform packing. The platform
enabled a study of biotransformation of L-phenylalanine and five unnatural substrates
by consecutive reactions using same PAL-ecMNP loading. With the aid of the platform,
we first demonstrated that PAL can catalyze the ammonia elimination from the noncyclic
propargylglycine as substrate.
Keywords: Magnetic nanoparticles, Magnetic chip reactor, Microfluidic reactor,
Enzyme reaction, Phenylalanine ammonia-lyase
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1. Introduction
Microreactors are usually defined as miniaturized reaction systems fabricated using methods
of microtechnology and precision engineering. The term “microreactor” is the proposed name
for a wide range of devices, having typically submillimeter channel dimensions which can be
further divided into submicron sized components, for example, microparticle and nanoparti‐
cle carriers [1].
Before evolution of microreactor technology, the traditional way to conduct solution phase
synthesis and analysis was the batch mode in stationary reactors with stirring or shaking to
mix the reactants. Nowadays, microstructured devices offer greatly enhanced performance
compared with conventional batch systems due to effects arising from the microscale domain:
• Batch processes are space-resolved; therefore, the process must be readjusted in each
demand for larger product quantities. In contrast, flow microreactor processes are time-
resolved; therefore, the output of the reaction is determined by the flow rate and the
operation time, and no further optimization is needed. This also leads to accelerated process
development and enhanced safety due to smaller reactor volumes [2].
• Microreactors with high surface-to-volume ratio (SVR) are able to absorb the heat evolv‐
ing in an exothermic reaction more efficiently than any batch reactor. Therefore, the
temperature distribution inside the microreactor is homogenous in the whole volume. In
contrast, small SVR usually leads to uneven temperature distribution in large-scale batch
reactors, decreasing the product yield [2].
• Mixing quality is crucial for many reactions, where the molar ratio between the reactants
needs to be controlled precisely. Short diffusion paths provide efficient mixing in micro‐
reactors, which overrides the achievable mixing efficiency of batch reactors [2].
• In biocatalytic applications, the efficiency of the microreactor can be further improved by
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ity of the biocatalyst makes the process economical and more environmentally friendly.
• To perform similar analyses in shorter timescale even in parallel is an anticipated objec‐
tive for screening and routine use in protein and enzyme research [3]. A desirable goal is
the high throughput screening of enzymes and their substrates and inhibitors. The pro‐
spective fields of application of microreactors are quite wide and include biotechnology, as
well as combinatorial chemistry and enzyme-targeted drug discovery [4].
• Analytical systems which comprise microreactors are characterized by outstanding
repeatability and reproducibility, due to replacing iterative steps in batch and discrete
sample treatment by flow injection systems [4]. Benefitting from system automation, this
also eliminates errors associated with manual protocols.
• Small reagent volume is also a benefit of microreactors enabling economical and efficient
screening of novel reaction paths and substrates.
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• Microreactors have a high potential in industry, as developments by microreactors can be
faster transferred into production at lower costs than batch processes.
Despite of the rapid development of enzymatic microreactors in the recent decade, impor‐
tant design questions still need to be answered.
Reaction kinetics is a key parameter of device design. Widely used kinetic parameters are
deduced from the Michaelis–Menten model, which is valid only in batch reactions. In flow
systems, the flow effects should be also considered. Immobilization of the enzymes causes
further complication in modeling. Immobilization may affect the intrinsic kinetic parameters
and may influence the availability of the enzyme. The kinetic model should also consider that
the liquid phase containing the substrate and product is moving compared to the solid phase
containing the immobilized enzyme.
When supported catalyst-filled microreactors are used, reproducible filling of the supported
catalyst into the reactor space is not always straightforward. Even more challenging is the
quantification of the actual load of the carriers.
Long-term stability of the reactor and the reproducibility of the measurements may be affected
—among other factors—by the flow rate, the substrate concentration, and the morphology of
the immobilized biocatalyst.
This chapter presents results carried out by a microfluidic microreactor system, the so called
MagneChip platform including four serial reaction chambers with individually removable
permanent magnets. The results were achieved by experiments using phenylalanine ammo‐
nia-lyase (PAL) from Petroselinum crispum immobilized on the surface of magnetic nanoparti‐
cles (MNPs) and filled into one or more chamber of the MagneChip.
Biotransformations with PAL under different conditions were performed mostly using the
natural substrate L-phenylalanine to study
• the reproducibility of biotransformation in the microreactor system,
• the effects of the long-term use and cyclic reuse of the biocatalyst on the biocatalytic activity,
• the effects of the particle size on the biocatalytic activity,
• the optimal substrate concentration and flow rate of the in-chip biotransformation,
• the effect of immobilization and the use of flow microreactor on the kinetic constants, and
• the biotransformations of further substrates with PAL.
2. Background
2.1. Microreactors
Analytical systems which comprise microreactors are characterized by outstanding repeata‐
bility and reproducibility, due to replacing batch iterative steps and discrete sample treat‐
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ment by flow injection systems [4]. The possibility of performing similar analyses in parallel
is an attractive feature for screening and routine use [3]. Microreactors have been integrated
into automated analytical systems, as well as providing benefits from system automation, and
this also eliminates errors associated with manual protocols [4].
Applications of microreactors can be divided into three classes [4]:
• Organic synthesis, when a target molecule is formed from components in flow
• Analytical use of biocatalysts to transform an analyte difficult to measure to an easy to
measure form
• Screening of substrates and enzymes examines their kinetic characteristics
Microreactor systems can be further divided into classes based on the physical localization of
the catalyst:
Laminar flow reactors: The majority of the commercial flow synthesis systems utilize laminar
flow with soluble components and enzymes [5]. Losing the catalyst is a major drawback of this
technique.
Figure 1. Lab-on-a-chip microreactors: (a) a monolith silica reactor [8], (b) a packed bed silica reactor [9], and (c) a
packed bed MNP reactor [10]. Stability of immobilized enzymes: (d) after reuse of asparaginase in 10 cycles, 10 min
each [7] and (e) during long-term operation of immobilized GOD [8].
Filled reactors: Microreactors utilizing immobilized catalysts (e.g., enzymes) have many
advantages over the traditional flow reactors. First of all, the catalyst (enzyme) can be recycled
after usage; therefore, the process is more economical and environmental friendly. The
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reactions are highly reproducible as the catalyst (enzyme) concentration is fixed in the system.
Immobilization of enzymes often causes decrement in biocatalytic activity and choosing the
appropriate immobilization technique is challenging [6]. It was reported that immobilized
asparaginase retained 95.7% of its activity after 10 cycles of use [7] (Figure 1d), while immo‐
bilized glucose oxidase enzyme (GOD) retained 97% of its original activity after cyclic
regeneration and reuse [8]. Immobilization often extends the long-term stability and temper‐
ature resistance of the enzymes, and in several cases, even the catalytic activity is increased
compared with the soluble form. Immobilized asparaginase retained the 72.6% of its original
activity for 10 weeks [7], and immobilized GOD retained the 95% of its activity [8] (Figure 1e)
for 30 days.
The reactors filled with immobilized (bio)catalyst can be further divided into two groups
according to the type of the supporting material of the (bio)catalyst:
• Monolith reactors: The reactor is defined as monolith reactor where the supporting materi‐
al is fixed in the reactor volume, and the (bio)catalyst is nonremovable; therefore, the chip
is single use. Nanostructured materials are used to further increase the SVR. Examples
include silica monolith reactors [8] (Figure 1a) or most recently reactors incorporating
nanofibrous material made by electrospinning [11].
• Packed bed reactors: The reactor is defined as packed bed reactor where the supporting
materials are beads, even on microscale or nanoscale. The (bio)catalyst is immobilized onto
their surfaces. Nanotechnology enables functional modifications of the beads, for example,
making them magnetic. The reactor can be loaded with the suspension of the beads
(Figure 1b) and viscous [9] or magnetic [12, 13] forces are utilized to keep the particles fixed
in the reaction chamber.
Kinetic studies could be carried out with ease in microreactors by changing the attributes of
the reaction, for example, the inflow substrate concentration. Because the most often used
Michaelis–Menten model cannot be applied to flow reactors; in several cases [9, 14], the Lilly–
Hornby model [15] was applied. Dependency of the kinetic parameters on the flow rate—and
occasionally on further other parameters—was reported in many cases implying the limita‐
tions of the Michaelis–Menten model [8, 9, 14, 16].
In every on-chip study, Km and kcat as kinetic parameters were determined using various ways
of product quantification such as capillary electrophoresis (CE) [7], amperometry [8], and
fluorescent imaging [9, 16].
References Enzyme Method Reusability Stability Particle [E] measurement
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References Enzyme Method Reusability Stability Particle [E] measurement
He et al. [8] GOD Michaelis–
Menten,
EH plot







Kerby et al. [14] Alkaline
phosphatase







Slovakova et al. [16] Trypsin Michaelis–
Menten,
LB plot
80% N/A MNP Approximated
Km, kcat 600 nm




Table 1. Lab-on-a-chip microreactors with immobilized enzymes.
2.2. Magnetic nanoparticles in microreactors
The importance of MNPs as potential carriers of biomolecules is growing rapidly in biotech‐
nology and biomedicine. In LoC systems, nanosized magnetic particles provide quasi-
homogeneous systems, high dispersion, high reactivity, low diffusion limits, and possibility
of magnetic separation. The MNPs are usually collected in microsized reaction chambers. The
collection and separation from the fluid stream are accomplished by external magnetic field.
Such microreactors were found to be highly effective in biodetection [24], biocatalytic [17], and
bioanalytical [18] applications (Table 1).
Magnetite nanoparticles exhibit superparamagnetic or soft ferromagnetic behavior with high
saturation magnetization resulting in high permeability values [19]. To date, magnetic
manipulation of magnetic beads utilizing a magnetic bead separator array seems to be one of
the most promising technique of precise handling of biocatalysts in chip. Do et al. [12]
developed a microfluidic platform, where the magnetic field was concentrated between
permalloy patterns (50 × 100) to produce a high magnetic field gradient over the edges of them,
thus being able to trap the magnetic beads. Li et al. [13] used external hard magnet to develop
a concentrated magnetic field perpendicular to the channel at a certain position of the chip.
The particles accumulated at the designated place. Slovakova et al. [16] used a pair of hard
neodymium magnets positioned in a given angle to develop a magnetic field parallel to the
channel structure. It was reported that in this case, the particles are arranged parallel with the
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channel axis, and also, the reaction efficiency was reasonably higher than in orthogonal
configurations. Lien et al. [10] used an integrated electromagnet with active cooling for the
entrapment of the magnetic particles in the reaction chamber (Figure 1c).
Because of the widespread applications of MNPs in biotechnology, biomedical, and material
science, more and more synthesis techniques have been developed to obtain different kinds
of MNPs. Exhaustive discussions on the available synthesis techniques (e.g., coprecipitation,
microemulsion, thermal decomposition, solvothermal, sonochemical, microwave assisted,
chemical vapor deposition, combustion synthesis) can be found in several reviews [20, 21]. The
synthetic methods will determine the shape, the size distribution, size, the surface chemistry
of the particles, and consequently their magnetic properties. Various optimization methods
could be used to obtain proper MNPs suitable for the desired research and commercial
applications [21].
In our study, the surface of MNPs was chemically modified by sol–gel method, which resulted
in the formation of a core–shell silica-MNP carrier. Then, the surface was functionalized by
epoxy groups, which were able to form stable, covalent binding with the amino, thiol, or
hydroxide groups of the enzyme. The immobilization of PcPAL was carried out in liquid phase.
For a detailed description, see [18]. After immobilization, negligible protein contents in the
supernatants of the washing procedure were determined by the Bradford assay method [22].
The resulted enzyme-coated magnetic nanoparticles (ecMNPs) were used in two size varia‐
tions, with 250 and 600 nm diameters. Where otherwise not indicated the nominal ecMNP
diameter is 250 nm.
3. The MagneChip platform: construction and operation
MagneChip is a microfluidic platform centered on a chip consisting of several reaction
chambers enabling accumulation (and release) of MNPs. This magnetic microreactor chip can
utilize the benefit of excellent separation ability of MNPs in magnetic field. In various
applications, the MNPs covered by biologically active molecules (e.g., bioreceptors) are
immobilized on their surfaces may be used. Magnetic techniques enable anchoring the
particles inside certain compartment of microreactors, where the accumulated magnetic
particles can form a dense layer. After filling (in a consecutive step), reagents can flow through
the chip, while bioreaction occurs inside the microchambers and the resulted product flows
through the chip. The outflow can be collected and/or quantified outside the chip, for instance
by absorbance method. Because the enzyme to be immobilized on the MNP surfaces can be
chosen freely, a wide variety of applications are possible (Figure 2). Taking the advantage of
the continuous-flow operation, product formation can be monitored for a long time under
various conditions over the same anchored ecMNP layer. MagneChip can be reinitialized
periodically which enables multiparameter experiments, and therefore, reaction kinetics can
be characterized in a fully automated way. Because the flow control system of the platform
allows changing the actual substrate over the ecMNP layer, reactions can be screened even
with unexplored substrates (Scheme 1). This feature renders MagneChip as a tool for substrate
discovery as well.
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Figure 2. Possible applications of MagneChip platform. Reaction chambers are filled with bio-functionalized magnetic
nanoparticles, product formation is measured by in-line UV detector.
Scheme 1. Ammonia elimination from different amino acids (1a-f) catalyzed by PcPAL immobilized onto MNPs with‐
in the MagneChip.
Lab-on-a-Chip Fabrication and Application164
Figure 2. Possible applications of MagneChip platform. Reaction chambers are filled with bio-functionalized magnetic
nanoparticles, product formation is measured by in-line UV detector.
Scheme 1. Ammonia elimination from different amino acids (1a-f) catalyzed by PcPAL immobilized onto MNPs with‐
in the MagneChip.
Lab-on-a-Chip Fabrication and Application164
3.1. Basic aims and principles
A microfluidic test bench was developed for carrying out microreactor experiments with
MagneChip (Figure 3). The test bench consisted of two syringe pumps for dispensing reagents,
a thermostable chip holder and a zoom microscope for the optical inspection of the chip. The
chip holder had four magnet drawers enabling to push permanent magnets under reaction
chambers of the chip and also pull them out as the magnetic field is no longer required.
Figure 3. Schematic diagram of the fluid control system of MagneChip platform [22].
MagneChip reaction chambers (volume of ~1 μl) were designed to accomplish the following
requirements:
• Because (bio)chemical reaction occurred inside the reaction chambers operating under
continuous-flow conditions, a relative homogenous flow velocity distribution was re‐
quired. This condition could be fulfilled because laminar flow was developed in the
chamber.
• MNPs were accumulated in the chambers, and their drifting was prevented by an exter‐
nal magnetic field. The critical flow rate and the amount of accumulated ecMNPs could be
increased using prolated channels providing sufficient amount of (bio)catalysts to reach
reasonable conversion of the desired reaction.
• A resonant coil magnetometer was installed under the reaction chambers. Using the
magnetometer, the accumulated amount of ecMNPs could be measured with high accuracy.
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A four reaction chamber MagneChip layout is presented in Figure 4a. CFD simulations
revealed that the flow velocity distribution inside of the chambers varied in a scale of two
(Figure 4b). Depending on the typical flow rates used in MagneChip, reaction residence time
in the chambers may vary from 1 to 10 s (Figure 4c).
Figure 4. (a) Layout of the four chamber MagneChip; (b) flow velocity distribution inside the reaction chambers (units
are in mm s−1); (c) residence time vs. flow rate in MagneChip reaction chambers.
3.2. Construction method of MagneChip
Figure 4a depicts the arrangement of a four-chamber chip used for testing the enzymatic
reactions.
The chip was constructed by PDMS molding technology. SU-8 photoresist structures were
prepared as a molding master, resulting in a channel height of 110 μm. PDMS was poured on
the master and was kept on room temperature for 1 day. After cross-linking, the PDMS replica
was released and the PDMS channel bodies were bonded to standard microscope glasses after
oxygen plasma treatment. Some of the chips were equipped with a resonant coil magnetome‐
ter placed under the chambers for MNP quantity measurement [23]. The coil was embedded
in an intermediate PDMS layer. For further construction details, see [23].
3.3. Method of MNP quantification in the reaction chambers
The magnetic behavior of MNPs initiated the development of an inductive method to quantify
the nanoparticles. The measurement is based on the resonance frequency shift of a passive
electrical resonant circuit, where a flat inductor coil integrated in a silicone elastomer film acts
as a sensor. From the suspension of MNPs flowing into the chip, MNPs were anchored within
the reaction chambers by external permanent magnets. The ecMNP amount inside the chamber
affected the inductance; therefore, the resonance frequency was changed. The method also
enabled on-line monitoring of the actual ecMNP quantity in the chamber. This test arrange‐
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ment enabled to study the effect of particle size and arrangement on the chamber filling MNP
mass and also on the catalytic activity of the PAL bound to the ecMNPs [23].
3.4. Operation methods of MagneChip
3.4.1. Fluid handling steps
The experiments in MagneChip (Figure 3) involved four steps: (1) filling up the chip with
MNPs, (2) absorbance calibration, (3) experiment cycles, and (4) chip cleaning.
Chip filling. In the chip-filling step, an MNP suspension was driven through the chip by
applying a slight air pressure (0.2–0.3 bar) to the vial containing the MNP suspension and
connected to the inlet of MagneChip via a PTFE tube (Figure 3) at 25°C. During the filling
process, the MNPs were accumulated in the reaction chambers due to the permanent mag‐
nets placed in moveable drawers enabling “on/off” switching of the magnetic field. Once the
chamber most distant from the inlet (Figure 3, Chamber 4) was saturated, the permanent magnet
of the chamber at preceding position was turned on (Figure 3, Chamber 3). The same proce‐
dure was repeated (Figure 3: Chambers 2 and 1) until all chambers were filled up. Each chamber
of the MagneChip device could capture ca. 250 μg of ecMNP biocatalyst [23].
Calibration and experiment cycles: During the forthcoming steps, the valve at the inlet of the
MagneChip (Figure 3) was switched to the substrate (reagent) circuit. The flow controller
performed the dosage of the substrate and other chemicals as dictated by the programmed
sequence.
Chip cleaning: At the final, chip-cleaning step, the magnetic drawers of the MagneChip
(Figure 3) were drown out and a washing solution was driven through the chip to remove
ecMNPs.
The individual steps in a series of experiments, called experiment cycle (Figure 3, Experiment
cycles), involved a Reaction step and a Re-initialization step. A series of experiments could consist
of several experiment cycles depending on the number of parameters to be changed.
Reaction step. In a Reaction step, a substrate-containing solution was flowing through the chip
at a constant flow rate, and the specific absorbance of the product was continuously moni‐
tored in the outflow of the chip.
Re-initialization step. In the Re-initialization step, the feed of the substrate-containing solution
was stopped, and the chip was flushed with a washing buffer, while the magnetic particles
were retained by the permanent magnets.
3.4.2. Reaction step variants
The substrate feed (with continuous monitoring of the absorbance in the outflow at a previ‐
ously selected wavelength) was accomplished according to one of the following variants. The
cycle ended when the predesigned step time had been passed or when the reaction reached
saturation.
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• Repeatibility test. The feed of the substrate started (1st cycle) or continued at unchanged flow
rate.
• Flow rate test. The feed of the substrate started (1st cycle) or continued, while the flow rate
changed cycle by cycle.
• Substrate concentration test. The substrate-containing solution and the washing buffer were
feed in parallel at a predesigned ratio resulted in a predefined dilution of the substrate at
the chip inlet. The dilution ratio could be different cycle by cycle.
• Substrate screening. The actual substrate was loaded into the substrate syringe through a
bypass valve from the actual container of the substrate stock (A-F, in Figure 3), and the feed
of the substrate began at a predefined flow rate. To change to the next substrate, a Re-
initialization step was performed, followed by loading the next substrate into the substrate
syringe from the substrate stock (A-F).
3.5. Quality assessment of the operations in MagneChip
A series of subsequent measurements performed by the system were considered as reliable if
all the following conditions were met [22]:
• independent measurements were reproducible using the same type of ecMNP biocatalyst,
• the product of the enzyme reaction could be measured selectively in the UV–Vis range,
• product and substrate could be completely removed through the washing steps,
• the enzymatic activity of the ecMNP biocatalyst remained unchanged during the measure‐
ment
• and last but not least, the ecMNP layer in the magnetic reactors remained unharmed during
the measurement cycles.
In order to test the fulfillment of the first group of conditions, a control measurement was
performed after each series of experiments; that is, the first step of the sequence was repeat‐
ed in the last step under the same conditions, and the specific activity of the immobilized
biocatalyst (UB) at saturation concentrations of L-phenylalanine (L-1a in Scheme 1) in the first
and last cycles was compared.
3.5.1. Reproducibility of the individual measurements
Reproducibility of the chip-filling process: The first single chamber of the MagneChip was filled
with MNP suspension. Biotransformation of L-1a to 2a (Scheme 1) was performed in flow-
through mode and monitored by in-line UV–Vis. After reaching the stationary state (i.e.,
constant level of product formation), the magnet of the chamber was released and the ecMNPs
were captured in the next chamber. The experiments performed in three consecutive cham‐
bers were repeated three times resulting in UB = 8.01 ± 0.14 μmol g−1 min−1 [22].
The filling–refilling results indicated that neither that the homogeneity of the MNP suspen‐
sion nor the filling procedure of the chambers had remarkable effect on the reproducibility of
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the measurements. The significant difference between the UB values of MNP biocatalyst in
shake vials and in MagneChip indicated increased effectivity of the biocatalysts in MagneChip
device [22].
Reproducibility of independent measurements: Biotransformation of L-phenylalanine (L-1a) to (E)-
cinnamic acid (2a) by MNP biocatalyst suspension (Scheme 1) was performed in shake vial as
three parallel reactions and resulted in UB = 2.91 ± 0.08 μmol g−1 min−1 ensuring that the
homogeneity of the MNP suspension was sufficient [22].
3.5.2. Optical inspection of the reaction chambers
During the experiments, the chip was optically inspected by a zooming microscope and a
monochrome hi-speed smart camera. Before evaluating the measurement sequence, the plan
view of the chip was stored as a reference (∏ref). At the end of the step i of the measurement
sequence, the plan view of the chip was sampled again (∏seq,i) and it was compared to the
reference as follows [22]:
Figure 5. MagneChip device with four MNP-filled and external magnet-equipped microchambers (top left) and SEM
image of the MNP layer (top right). The effect of air bubble passage through the reaction chamber [(a)–(f)]: (a) photo‐
graph, before passage; (b) difference image (difference score SC = 5073), after passage; (c) calculated flow velocity field
before and (d) after the passage; (e) velocity profile in the middle cross section of the chamber before and (f) after the
passage [22].
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where (j,k) are the pixel coordinates of the plan view image; therefore, the changes in accord‐
ance to the reference image are indicated by white pixels. The total number of white pixels is
defined as chamber difference score (SC) used as a marker for describing the changes of the MNP
layer arrangement. Therefore, the changes compared with the image of the first cycle
(reference) were indicated by white areas during the consecutive cycles of the measurement.
In practice, SC values under 2000 reflected to negligible changes. However, SC > 3000 indicated
serious structural change of the ecMNP layer, for instance, the complete breakthrough of a
bubble (Figure 5b) [22]. Air bubbles usually did not split at the channel entrance, rather passed
at one side along the chamber wall. Numerical simulations revealed (Figure 5c–f) that the
velocity profile became asymmetric due to the bubble passage and the overall mass flow rate
through the porous MNP layer significantly decreased (28.6–20.7 μL min−1, roughly 72% of its
original value), while the remaining fluid passed through the developed tunnel. The passing
bubble could drift away particles which decreased the total mass of the biocatalyst in the
reaction chamber. Therefore, the biocatalytic activity of the damaged chamber decreased and
the consequent measurements were no longer reliable.
Reliability assessment of the measurements was based mostly on the following parameters:
1. Chamber difference score (SC)—Over SC > 4000 (average), the measurement was declined.
2. Control measurement—Over 5% of error, the measurement was declined.
Each of the experiments carried out by the platform was justified based on the above criterion.
3.5.3. Reproducibility of cyclic reactions
Figure 6. Time plot of the periodic absorbance change during the cyclic measurement (attempt 1, stable layer). The
chip is re-initialized between the reaction steps (reaching zero absorbance) by washing out substrate and product com‐
pletely [22]. The last measurement served as a control.
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A crucial feature is the reproducibility of cyclic reactions performed by the system. To check
the reproducibility of the test reactions, the MagneChip was filled with MNP biocatalyst, and
biotransformation of L-1a to 2a was performed in seven consecutive cycles, while the chip was
re-initialized during the steps by washing out the substrate and product completely [22]. The
absorbance plot at 290 nm in Figure 6 with the aid of the previously measured extinction
coefficient of the product (2a) indicated the concentration changes of 2a.
The product quantity in cycle by cycle—calculated by taking the integral of the absorbance
plot—clearly indicated that the chip was successfully re-initialized in every cycle through‐
out the experiment, and the reaction was repeated reproducibly seven times (average product
quantity of P = 0.12 ± 1.5% μmol) [22]. The moderate mean value of the chamber difference
score SC = 1322 (1609 max) reflected negligible changes in the MNP layer.
4. The MagneChip platform: application examples
4.1. Characterization of the PAL reaction with L-phenylalanine (L-1a) in MagneChip
4.1.1. Influence of the substrate flow rate on the biotransformation
Figure 7. Dependence of the reaction rate of L-1a conversion to 2a on the flow rate in MagneChip filled by ecMNP.
Saturation was reached at 25 μL min−1 [22].
MagneChip was filled with ecMNP biocatalyst, and biotransformations of L-1a to 2a (Scheme 1)
at various flow rates were performed in seven consecutive cycles, while the chip was re-
initialized at the end of each cycle and a new substrate flow rate was set between 3.6 and 28.6
μL min−1. The first (reference) measurement was repeated in the last cycle as a control. The
negligible difference of specific biocatalytic activity (UB) between the reference and control
measurements (only 3%) and low SC score (SC < 338) indicated that the shear forces did not
caused irreversible changes on the biocatalytic activity even at high flow rate (up to 28.6 μL
min−1) [22].
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The reaction velocity was calculated for each cycles. By increasing the flow rate, the calculat‐
ed reaction velocity increased until reaching saturation at about 25 μL min−1 (Figure 7).
4.1.2. Calculation of kinetic parameters
MagneChip was filled with ecMNP biocatalyst, and biotransformations of L-1a to 2a (Scheme 1)
at various concentrations of L-1a (S0) were performed in 10 consecutive cycles, while the chip
was re-initialized at the end of each cycle and a new substrate concentration was set. It was
found that the reaction followed the first-order kinetics up to (S0) = 3 mM and saturated roughly
at (S0) = 20 mM [22].
The linear fitting method proposed by Lilly et al. [15] was applied for the calculation of the
kinetic constants of the biotransformation of L-1a to 2a in the MagneChip (Figure 8, bottom).
The values of the kinetic constants are summarized in Table 2 [22].
Figure 8. (a) Dependency of the substrate concentration on reaction velocity in MagneChip for the transformation of
L-1a to 2a by MNP biocatalyst. Saturation concentration was reached at 20 mM. (b) Linear fit based on the Lilly–Horn‐
by model [15] to determine Km (resulting in Km = 2.5 mM) [22].
Kinetic parameter MagneChip Shake vial
Km (mM) 2.5 9.1
kcat (s−1) 2.8 × 10−2 3.2 × 10−2
kcat/Km (s−1 M−1) 11.3 3.5
Tablee 2. Kinetic constants in biotransformation of L-1a to 2a with MNP in shake vial and in MagneChip [22]
It was found that the apparent Km value was reasonably smaller in MagneChip (2.5 mM) than
in shake vial (9.1 mM). Turnover number (kcat) and specificity constant (kcat/Km) were deter‐
mined also for both reaction modes. While in the shake vial, the turnover number was
somewhat higher (3.2·× 10−2 s−1) than the in chip (2.8·×·10−2 s−1), the specificity constant turned
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out to be significantly higher in chip (11.3 s−1 M−1) as compared with the shake vial (3.5 s−1 M−1).
This may be attributed to the smaller Km value in the MagneChip indicating significant
contribution of diffusion effects to the higher apparent Km value in shake vial.
4.2. Effect of particle size on the enzyme activity
The accumulated quantity of ecMNPs in the reaction chambers was determined by the
embedded resonant magnetometer of the MagneChip device [23]. The measurements revealed
that the total mass of the accumulated particles was approximately the same for two differ‐
ent particle sizes (m = 241.6 μg, ecMNP600, d = 600 nm and m = 248.3 μg, ecMNP250, d = 250 nm)
[23]. The total particle mass could be only increased using a binary mixture (m = 283.6 μg,
MNP250:600) of the particles. This experiment resulted in a significantly higher MNP mass (17%)
captured in the magnetic chamber as compared with the chamber capacity filled with MNPs
of uniform particle sizes [23].
MagneChip was filled with different sized MNP biocatalysts, and biotransformations of L-1a
to 2a (Scheme 1) were also performed [23]. Compared with the larger particles (ecMNP600), the
total surface area increased both in the ecMNP250 (2.5 times) and the mixture cases (2.06 times).
Note that differences in biocatalytic activity can be expected only due to changes of trans‐
port limitations as the enzyme to MNP mass ratio was kept to be constant of 15% in both cases.
Figure 9. Specific absorbance of cinnamic acid (2a) at 295 nm at the chip outlet using MNP600, MNP250, and 1:1 mixture
of the two kind of particles in the chip [25].
Results of the measurement using variously sized ecMNPs as biocatalysts are summarized in
Figure 9. In fact, the ecMNP600-filled chambers yielded the lowest final concentration of product
as indicated by the lowest specific absorbance (AU = 1.07, at 295 nm) at the chip outlet. Filling
the chip by ecMNP250 resulted in an increase of the measured absorbance by 46% (AU = 1.56,
at 295 nm). Because the chambers contained the same filling mass (m = 241.6 μg for ecMNP600
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and m = 248.3 μg for ecMNP250) and therefore the same enzyme amount, the difference between
the MNP250- and the MNP600-filled reactors can only be attributed to other factors, for exam‐
ple, to the differences in total surface area [23].
The major difference can also stem from the remarkably smaller average microchannel
diameters between the particles within the ecMNP250-filled chamber as compared to the
ecMNP600-filled one. This can result in shortened diffusion path and therefore better mass
transport [23]. An additional 40% increment was achieved using the 1:1 particle mixture, which
was obviously resulted as a synergy of the higher enzyme content (17%) due to the higher
chamber capacity and enhanced transport phenomena due to the small average microchan‐
nel diameter [25].
4.3. Testing multiple substrates in MagneChip
Substrate screening experiments were performed with a single ecMNP-loading in the chip
passing the solutions of the different substrates (Scheme 1: L-1a and rac-1b-f) through the same
chip according to a predefined sequence [22]. The intensive washing procedure between the
individual tests with various substrates ensured complete removal of any substrate or product
from the preceding cycle (reaction). In the first cycle, the ammonia elimination was meas‐
ured from L-1a (the natural substrate of PAL). This reaction was chosen as reference for
comparison to the other elimination reactions of PAL from the further substrates (rac-1b-f).
The difference between the initial and final (control) measurement with L-1a was found to be
only 1.5%, while the SC score remained below 2000. Surprisingly, in the MagneChip device,
higher biocatalytic activities (UB) were observed with four of the unnatural substrates
(rac-1b,c,e,f), than with the natural substrate L-phenylalanine L-1a (Figure 10).
Figure 10. Comparison of the specific biocatalytic activity of PcPAL immobilized on MNPs with substrates L-1a and
rac-1b-f in MagneChip system [(S) = 20 mM, flow rate: 48.6 μL min−1] [22]. *Control measurement.
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Noteworthy, all the four unnatural substrates (rac-1b,c,e,f) which were transformed by the
MNP biocatalyst with higher specific biocatalytic activity (UB) than that of L-phenylalanine
L-1a contained slightly more electron-withdrawing aromatic moieties than the phenyl group.
This difference from the productivity ranks observed with homogenous PcPAL so far may be
due to the reduced contribution of the reverse reaction (equilibrium effect) to the apparent
forward reaction rates in the continuous-flow system at high flow rates [22].
4.4. Characterization of an enzyme reaction with a novel substrate
By a reaction performed in the MagneChip device, it was first demonstrated that PAL can
catalyze the ammonia elimination from the acyclic DL-propargylglycine (PG) to yield (E)-
pent-2-ene-4-ynoate, indicating new opportunities to extend the MIO-enzyme toolbox toward
acyclic substrates. Deamination of PG, being acyclic, cannot involve a Friedel–Crafts-type
attack at an aromatic ring [18].
MagneChip, filled by PAL-ecMNPs, was used for the microscale biotransformation of DL-
propargylglycine in sodium carbonate-buffered D2O. The device enabled to detect the
formation of (E)-pent-2-en-4-ynoate at 242 nm and to produce measurable quantities of the
product for recording 1H-NMR spectra without any work-up. Besides the significant in‐
crease of the UV-signal at 242 nm (up to A = 1.2) in the in-line UV-cell (Figure 11), the
appearance of olefin hydrogen signals in the 1H-NMR spectrum of the reaction mixture [at δ
= 6.34 (d) and 6.85 (d) ppm] indicated unambiguously the formation of (E)-pent-2-en-4-ynoate.
On the other hand, emergence of the UV signal at 274 nm during the process indicated the
formation of further by-product(s) apart from (E)-pent-2-en-4-ynoate (Figure 11).
Figure 11. Ammonia elimination from DL-propargylglycine in MagneChip filled with PAL immobilized on MNPs and
equipped with in-line UV–Vis detector (reaction in D2O at pD 8.8, 37°C) [18]. The progress of the reaction was followed
by full UV-spectra.
5. Conclusion
Our results proved that the MagneChip microfluidic device is a reliable, reproducible, and
efficient tool which was capable of fast, reliable, and fully automated screening and kinetic
characterization of PcPAL substrates using minimal solvent (~500 μl) and biocatalyst (~1 mg
MNP) amounts for a test compound. Compared with shake vial, the volumetric productivity
of the MNP biocatalyst in the chip exceeded the one of the shake vial by more than three orders
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of magnitude. The platform was also capable of studying enzymatic reactions with undiscov‐
ered substrates of PcPAL. The above results suggest that the MagneChip platform would be
successfully utilized as a novel and flexible tool for enzyme-catalyzed biotransformations.
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Abstract
Biosensing technology is an advancing field that benefits from the properties of biological
processes  combined to  functional  materials.  Recently,  biosensors  have emerged as
essential tools in biomedical applications, offering advantages over conventional clinical
techniques for diagnosis and therapy. Optical biosensors provide fast, selective, direct,
and cost-effective analyses allowing label-free and real-time tests. They have also shown
exceptional potential for integration in lab-on-a-chip (LOC) devices. The major chal‐
lenge in the biosensor field is to achieve a fully operative LOC platform that can be used
in any place at any time. The choice of an appropriate strategy to immobilize the biological
element on the sensor surface becomes the key factor to obtain an applicable analytical
tool. In this chapter, after a brief description of the main biofunctionalization proce‐
dures on silicon devices, two silicon-based chips that present an (i) IgG antibody or (ii)
an Id-peptide as molecular probe, directed against the B-cell receptor of lymphoma cancer
cells, will be presented. From a comparison in detecting cells, the Id-peptide device was
able to detect lymphoma cells also at low cell concentrations (8.5 × 10−3 cells/μm2) and in
the presence of a large amount of non-specific cells. This recognition strategy could
represent a proof-of-concept for an innovative tool for the targeting of patient-specific
neoplastic B cells during the minimal residual disease; in addition, it represents an
encouraging starting point for the construction of a lab-on-a-chip system for the specific
recognition of neoplastic cells in biological fluids enabling the follow-up of the changes
of cancer cells number in patients, highly demanded for therapy monitoring applications.
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1. Introduction
Biosensing is a scientific and technological hot topic, given its potential in the field of medical
diagnosis [1], healthcare [2], environment [3], defense [4], and food security [5].
Nowadays, the healthcare and pharmaceutical sectors continuously demand more powerful
analytical and diagnostic tools for the identification of disease, the development of new
medicines, and better diagnostic tests. In these fields, the specific and sensitive detection of
targets in short-time analyses plays a key role. While a number of commercial bioassay kits
are already on the market, there still remains a major challenge to develop novel biodetec‐
tion methods to meet the ever-increasing request. High-capability optical biosensing sys‐
tems are actually emerging as a way to reach this aim [6].
Optical biosensing is a powerful analytical tool used to detect optical changes upon the
interaction between an analyte of interest and its ligand, previously immobilized on the
sensing device as biological probe; the intensity of obtained signal can be measured, and its
value is a function of the analyte concentration in the sample [7, 8]. Generally, optical
biosensors use two different detection protocols: direct detection of the analyte (label-free
detection) or indirect detection through optically labeled probes (label-based detection). In
label-based detection, fluorescent, enzymatic, or radioactive tags, linked on target or on probe
molecules, are used; the intensity of the signal indicates the presence of analyte and the
interaction with the recognition molecule. This type of detection is extremely sensitive, since
it is possible to detect up a single molecule [9, 10]; nevertheless, complex procedures are needed
for labeling, and they may interfere with the functionality of the target molecule. In contrast,
in label-free detection, target molecules are not labeled or altered and are free to interact in
their natural forms: Recent progresses in this field are showing promising results [10]. This
strategy is relatively easy and cheap to perform and allows for quantitative and kinetic
measurement of molecular interactions. These advantages, with low detection limit, non-
destructive approach, and with the ability to recognize a wide variety of analytes or multi‐
ple analytes at the same time with fast signal monitoring and analysis [11], make label-free
optical detection one of the leading recognition methods in the biosensor field.
Label-free biosensors are very versatile platforms, since they can be developed in different
materials, such as silicon or its compounds, glasses, metals, or polymers, and they offer
different detection modes and configurations that can be combined [12]. In perspective, optical
label-free biosensors are expected to replace fluorescent biosensors in DNA micro-arrays and
lab-on-a-chip (LOC) applications [13–15].
The use of silicon-based technology—the same developed for microelectronics—could allow
the integration of microfluidic circuits for analyte handling, sensing elements, and control/
reading electronics into a single chip. This could pave the way to the mass production of micro
total analysis systems and LOCs capable to provide rapid, sensitive, and multiplexed
measurements in any place at any time.
The selection of the biological element to immobilize on the sensor surface is dictated by the
application and must be chosen to be highly specific for the target molecule and stable enough
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to be immobilized without losing functionality. Several types of routes can be used to
biofunctionalize the sensor surface [16], and the choice of an appropriate immobilization
procedure has become a key factor in the biosensor area. An ideal immobilization procedure
should guarantee an efficient coverage by the molecular probes of the sensing layer without
interfering with their properties (structure, biological activity, affinity, specificity). In addi‐
tion, the possibility to preserve their stability in normal storage conditions and also for
regeneration could be useful in the case of integration in portable LOC. Despite enormous
research efforts have been made to find novel strategies according to the application, a
universally valid procedure has not yet been developed and the realization of cheap hand‐
held platforms is almost limited. For this reason, the choice of the most effective strategy of
immobilization represents the critical step that turns a sensing device into an applicable
analytical tool with the required quality standards. Currently, a lot of biomolecules can be used
as bioreceptors (antibodies, nucleic acid, peptides, enzymes, cell receptors, and many others).
Among these, artificial peptides provide an opportunity to develop the desired molecular
biosensor due to their desirable properties such as diversified structure, high affinity to
ligands, matured synthesis protocol, and modified approach [17].
2. Biosensing application in cancer
Cancer is one of the main causes of death worldwide. Early diagnosis is the key to enhance
the success of medical treatment. In the last few years, in parallel with a growing interest in
detecting cancer cells, a wide variety of techniques were developed for detection at the cellular
level [18–21]; nevertheless, most of these modalities are expensive and time-consuming, and
they are often associated to risks deriving from radioactive tracers.
At this point, despite some considerable achievements, the realization of simple, rapid, non-
destructive, and low cost methods for early detection of cancer and minimal residual disease,
important for diagnosis and reduction in mortality for certain cancers, still remains an
unfulfilled goal [22, 23]. To meet these specific requirements, biosensors have attracted
increasing attention since biosensing technology, taking advantage of the properties of
biological systems combined to functional advanced materials, is providing rapid, reprodu‐
cible, and highly sensitive cell detection.
Among the various types of cancer, lymphoma is the most common blood cancer, which
incidence is recently increasing. This malignancy is a clonal expansion of neoplastic cells that
may result in fatal outcomes [24]. Despite the great progress that has been made over the last
several decades in the treatment of lymphoma, the prognosis for patients with particular sub-
types of disease remains quite poor. Lymphomas are a heterogeneous group of tumors arising
in the reticuloendothelial and lymphatic systems. The major types are Hodgkin lymphoma
and non-Hodgkin lymphoma. Great progresses in the use of monoclonal antibodies, chemo‐
therapy, radioimmunotherapy, and peripheral blood stem cell transplants have achieved
significant responses in the treatment of these diseases and also markedly improved the
outcome of the cure among elected sub-populations of patients, since not all the patients or
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subtypes of lymphoma are responsive to these “conventional” approaches. For example,
tumorigenic B-cell lymphomas are sensitive to anticancer treatments, including convention‐
al chemotherapy, radiation therapy, and corticosteroids [25]. Nevertheless, the disease is
associated with incomplete response to clinical treatments that result in a minimal residual
disease in which a few neoplastic cells undetected in vivo replenish the cancer cell reservoir.
This grim scenario calls for novel strategies to detect tumorigenic B cells. Random peptide
libraries (RPLs) allow the selection of therapeutic peptides for tumor cell-surface receptors.
Idiotypic determinants of the Ig-BCR, expressed by lymphoma cells, function as a specific
tumor antigen that may be exploited for cell-specific detection or targeted therapy. Here, we
present the complex different strategies that we adopted in order to construct a biosensor for
the detection of tumorigenic lymphoma B cells and discuss all the difficulties that we encoun‐
tered and the approaches we adopted for their overcoming.
3. The choice of appropriate support for biosensing
Our vision was to create a highly sensitive, label-free optical biosensing system for the targeting
of patient-specific neoplastic B cells during the minimal residual disease. The material used to
develop this unique tool for biosensing include mainly silicon, since it possesses great potential
because of its many unique properties, including biocompatibility, which is an important
precondition for biological and biomedical applications, abundance, tailorable surface
chemistry, and unique electronic, optical, photonic, and mechanical properties, among others.
In addition, high surface-to-volume ratio of silicon derivatives offers exciting opportunities to
design high-performance silicon-based functional devices for biomedical applications.
Moreover, silicon is very abundant on earth allowing inexpensive resources for large-scale and
low-cost preparation for practical applications. Taking advantage of these attractive features,
the interest in the use of silicon is widely grown leading to its applications not only in biology
but also in a lot of other fields [26].
In our research activity, flat silicon devices of fixed thickness (400 μm) were obtained from
highly doped p+ type, 0.003 Ω cm resistivity, (100)-oriented silicon wafers, cut into 10 × 10 mm
square pieces. The wafers were cleaned by a standard RCA process [27] and thermally oxidized
at 1050°C for 5 h. An electrochemical etching process of planar silicon was used to pattern
porous silicon with a high specific surface (up to 500 m2/cm3). An advantage in the use of porous
silicon is that its morphology can be tuned by modification of process parameters [28] so that
the resulting structures can be adapted to obtain the best performance for chemical and
biological processes that happen on their surface. Moreover, the porosity of the material
coupled to the low-cost production makes porous silicon an ideal bulky model system to follow
each functionalization step: The concentration of reagents and molecules in the pores allow to
quantify few nanometers thick films of passivating agents, exploiting signal enhancements,
that cannot easily measured on flat supports.
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4. Chemical functionalization procedures
The selection of an appropriate procedure for the immobilization of a biological element on
the sensor surface that interacts with the desired target for the specific recognition of an analyte
has become a critical step in the biosensor area, and enormous efforts are continuously invested
in order to optimize novel strategies according to the application. The biofunctionalization of
chemical modified surfaces can be achieved in several manners that can be grouped in just two
approaches: (i) direct adsorption and (ii) physical adsorption [29–33]: in both cases, each
immobilization route presents advantages and drawbacks.
In the direct adsorption method, there is no bond formation between probe and device,
reagents are not required so either structure or functionality of biomolecules is not affected.
Nevertheless, the efficiency of this strategy is very low.
The bioreceptor physisorption is a quick and widely used approach to immobilize biomole‐
cules on chip surfaces based on electrostatic, hydrophobic, and covalent interactions. Despite
the efficiency and the simplicity, electrostatic, and hydrophobic approaches are direct fast
methods, since no linker molecules are needed, but are limited to situations that require no
directional orientation of the bioprobes. Moreover, both techniques request long incubation
times and the risk of folding and desorption due to changes of parameters, such as pH, ionic
strength, or temperature, cannot be excluded. The covalent attachment of probe is more
efficient in terms of stability and binding strength. Generally, the binding occurs between a
functional chemical group of the biomolecules, whose blocking does not affect the function‐
ality, and one on the modified surface. For proteins covalent coupling, amino, carboxylic, or
thiol groups are preferred, whereas in the case of nucleic acids, it is possible to take advant‐
age of the versatility of their synthesis to insert reactive groups at the end of the sequence.
More difficult is the immobilization of immunoglobulins in a correct orientation, which can
be achieved by controlled linkage of carbohydrates groups in the constant region or using
affinity proteins (such as A or G Protein) [31]. In all physical adsorption types, a chemical
modification of the platform surface is required to the extent that the material properties are
tuned to accomplish the best analytical characteristics.
The drawing up of an efficient and correct immobilization procedure is a crucial point to avoid
a wide variety of factors that may negatively affect the biosensor functionality. The orienta‐
tion of probe, the density of coating on the detection surface, pH, target concentration,
operating conditions, and chemical environment provided by transducer must be closely
explored. An efficient biofunctionalization process should take in account few important
observances: The preservation of the molecular probe structure to guarantee subsequent
binding of analyte; limited chemical steps and minimal consumption of reagents and sam‐
ples to make the whole procedure lean and easily reproducible; low optical adsorption at the
working wavelengths; homogeneously thin layer formation compatible with evanescent field
sensing; uniform surface coating; saturation of eventually free binding sites to reduce the
possibility of false-positive signals; biocompatible conditions; integrability with large-scale
fabrication. The exploration of these traits offers the possibility to improve biosensors features
increasing the power of detection.
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Figure 1. Types of silicon surface chemical modifications for biosensors: (a) organosilane-based, (b) phosphonate-
based, and (c) glutaraldehyde-based strategies.
Figure 1 represents the main functionalization approaches employed to construct integrated
optics (IO) biosensors. Before the biofunctionalization step, a previous chemical activation of
the sensor surface is always needed. To this aim, our group employed the self-assembly of
organofunctional alkoxysilanes (Figure 1a), an easy and versatile system for organic conju‐
gating [34]. However, silicon-based surfaces require a prior activation step to oxidize the
surface and to expose the silanol groups for cross-linking with the silane. The formation of a
thin silane self-assembled film allows applying a great number of chemical reactions.
Immediately before silanization, surfaces are cleaned with oxidant media to remove organic
pollutants and to increase the hydroxyl moieties on the surface [35]. The used oxidant is
piranha solution [36–39], consisting of a concentrated sulfuric acid mixed with hydrogen
peroxide at 3:1 ratio. This treatment is performed by heating for 30 min only. Hundreds of
different organosilanes with different structures and functionalities are nowadays commer‐
cially available, although the most commonly employed are those with short alkyl chain that
present an amino, thiol, epoxy, or carboxylic group at the terminus. Among this vast variety
of compounds, 3-aminopropyltriethoxysilane (APTES) was chosen for its reactivity to
aldehyde, carboxylic acid, and epoxy functionalities.
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The reaction between the oxidized surface and the organosilane is based on the condensa‐
tion between the Si–O–Si of the silane and the OH present on the device; generally, besides the
hydroxyl groups already present on the native silicon oxide layer, a thermal oxidation is a
common procedure to form a new efficient oxide film [40–42] in order to assure a plenty of
silanol groups for an efficient coverage of the organic layer.
Furthermore, after silanization, APTES layer was cured at high temperature [43]. The
aminosilane is more reactive, and it can be applied on a surface using pure organic solvent.
The advantage of the curing is that a more controlled deposition of the compound can be
obtained to create a thinner film of the aminopropyl groups on the chip. The self-assembled
monolayers generally present a thickness in the range of 1–3 nm and create a nanometer-scale
organic thin coat [44, 45].
5. Choice of biomolecular probe
At this point, a wide variety of biomolecules (antibodies, nucleic acid sequences, peptides,
enzymes, cell receptors) can be used as bioreceptors (Figure 2).
Figure 2. Types of bioconjugation methods on aminated surfaces: (a) N-hydroxysuccinimide–based, (b) succinic anhy‐
dride–based, (c) p-phenylenediisocyanate–based, and (d) glutaraldehyde-based strategies.
The choice of bioreceptor depends on the intended application of biosensor and it must meet
two important requirements: high specificity for the target molecule and high stability to retain
its biological activity when immobilized on the support.
A first biofunctionalization approach, based on the covalent bind of a biomolecule on the
activated silicon sensor surface, included the use of an IgG antibody as molecular probe
directed against B-cell receptor. The chip was treated with the homobifunctional cross-linker
glutaraldehyde (GA): This molecule, besides to be employed to form an aldehyde-terminat‐
ed surface, which allows the reaction of amine groups, by the formation of imines (Schiff bases),
acts as spacer in order to keep away from the surface the immobilized bioprobe that can react
freely with target molecules [46, 47]. By this strategy, the antibody has been immobilized on
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the surface via protein A in an oriented fashion [48]. The whole process is checked monitor‐
ing surface changes by ellipsometric measurements and FTIR spectromicroscopy. As report‐
ed in Table 1, using a random sampling of four different wells, it was observed for all of them
after each functionalization step the surface layer thickness.
Thickness (nm)
Film Sample 1 Sample 2 Sample 3 Sample 4
Oxide 75.8 ± 0.4 72.4 ± 0.2 75.0 ± 0.3 73.4 ± 0.2
Aptes + GA 3.0 ± 0.4 3.1 ± 0.3 3.1 ± 0.3 2.1 ± 0.2
Protein A 0.68 ± 0.09 0.67 ± 0.08 0.75 ± 0.1 0.85 ± 0.1
χ2 0.54 0.43 0.47 0.45
Table 1. Surface layer thickness on four random samples after each step of functionalization measured by ellipsometry
technique.
The analyses of the FT-IR spectra led to the identification of several characteristic vibration
bands that were coherent with the various functionalization steps. Table 2 reports a list of the
major bands identified together to peak assignment.
Predicted peak Frequency cm−1
Sample 1 Sample 2 Sample 3 Sample 4 Sample 5 Sample 6
Si–O str – 1127 – – – –
Si–O–C as str – – 1250 1250 1258 1258
–(CH2)–str – – 1295–1305 – – –
–O–CH2–str – – 1445–1475 – – –
Amide II – – – – – 1531
C=O str – – – – 1635 1642
Saturated primary ammine (–NH2 def) – – 1650 – – –
Amide I C=O str – – – – 1650–1680 1638–1687
C=O str – – – – 1685–1705 1774
N–H str – – – – – 3121
Primary ammine –NH2 str – – 3250–3677 – – –
Table 2. Major bands identified by FTIR spectromicroscopy and corresponding assigned peaks.
As experimental model, it was chosen a murine lymphoma cell line (A20) [49] that expresses
high levels of membrane IgG. The most interesting point of this first approach is that the
microfabricated biochip appears to be suitable to reveal specific bindings such as that between
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cell-surface proteins (receptor) and corresponding specific antibody. In addition, the num‐
ber of cells detected by the devices was 2.0 × 10−3 cells/μm2.
Anyway, since this detection limit does not seem satisfactory and the idea that the contact
probability between cells and antibodies on capture specific surface could be improved, we
took advantage of a new functionalization strategy exploiting an Id-peptide as biomolecular
probe. The choice of an Id-peptide was dictated by two main reasons: (i) Artificial peptides
provide an opportunity to develop the desired molecular biosensor due to their desirable
properties such as diversified structure and high affinity [50]. In addition, peptides with
specific sequences can provide high affinity to particular ligands and be obtained by screen‐
ing and optimization of artificial peptide libraries; (ii) the used idiotype peptide is a small
peptide ligand able to be recognized with high affinity and specificity from the B-cell recep‐
tors present on the lymphoma B cells [51–53]. The use of a small ligand as biorecognition
element endowed with great specificity could highly enhance affinity and selectivity of the
detection layer. In addition, it simplifies the functionalization procedure with respect to that
employed for antibodies in which controlling protein orientation is still very challenging [54].
The peptide was immobilized on the silicon surface following the functionalization strategy
schematized in Figure 3.
Figure 3. Functionalization approach utilized on silicon surface to conjugate an Id-peptide to detect lymphoma cells.
After each passivation step, the new synthesized layer is reported in the figure with the same color of the molecule
used in the chemical reaction (APTES is blue, BS3 is red, Id-peptide is green).
This chemical procedure was developed on both crystalline flat and porous silicon samples;
the nanostructured porous was chosen because its peculiar morphology allows the immobi‐
lization of a greater number of molecules with respect to a planar substrate and a number of
functionalization investigation methods could be more easily exploited [55]. The aminosilan‐
ized surface has been activated by the homobifunctional cross-linkers bis[sulfosuccinimidyl]
suberate (BS3), which, acting as spacer, provide succinimidyl-activated carboxyl group that
could react with amine-ended peptide to form an amide bond. Changes in chemical compo‐
sition of PSi surface were monitored by FTIR spectroscopy after each functionalization step
until BS3 (Figure 4).
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Figure 4. FTIR spectra of silicon surface after each chemical modification step.
The analysis of the FTIR spectra in the range from 2500 to 500 cm−1 highlighted characteristic
peaks of each molecule used in the different passivation steps, demonstrating the effective‐
ness of the functionalization procedure. Indeed, the characteristic peaks of Si–Hx bonds
corresponding to the PSi after electrochemical etching (2100 and 680–630 cm−1) are no longer
visible when the devices were thermally oxidized, whereas the appearance of the Si–O–Si
characteristic band at 1100 cm−1 was detected.
The formation of the silane film was confirmed by the presence of peaks in the span 1440–1390
cm−1, relative to CH3 from APTES ethoxy moieties, and at 1655 cm−1 relative to an imine group
from oxidation of an amine bicarbonate salt [56]. Moreover, the appearance of the peaks at
1640 and 1550 cm−1 that correspond to CO– and NH– groups of an amide bond, confirms the
deposition of the BS3.
The functionalization of porous silicon surface was also confirmed by spectroscopic reflec‐
tometry.
Figure 5. Reflectivity spectra on porous silicon surface before (solid line) and after APTES silanization (dashed line),
and after BS3 functionalization (short dashed line).
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Reflectivity spectra of porous silicon devices during functionalization steps are reported in
Figure 5. The deposition on pores walls of a thin layer, constituted by the different organic
chemical compounds, produces red shifts of spectra due to the increase of the average
refractive index of porous silicon surfaces [57]. After silanization and cross-linker modifica‐
tion, a red shift of 21 and 15 nm was recorded, respectively. The same chemical modifica‐
tions were performed also on flat silicon devices; in the latter, the whole functionalization
procedure was followed by spectroscopy ellipsometry, in order to quantify layer thickness
variations after thermal oxidation (SiO2), silanization (APTES), and cross-linker functionali‐
zation (BS3). As showed in Table 3, the thickness of oxidized silicon devices was 74 ± 1 nm; this
value increased of 3 and about 2 nm after treatment with aminosilane and BS3, respectively.
Thickness (nm)
Film Sample 1 Sample 2 Sample 3 Sample 4
Oxide 74.9 ± 0.3 74.9 ± 0.2 73.5 ± 0.2 74.7 ± 0.3
Aptes 3.5 ± 0.2 2.9 ± 0.3 3.1 ± 0.2 2.7 ± 0.4
BS3 1.72 ± 0.08 1.84 ± 0.03 1.82 ± 0.03 1.78 ± 0.02
The values reported are the average of five determinations on each sample.
Table 3. Surface layer thickness on four random samples after each step of functionalization measured by ellipsometry
technique.
6. Biosensing
Once the chemical modified silicon chips have been obtained, a procedure to immobilize a
small peptide for label-free detection of cancer cells was settled. The used experimental system
takes advantage of the properties of an idiotype peptide isolated from peptide libraries able
to bind the variable region of the B-cell receptor on A20 lymphoma cells [51]. The selected
peptide, named A20-36 (pA20-36), whose sequence is EYVNCDNLVGNCVI, was linked on
silicon-modified surfaces and used as molecular probe. A random peptide (RND),
SSAYGSCKGPCSSGVHSI, was used as negative control. To determine the optimal peptide
concentration to obtain a uniform coverage of planar and porous surfaces, a titration was
carried out. Based on the obtained results [58], 150 μM concentration was used for both
peptides.
The detection of lymphoma cancer cells fulfilled on both planar and porous peptide-modi‐
fied silicon surfaces is showed in Figure 6. The panels a and b report microscope light images
of the planar device surfaces after incubation with a low (100 cells) or high number (50,000
cells) of A20 cells. The choice of the high number of cells was made in order to have satura‐
tion binding conditions. The same number of cells (50,000) was incubated on A20-36-peptide-
modified porous silicon surface, but a lower number of detected cells were observed on light
microscope (Figure 6, panel c). The chip was not able to bind lymphoma cells when function‐
Bioengineered Surfaces for Real-Time Label-Free Detection of Cancer Cells
http://dx.doi.org/10.5772/62845
189
alized with RND peptide (Figure 6, panel d), whereas no myeloma cells (5T33MM), a surface
IgG-positive B-cell line unable to bind to pA20-36 peptide [51], were detected when incubat‐
ed on the device functionalized with pA20-36 (Figure 6, panel e).
The number of A20 cells detected on functionalized planar surface device was about 8500 and,
taking in account an average area of 80 μm2 for a single cell, filled ~680,000 μm2, a value
concordant with the available functionalized area (~1.0 × 106 μm2); when the detection was
performed on porous silicon device, the number of cells that effectively bind the chip was
lower (400), filling an area of about 32,000 μm2. The exiguous number of A20 cells on the porous
silicon surface was probably caused by the peculiar morphology of the support; being highly
porous, with pore diameter of about 50 nm, and pore upper edges lower than 1 nm in thickness,
its inner surface is many order of magnitude greater than the top active one. Hence, just a very
low number of peptides are really available on the pore upper edges to bind the cells (that
cannot enter into the pores). Therefore, the consequence of this condition is the decrease in the
number of cells detected on porous silicon biochip resulting lower respect to that on the planar
surface.
Figure 6. Optical images of A20 cell detection on both planar and porous silicon devices. Planar silicon pA20-36 modi‐
fied sensor after incubation with 1 × 104 A20 cells/mL (a) and 5 × 106 A20 cells/mL (b). Porous silicon pA20-36 modified
surface after incubation with 5 × 106 A20 cells/mL (c). Planar silicon RND-modified-sensor after incubation with 5 × 106
A20 cells/mL (d). Planar silicon pA20-36 modified sensor after incubation with 5 × 106 5T33MM cells/mL (e).
The surface of each silicon chip presents a functionalized available area of about 1.0 × 106 μm2
so the maximum number of cells that can be bound on the device was 10,000 (covering an area
of about 800,000 μm2). Since the number of cells detected on planar and porous silicon surfaces
was by count 8500 and 400 (evaluated by optical microscopy), the efficiency of detection is 85
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and 4%, respectively. Moreover, comparing the efficiency of detection of the flat silicon device
based on Id-peptide-BCR recognition with an analogous silicon-based bioanalytical system in
which an anti-IgG-BCR was used as molecular probe [48], it is clear that the first biochip
resulted more efficient in detecting A20 cells (8.5 × 10−3 vs. 2.0 × 10−3 cells/μm2, respectively).
This difference is likely due to the better accessibility of the A20-36 Id-peptide on the BCR with
respect to the anti-IgG. In fact, the binding of the idiotype peptide should occur with the more
exposed variable region of the receptor in contrast with the interaction between IgG and BCR
in which the variable regions of the immunoglobulin bind the less exposed constant region of
the receptor. Furthermore, also the difference in affinity constants between the two ligand-
receptor systems coupled to diverse functionalization approaches might have had a decisive
role in the detection efficiency.
Cell detection was also investigated by atomic force microscopy analysis (AFM) (Figure 7).
Figure 7. Representative AFM image in the trace direction of live A20 cells detected on silicon surface.
Both light microscopy and AFM analysis showed a good biocompatibility of substrate since
viability and cell morphology were not affected.
At this point, since cancerous cells are coexisted with other cell types in the body and it is very
important to selectively differentiate cancer cells from other ones, in order to assess the real
performance of the biochip, lymphoma cells detection was carried out on devices incubated
with mixed samples of A20 and 5T33MM cells (3.5 × 105/mL). The detection of lymphoma cells
in system mixed is reported in Figure 8.
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Figure 8. Detection of A20 cells (green) in system mixed with 5T33MM cells (red) by fluorescence macroscopy after
incubation on planar silicon pA20-36 modified sensor.
The mixed system has been prepared in three different ratios (A20:5T33MM = 1:1, 1:10, 1:100)
of the two labeled live cell lines [59]. The efficiency of detection also in a complex system
demonstrated the high selectivity of the device, confirming that the use of an Id-peptide
immobilized on a silicon-based chip could be a good proof-of-concept for future researches.
7. Conclusions
In this chapter, we focused on the functionalization and activation of crystalline and porous
silicon surfaces to develop devices allowing the identification of specific ligand-receptor
interactions.
As an example, we report new results about the realization of devices suitable to highlight the
specific interaction between cell surface receptors and corresponding specific ligands. One of
these devices was applied to detect the binding of extremely aggressive murine A20 lympho‐
ma cells to a specific IgG antibody as molecular probe directed against B-cell receptor. The
result was encouraging and prompted us to develop an improved device, more sensitive, for
the specific recognition of different types of tumor cells. Another approach was based on the
specificity of an idiotype peptide endowed with high-affinity toward A20 lymphoma cells.
Particularly, the use of an Id-peptide as probe allowed to obtain a uniform sensor surface
coating, thus enhancing capture ability also at low cell concentrations. Moreover, the biosen‐
sor was biocompatible and showed high repeatability as well as selectivity in label-free cell
detection.
The improved device opens the way to the development of unique diagnostic tools in point-
of-care testing for recognition and isolation of patient-specific neoplastic B cells during the
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minimal residual disease. Any idiotype peptide is ideally endowed with a unique, clone-
specific antigenic reactivity. Of course, this approach requires the selection of Id-peptides for
each patient through laborious and costly procedures. This might be overcome focusing on a
specific B-cell tumors, where a consistent number of patients share the same antigenic
reactivity against a restrict pool of Id-peptides. Nevertheless, this strategy can be utilized for
the characterization of other specific peptide–receptor interactions through the screening of a
recombinant phage library.
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The necessity of on-site, fast, sensitive, and cheap complex laboratory analysis, 
associated with the advances in the microfabrication technologies and the 
microfluidics, made it possible for the creation of the innovative device lab-on-a-chip 
(LOC), by which we would be able to scale a single or multiple laboratory processes 
down to a chip format. The present book is dedicated to the LOC devices from two 
points of view: LOC fabrication and LOC application.
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